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The neuromuscular junction (NMJ) has been studied for over a century, yet we still do not 
have a complete picture of all its structural and functional components, knowledge of which 
is paramount in devising treatment strategies for neuromuscular diseases. Previous 
microarray-based approaches aimed at elucidating novel NMJ components were hindered by 
technological limitations. Recent technological advancements propelled next-generation 
RNA-sequencing with its wider dynamic range to the forefront of transcriptome-level gene 
expression profiling.  
 
We utilized laser-capture microdissection to isolate myonuclei underlying the NMJ 
combined with RNA-sequencing and successfully generated NMJ gene expression profiles of 
fast-twitch extensor digitorum longus (EDL) and slow-twitch soleus (SOL) muscles and 
identified a large number of potential novel NMJ genes. The expression levels of canonical 
NMJ genes were nearly identical between the EDL and SOL, which suggests that the core NMJ 
gene program might be well conserved between different skeletal muscle types. We used in 
vivo muscle electroporation to overexpress one of our candidate genes, the transcription 
factor T-box 21 (TBX21), in the tibialis anterior (TA) muscle and observed an increased 
density of postsynaptic acetylcholine receptors. TBX21 may thus represent a novel 
transcription factor contributing to the regulation of the NMJ gene program, with a role in 
postsynaptic sensitivity. 
 
We also generated NMJ gene expression profiles of the TA muscle of 10-month-old 
(“young”) and 30-month-old (“old”) mice to investigate the effect of aging on the NMJ gene 
program. Strikingly, the NMJ gene program was remarkably stable, with nearly identical 
expression levels of canonical NMJ genes between young and old mice. This implies that age-
related perturbations of the NMJ are likely caused by external factors, such as accumulated 
myofiber damage and changes in nerve input, rather than by gradual dysregulation of the 
NMJ gene program with increasing age. Our findings argue against the hypothesis that aging 
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leads to a broad deterioration of the NMJ gene program that would contribute to 
perturbations of NMJ structure and function. 
 
Furthermore, functional annotation analysis of our different NMJ gene expression 
datasets strongly indicates the importance of an extensive number of hitherto unknown 
glycoproteins, as well as of posttranslational modifications, especially glycosylations, at the 
synaptic basal lamina. We highlight a set of candidate genes that encode for enzymes 
putatively involved in these processes at the NMJ, and which are potentially involved in the 
pathophysiology of neuromuscular diseases such as congenital myasthenic syndromes. This 
thesis expands our understanding of the complexity of the NMJ and lays the foundation for 
further research that will functionally characterize novel synaptic components and provide 
the basis for novel therapeutic treatment strategies. 
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List of Abbreviations 
α-BTX α-Bungarotoxin 
AAV Adeno-associated virus 
ACHE Acetylcholinesterase 
AChR Acetylcholine receptor 
ActRII Myostatin/activin type II receptor 
AKT1S1/PRAS40 Proline-rich AKT1 substrate 1 
Akt/PKB Protein Kinase B; Serine-Threonine Protein Kinase 
AMPK AMP-activated protein kinase 
APOE Apolipoprotein E 
APLP2 Amyloid beta (A4) precursor-like protein 2 
AQP4 Aquaporin 4 
ARHGEF3/XPLN Rho guanine nucleotide exchange factor (GEF) 3 
ATP Adenosine triphosphate 
ATPase Adenosine triphosphate hydrolase 
ATP5D  ATP synthase subunit delta, mitochondrial 
ATAC-seq Assay for Transposase-Accessible Chromatin using sequencing 
autoLPC Automated laser-pressure catapulting 
BDNF Brain-derived neurotrophic factor 
BP Biological process (Gene Ontology term) 
B4GALNT3 Beta-1,4-N-acetyl-galactosaminyl transferase 3 
BSA Bovine serum albumin 
CC Cellular component (Gene Ontology term) 
CCND1 Cyclin D1 
cDNA Complementary DNA 
CHPF Chondroitin polymerizing factor 1 
CHPF2 Chondroitin polymerizing factor 2 
CHRNE Cholinergic receptor, nicotinic, epsilon polypeptide 
CKMT2 Creatine kinase, mitochondrial 2 
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CMS Congenital myasthenic syndrome 
ColQ  Acetylcholinesterase collagenic tail peptide 
CPM Counts per million 
CR Caloric restriction 
CRYM Crystallin, mu 
CSA Cross-sectional area 
CT Control group 
DAPI 4′,6-diamidino-2-phenylindole 
DAVID Database for Annotation, Visualization and Integrated Discovery 
D-BSSE Department of Biosystems Science and Engineering 
DCN Decorin 
DEPTOR DEP domain-containing mTOR-interacting protein 
DGC Dystrophin-associated glycoprotein complex 
DAGK Diacylglycerol kinase 
DAGKZ Diacylglycerol kinase zeta 
DHPR Dihydropyridine receptor 
DLK1 Delta like non-canonical Notch ligand 1 
DMD Dystrophin 
Dok-7/Dok7 Docking protein 7 
DPAGT1 Dolichyl-phosphate (UDP-N-acetylglucosamine) N-
acetylglucosaminephosphotransferase 1 
DSHB Developmental Studies Hybridoma Bank 
ECM Extracellular matrix 
EDL Extensor digitorum longus muscle 
eGFP Enhanced green fluorescent protein 
EIF4E Eukaryotic translation initiation factor 4E 
EIF4EBP1/4E-BP1 Eukaryotic translation initiation factor 4E binding protein 1 
EtOH Ethanol 
ETV5/ERM ETS variant 5; Ets-Related Protein ERM 
EX Resistance-exercise group 
FDR False discovery rate 
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FNDC5 Fibronectin type III domain-containing protein 5 
FoxO Forkhead-box-protein 
GABPα GA repeat binding protein alpha 
GABPβ GA repeat binding protein beta 
GAS Gastrocnemius muscle 
GC Glucocorticoids 
GDNF Glial cell line derived neurotrophic factor  
GEF Guanine nucleotide exchange factor 
GFPT1 Glutamine-fructose-6-phosphate transaminase 1 
GO PANTHER Gene Ontology Enrichment 
GTP Guanosine triphosphate 
GTPase Guanosine triphosphate hydrolase 
H2-Aa Histocompatibility 2, class II antigen A, alpha 
HPRT Hypoxanthine guanine phosphoribosyl transferase 
HSPG Heparan sulfate proteoglycan 
HS6ST Heparan sulfate 6-O-sulfotransferase (Drosophila) 
HS6ST1 Heparan sulfate 6-O-sulfotransferase 1 
HS6ST2 Heparan sulfate 6-O-sulfotransferase 2 
IDH2 Isocitrate dehydrogenase 2, mitochondrial 
IFITM10 Interferon induced transmembrane protein 10 
IFN-γ Interferon gamma 
IGF-1 Insulin-like growth factor 1 
IGF-2 Insulin-like growth factor 2 
IGFBP2 Insulin-like growth factor binding protein 2 
IL-1β Interleukin-1 beta 
IL-6 Interleukin-6 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LAT1/SLC7A5  Solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 5 
LC3 Microtubule-associated protein 1A/1B-light chain 3 
logCPM Log2-transformed counts per million 
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LPAAT Lysophosphatidic acid acyltransferases 
LRP4 Low-density lipoprotein receptor-related protein 4 
MAFbx/Atrogin-1 F-box protein 32 
MARP Muscle ankyrin repeat protein 
MAPKAP1/mSIN1 Mitogen-activated protein kinase associated protein 1 
MDa Megadalton 
MDS Multidimensional scaling 
MF Molecular function (Gene Ontology term) 
MLST8 Mammalian lethal with SEC13 protein 8 
MMP2 Matrix metallopeptidase 2 
MND Myonuclear domain 
MPB Muscle protein synthesis 
MPS Muscle protein breakdown 
MSTN Myostatin 
mTOR Mammalian/mechanistic target of rapamycin 
mTORC1 Mammalian target of rapamycin complex 1 
mTORC2 Mammalian target of rapamycin complex 2 
MuRF1/TRIM63 Muscle RING finger 1 
MuRF2/TRIM55 Muscle RING finger 2 
MuSK Muscle-specific tyrosine kinase 
MyHC Myosin heavy chain 
NA Numerical aperture 
Na+-K+-ATPase  Sodium-potassium adenosine triphosphatase; sodium-potassium 
pump 
NELL2 NEL-like 2 
NES Nestin 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMJ Neuromuscular junction 
NRB1 NRB1, autophagy cargo receptor 
NRF1/NFE2L1 Erythroid-derived 2-related factor 1 
NSF N-ethylmaleimide sensitive fusion protein 
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OGDH Oxoglutarate dehydrogenase 
PA Phosphatidic acid 
PBS Phosphate-buffered saline 
PDZRN3 PDZ domain-containing RING finger protein 3 
PDZRN4 PDZ domain-containing RING finger protein 4 
PCoA Principal coordinate analysis 
PFA Paraformaldehyde 
PLA Plantaris muscle 
PLCG1 Phospholipase C, gamma 1 
PLD Phospholipase D 
PPARGC1A/PGC-1α  Peroxisome proliferative activated receptor, gamma, coactivator 1 
alpha 
PRR5/PROTOR1 Proline Rich 5; Protein Observed With Rictor-1 
PRRL5/PROTOR2 Proline Rich 5 Like; Protein Observed With Rictor-2 
qPCR Semiquantitative real-time polymerase chain reaction 
QUAD Quadriceps muscle 
RAP2A Ras-related protein Rap-2a 
RAPSYN 43 kDa receptor-associated protein of the synapse 
RPTOR Regulatory-associated protein of mTOR 
RE Resistance exercise 
RHEB Ras homolog enriched in brain 
RICTOR Rapamycin-insensitive companion of mTOR 
RIN RNA integrity number 
RM Rapamycin 
RPS6 Ribosomal protein S6 
RPS6KB1/p70S6K Ribosomal protein S6 kinase, polypeptide 1 
RWE Resistance-wheel exercise 
RYR1 Ryanodine receptor 1, skeletal muscle 
SCN3B Sodium channel, voltage-gated, type III, beta 
SED Sedentary control group 
SERCA1 Sarco/endoplasmic reticulum Ca2+-ATPase 
 List of Abbreviations 
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SERPINB1A Serine (or cysteine) peptidase inhibitor, clade B, member 1a 
SMA Spinal muscular atrophy 
SMAD2/3 SMAD family member 2/3 
SMARCD3/BAF60C  SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 3 
SNTA1 Syntrophin alpha 1 
SOL Soleus muscle 
SQSTM1/P62 Sequestosome 1 
SULF2 Sulfatase 2 
SWI/SNF SWItch/Sucrose Non-Fermentable 
TA Tibialis anterior muscle 
TBP TATA box binding protein 
TBX15 T-box 15 
TBX21 T-box 21 (T-Bet) 
TEAD TEA domain family transcription factors 
TELO2 Telomere maintenance 2 
TID1/DNAJA3 Tumorous imaginal discs 
TGF-β Transforming growth factor beta 
TNF-α Tumor necrosis factor alpha (Cachexin) 
TSC1 Tuberous sclerosis complex (TSC) subunit 1 (Hamartin) 
TSC2 Tuberous sclerosis complex (TSC) subunit 2 (Tuberin) 
TSC1/2 Tumor suppressor tuberous sclerosis complex TSC1-TSC2 
TT Transverse tubular system 
TTI1 TELO2-interacting protein 1 
UBR5 Ubiquitin protein ligase E3 component n-recognin 5 
UBTF Upstream binding transcription factor, RNA polymerase I 
UQCRC2 Ubiquinol cytochrome c reductase core protein 2 
UTRN Utrophin 
VTI Vinculin-talin-integrin system 
WWTR1/TAZ WW domain containing transcription regulator 1 
XPLN/ARHGEF3 Exchange factor found in platelets, leukemic, and neuronal tissues 
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YAP1 Yes-associated protein 1 
YFP Yellow fluorescent protein 
YY1 YY1 transcription factor 
 
 General introduction 
10 
1 General introduction 
1.1 The musculoskeletal system 
The musculoskeletal system provides stability, support, shape, and locomotion to the body. 
Skeletal muscles can voluntarily contract and enable movement by pulling on the bones of 
the skeleton, to which they attach via specialized connective tissue, the tendons. Unlike 
skeletal muscle, smooth muscle and cardiac muscle contract involuntarily. Smooth muscle is 
found within and in part composes the walls of blood vessels and of certain hollow organs of 
the body, such as the stomach and intestines. 
 
Skeletal muscle and exercise in whole-body metabolism 
Skeletal muscle is the largest organ of the human body and typically makes up around 40% 
of total body mass, but can reach levels of over 65% in professional male bodybuilders 
(Spenst, Martin et al. 1993). Apart from its roles in posture and locomotion, skeletal muscle 
also contributes significantly to whole-body metabolism, with a particularly important role 
in glucose tolerance and insulin handling, as skeletal muscle is the predominant site of 
insulin-mediated glucose uptake after food consumption (Stump, Henriksen et al. 2006). 
In fact, skeletal muscle insulin resistance likely is the primary defect in the development of 
type 2 diabetes mellitus (Warram, Martin et al. 1990, DeFronzo and Tripathy 2009). 
Thus, maintaining normal insulin sensitivity is essential to remain metabolically flexible in 
times of energy surplus (more glucose-based fuel usage) and scarcity (more lipid-based fuel 
usage) (Stump, Henriksen et al. 2006). Exercise improves metabolic control by acutely 
increasing glucose uptake into skeletal muscles and by priming muscle insulin sensitivity for 
up to two days following physical activity (Richter, Garetto et al. 1982, Wojtaszewski, 
Hansen et al. 2000). Even a single bout of exercise can improve skeletal muscle insulin 
sensitivity in diabetic patients (Devlin, Hirshman et al. 1987). In the basal state, skeletal 
muscle accounts for about 30% of the basal metabolic rate, but this contribution to whole-
body energy use can rise significantly during strenuous exercise, and whole-body metabolic 
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rate may rise more than 20-fold (Gaitanos, Williams et al. 1993). Thus, skeletal muscle 
evidently plays an important role in whole-body energy homeostasis and health status. 
 
Skeletal muscle is an active endocrine organ and as such contributes to systemic 
signaling and inter-organ communication via the production and secretion of various 
myokines, which are peptides or proteins that may exert multiple autocrine, paracrine, and 
endocrine effects. Muscle contraction is thought to be a major regulator of myokine 
expression and release, but not all myokines respond to contraction (Pedersen and 
Febbraio 2012). Some myokines work in autocrine or paracrine fashion within skeletal 
muscle itself and are not released into the circulation (Whitham and Febbraio 2016). 
Interleukin-6 (IL-6) is the prototypical and first-identified myokine originally detected in 
blood samples of marathon runners post-race (Ostrowski, Rohde et al. 1998). IL-6 is a 
myokine released from skeletal muscle during exercise and plays a role in glucose 
homeostasis and in stimulating hepatic glucose production (Febbraio, Hiscock et al. 2004). 
Interest in myokines has risen sharply in recent years, which is understandable considering 
their potential therapeutic use in metabolic disease, which opens up novel pharmacological 
approaches and puts emphasis on exercise as an important treatment and disease-
prevention strategy (Benatti and Pedersen 2015, Gorgens, Eckardt et al. 2015, Schnyder 
and Handschin 2015). 
 
Decorin (DCN), a small, leucine-rich dermatan sulfate proteoglycan, shows elevated 
levels upon muscle contraction in mice and humans. It is an exercise-regulated myokine 
secreted into circulation and is involved in a pro-hypertrophic response by binding directly 
to myostatin (MSTN) (Kanzleiter, Rath et al. 2014). The myokine MSTN itself is a member 
of the transforming growth factor beta (TGF-β) superfamily expressed during skeletal muscle 
development and mainly exerts negative effects on skeletal muscle mass (McPherron, 
Lawler et al. 1997). Decorin stimulates muscle cell differentiation, repair, and induces 
myogenic satellite cell proliferation by antagonizing TGF-β1 sensitivity (Bianco, Fisher et 
al. 1990, Li, McFarland et al. 2008). Treatment with growth hormone, but not testosterone, 
increased circulating DCN levels in humans (Bahl, Stone et al. 2018). Additionally, DCN 
plays a role in connective tissue formation in skeletal muscle and stimulates collagen 
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synthesis (Vogel and Trotter 1987, Neame, Kay et al. 2000). Decorin also seems to play a 
role in metabolism, as feeding a high-fat diet to DCN-knockout mice lead to impaired glucose 
tolerance concomitant with a downregulation of genes involved in the organization of the 
extracellular matrix and in triglyceride biosynthesis, as well as an upregulation of adipose 
tissue genes. Consistently, adipose-tissue DCN levels were found to be elevated in obese adult 
humans after profound fat loss. Taken together, these observations establish DCN as a 
myokine with an important role in glucose tolerance maintenance (Svard, Rost et al. 2019). 
Although DCN is secreted into circulation after exercise, it remains unclear whether 
increased circulatory levels, local production in the adipose tissue, or both, mediate these 
metabolic effects, and further research is required in this area. 
 
Irisin is another recently identified myokine. It plays an important role in lipid 
metabolism through the browning of white adipose tissue (Bostrom, Wu et al. 2012). Irisin 
arises through proteolytic cleavage from the fibronectin type III domain-containing protein 
5 (FNDC5), a transmembrane protein that is expressed under regulation of the peroxisome 
proliferator-activated receptor γ coactivator 1α (PGC-1α). PGC-1α is a transcriptional co-
activator readily inducible by exercise and exposure to cold, among other things, and is 
known for its distinctive effect on metabolism by greatly enhancing mitochondrial biogenesis 
(Handschin and Spiegelman 2008, Zhang, Chang et al. 2015, Mattson, Moehl et al. 
2018). Irisin is secreted into circulation upon exercise and leads to energy balance 
improvements. It might therefore find use as a possible treatment in metabolic disease and 
in counteracting systemic inflammation (Lecker, Zavin et al. 2012, Polyzos, Anastasilakis 
et al. 2018). However, conflicting results in human studies preclude conclusions about 
irisins’ effectiveness in white adipose tissue browning and further studies are warranted 
(Elsen, Raschke et al. 2014).  
 
Exercise-induced induction of PGC-1α and the concomitant release of irisin from 
skeletal muscle into the circulation induces brain derived neurotrophic factor (BDNF) 
production in different brain regions, linking exercise with beneficial neuroprotective effects 
and resilience to stress (Wrann, White et al. 2013, Phillips, Baktir et al. 2014, Zhan, 
Huang et al. 2018). BDNF is also produced by skeletal muscle upon exercise, conferring 
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enhanced lipid oxidation via activation of AMP-activated protein kinase (AMPK), and thus 
belongs itself to the myokine family of proteins (Matthews, Astrom et al. 2009). However, 
it appears that BDNF is not released into circulation in significant amounts, thus exerting its 
functions on skeletal muscle mainly in an autocrine/paracrine manner (Schnyder and 
Handschin 2015). Furthermore, it has recently been shown (see Appendix B) that BDNF is 
a mediator of glycolytic fiber-type specification in mouse skeletal muscle (Delezie, 
Weihrauch et al. 2019). Muscle-specific deletion of BDNF lead to reduced motor end plate 
volume and slower contractile properties of glycolytic fast-twitch muscles, such as the 
extensor digitorum longus muscle (EDL). Accordingly, muscle-specific overexpression of 
BDNF promoted a fast muscle-type gene program and lead to increased levels of the 
transcriptional regulators SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily D member 3 (SMARCD3; also known as BAF60C) and T-box 15 (TBX15), 
which control glycolytic muscle fiber identity (Meng, Li et al. 2013, Lee, Singh et al. 2015, 
Delezie, Weihrauch et al. 2019). Mechanistically it is still unclear how exactly BDNF 
modulates SMARCD3, TBX15, and the fast fiber gene program, and further research is 
warranted. 
 
Overall, skeletal muscle displays remarkable malleability in response to contractile 
activity, as well as nutritional- and health-status. It provides the body with a powerful means 
in metabolic control, and is involved in whole-body energy homeostasis and signaling via the 
expression and secretion of myokines. The importance and functionality of skeletal muscle 
evidently goes far beyond simple locomotion and even encompasses temperature control via 
shivering. The following sections will illustrate the immense ability of skeletal muscles to 
adapt to their environment and to the contractile and energetic demands placed on them. 
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Skeletal muscle plasticity 
Skeletal muscle fibers, also called myofibers, within the same and between different muscles 
may differ in fiber type, with each type demonstrating distinct contractile and metabolic 
properties. This myofiber type heterogeneity facilitates contractile flexibility in different 
tasks, e.g. high-intensity contractions when lifting a heavy weight, or low-intensity 
contractions to maintain posture. Myofibers are highly plastic, as they are capable of 
changing in size as well as type in response to mechanical loading and neuromuscular activity 
(Pette 2002). In general, two major types of myofibers are distinguishable through their 
predominantly oxidative or glycolytic metabolism and correspondingly their speed of 
contraction and resistance to fatigue (Schiaffino, Hanzlikova et al. 1970). Predominantly 
slow-twitch, oxidative “type I” myofibers are rich in myoglobin, mitochondria and oxidative 
enzymes. Type I myofibers are optimally equipped for continuous and sustained 
contractions. Predominantly fast-twitch, glycolytic “type II” myofibers contain less 
mitochondria and rely more on glycolytic metabolism. Type II myofibers are optimally 
equipped for powerful, yet fatigable contractions. Depending on their characteristics and 
expression of different myosin heavy chain (MyHC) proteins, they can be subdivided into 
type IIA, type IIB, and type IIX. Type IIA myofibers possess intermediate contractile 
characteristics between type I and type II, and express MyHC-2A, while type IIB and type IIX 
fibers express MyHC-2B and MyHC-2X, respectively (Schiaffino, Gorza et al. 1989). Fatigue-
resistance and contractile characteristics of type IIX myofibers lie between type IIA and IIB 
(Larsson, Edstrom et al. 1991). Notably, Type IIB myofibers are found in rodent, but not in 
human skeletal muscle (Schiaffino and Reggiani 2011). 
 
Myofiber heterogeneity is not limited to differences in contractile characteristics and 
metabolism alone. There is also a wide variability in terms of calcium handling in intracellular 
signaling and interrelated transmembrane ionic flux. For instance, muscle membrane 
excitability is a product of the abundance and activity state of sodium ion-channels. Sodium 
channel density is several times higher in fast-twitch myofibers, allowing them to respond to 
the high discharge rate of their associated motor neurons with powerful contractions (Ruff 
and Whittlesey 1992). However, this large sodium ion influx rate may be in excess of what 
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the sodium-potassium-ion-pump (Na+-K+-ATPase) can handle, thus contributing to the high 
fatigability of fast-twitch myofibers. The Na+-K+-ATPase works to maintain the resting 
membrane potential by actively removing three intracellular sodium ions in exchange for 
two potassium ions, resulting in a negative net-charge change. Although fast myofibers 
contain a larger amount of Na+-K+-ATPase, its activity during repetitive stimulations is 
several times lower than in slow myofibers, contributing to their lower fatigue resistance 
(Everts and Clausen 1992). 
 
Intracellular cytosolic free calcium levels are tightly controlled in myofibers, as 
calcium may trigger muscle contraction by binding to troponin, but also may influence 
various protein activity states through phosphorylation events caused by calcium binding to 
calmodulin, a multifunctional intermediate calcium-binding messenger. Specific transporter 
proteins (i.e. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA1)) and a generally larger 
volume of the sarcoplasmic reticulum enable a more efficient uptake of calcium ions in fast-
twitch, type II myofibers (Salviati, Sorenson et al. 1982, MacLennan, Brandl et al. 1987). 
Cytoplasmic calcium buffers, mitochondria, and the composition of the sarcolemma itself 
contribute to fine-tuned control of intracellular calcium concentration. Calcium transients 
reach a higher peak and decline approximately twice as fast in type II myofibers (Liu, Carroll 
et al. 1997, Baylor and Hollingworth 2003). These calcium transient kinetics directly 
determine the shorter time to peak as well as half-relaxation time of fast myofiber twitch-
contractions. 
 
Calcium release from the sarcoplasmic reticulum into the cytosol occurs through 
specialized calcium-release channels, called ryanodine receptor 1 (RYR1), which are coupled 
to L-type voltage-gated calcium channels, called dihydropyridine receptors (DHPR) (Rios 
and Brum 1987, Takeshima, Nishimura et al. 1989). DHPRs are found in the frequent 
invaginations of the sarcolemma, called the transverse tubular system (TT), which allows 
action potentials to travel towards the inner part of muscle cells (Adrian, Costantin et al. 
1969). Upon stimulation by action potentials, DHPRs facilitate activation of RYR1s and thus 
calcium release from the sarcoplasmic reticulum into the cytosol. This direct coupling 
between DHPRs and RYR1s ensures a fast and reliable release of calcium ions upon TT 
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depolarization by action potentials, ultimately causing muscle contraction (Catterall 1991). 
Fast myofibers contain about twice as many RYR1s (Franzini-Armstrong, Ferguson et al. 
1988). Furthermore, slow myofiber DHPR-to-RYR1-ratio is lower (Margreth, Damiani et 
al. 1993). Yet, intraluminal calcium levels may also influence RYR1 channel activity by 
facilitating binding of calmodulin and many other RYR1 modulators. Taken together, slow 
myofibers show reduced capacity of voltage-dependent calcium release due to a larger 
portion of DHPR-uncoupled RYR1s, which suggests that a greater emphasis is put on calcium-
induced calcium release in slow versus fast myofibers, presumably mediated via calmodulin 
(Tang, Sencer et al. 2002). 
 
The capability of a myofiber to buffer calcium directly influences its calcium transient 
kinetics. Cytosolic calcium-buffering proteins include, but are not limited to, troponin, 
calmodulin, and parvalbumin. High levels of parvalbumin are found in type IIB and IIX 
myofibers, while it is much less abundant in type IIA and type I myofibers (Celio and 
Heizmann 1982). Parvalbumin acts as a cytosolic calcium buffer in fast myofibers by quickly 
reducing cytosolic calcium levels after calcium release from the sarcoplasmic reticulum, and 
thus helps to enable faster twitch contractions by regulating relaxation speed (Schwaller, 
Dick et al. 1999). Calmodulin also contributes to calcium buffering, and, like parvalbumin, 
is more abundant in fast myofibers, although to a lesser extent (Campbell, Gordon et al. 
2001). In conclusion, it is clear that myofiber type differences extend far beyond myofibrillar 
protein composition and metabolic enzyme expression, and that myofibers are flexibly fine-
tuned to their exact functional demands. 
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Signaling pathways regulating skeletal muscle protein balance 
The perpetual process of muscle protein synthesis (MPS) and breakdown (MPB) governs the 
maintenance of skeletal muscle mass. Under normal conditions, overall daily rates of MPS 
and MPB are roughly equal. A wide variety of extracellular stimuli influences this dynamic 
regulation, and can activate or inhibit distinct intracellular processes that alter protein 
balance within myofibers. Anabolic stimuli, such as insulin-like growth factor 1 (IGF-1), 
testosterone, insulin, and β2-adrenergic agonists, may tip protein balance within myofibers 
towards MPS, resulting in protein accretion (Griggs, Kingston et al. 1989, Biolo, Declan 
Fleming et al. 1995, Glass 2005). For example, binding of IGF-1 and insulin to receptors in 
the muscle membrane activates signaling pathways mediated by protein kinase B (Akt/PKB) 
and mammalian target of rapamycin (mTOR), and thus promotes MPS and eventually 
myofiber hypertrophy (Schiaffino and Mammucari 2011). In contrast, catabolic factors, 
such as glucocorticoids (GC) and a wide variety of pro-inflammatory cytokines (such as 
tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin-1 beta (IL-1β), 
and IL-6) may tip muscle protein balance towards breakdown and thus lead to muscle 
wasting (Reid and Li 2001). In particular, GCs are elevated in many catabolic diseases, such 
as sepsis and cancer cachexia, in which they contribute to muscle wasting and functional 
decline, but are also elevated during physically and psychologically stressful conditions 
including fasting and exercise (Bodine and Furlow 2015). Elevated circulating GC levels 
may perturb muscle protein balance two-fold, by decreasing MPS as well as by increasing 
MPB, which is a commonly occurring theme in perturbations of muscle protein balance 
(Pereira and Freire de Carvalho 2011). 
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Figure 1-1. Schematic representations of mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2).  
 
The aforementioned mTOR signaling pathway exerts a large degree of influence on 
the maintenance of skeletal muscle mass (Yoon 2017). Mammalian target of rapamycin is a 
highly conserved serine/threonine protein kinase capable of sensing a plethora of 
environmental cues and intracellular changes, such as amino acid and nutrient availability 
(Sancak, Peterson et al. 2008, Sengupta, Peterson et al. 2010). It integrates these cues 
and influences a variety of cellular processes, most prominently cell growth and 
differentiation, but also plays a role in metabolism, autophagy and survival (Dibble and 
Manning 2013). Mammalian target of rapamycin forms two structurally and functionally 
distinct complexes, the mTOR complex 1 (mTORC1), which is involved in anabolic processes 
like protein synthesis, and mTOR complex 2 (mTORC2), which governs other cellular 
processes, such as angiogenesis and for example regulates glucose uptake in response to 
insulin and in endurance exercise (Inoki and Guan 2006, Ziegler, Hatch et al. 2016, 
Kleinert, Parker et al. 2017). While both mTORC1 and mTORC2 contain mTOR as their 
catalytic core, mTORC1 consists of the regulatory-associated protein of mTOR (RPTOR), the 
proline-rich AKT1 substrate 1 (AKT1S1; also known as PRAS40), the DEP domain-containing 
mTOR-interacting protein (DEPTOR), the complex of TELO2-interacting protein 1 (TTI1) and 
telomere maintenance 2 (TELO2), and the mammalian lethal with SEC13 protein 8 (MLST8). 
Mammalian target of rapamycin complex 2 shares DEPTOR, MLST8, and the TTI1-TELO2 
complex with mTORC1, but instead of RPTOR contains the rapamycin-insensitive companion 
 General introduction 
19 
of mTOR (RICTOR), the rho guanine nucleotide exchange factor (GEF) 3 (ARHGEF3; also 
known as XPLN), the proline rich 5 (PRR5; also known as PROTOR1) or the proline rich 5 like 
(PRR5L; also known as PROTOR2), and the mitogen-activated protein kinase associated 
protein 1 (MAPKAP1, also known as mSIN1) (Figure 1-1) (Hara, Maruki et al. 2002, 
Jacinto, Loewith et al. 2004, Frias, Thoreen et al. 2006, Jacinto, Facchinetti et al. 2006, 
Pearce, Huang et al. 2007, Sancak, Thoreen et al. 2007, Peterson, Laplante et al. 2009, 
Kaizuka, Hara et al. 2010, Khanna, Fang et al. 2013). 
 
Mammalian target of rapamycin complex 1 regulates mitochondrial oxygen 
consumption and oxidative capacity through cooperative activity modulation of the YY1 
transcription factor (YY1) and of PGC-1α (Cunningham, Rodgers et al. 2007). Perhaps 
unsurprisingly, resistance exercise (RE) activates mTORC1, which plays a fundamental role 
in the hypertrophic adaptive response of muscle (Egan and Zierath 2013). Specifically, 
mTORC1 regulates muscle protein balance by activation of its downstream targets ribosomal 
protein S6 kinase, polypeptide 1 (RPS6KB1; also known as p70S6K) and eukaryotic 
translation initiation factor 4E binding protein 1 (EIF4EBP1; also known as 4E-BP1) (Ma and 
Blenis 2009). The tumor suppressor tuberous sclerosis complex (TSC1/2) is formed by TSC 
complex subunit 1 (TSC1; also known as hamartin) and TSC complex subunit 2 (TSC2; also 
known as tuberin). The TSC1/2 complex acts as a guanosine triphosphate hydrolase 
(GTPase)-activating protein for the small GTPase ras homolog enriched in brain (RHEB), 
which facilitates upstream regulation of mTORC1. The TSC1/2 complex itself is regulated via 
Akt/PKB, which may phosphorylate TSC1/2 and thus inhibit its GTPase-activating function 
towards RHEB, leading to activation of RHEB (Inoki, Li et al. 2003). Activated RHEB in turn 
activates mTORC1, which results in phosphorylation and thus activation of RPS6KB1 and 
EIF4EBP1, which in turn promote protein synthesis by activating ribosomal protein S6 
(RPS6) and eukaryotic translation initiation factor 4E (EIF4E) (Parmar and Tamanoi 
2010). Protein kinase B (Akt/PKB) also inhibits mTORC1 independently of TSC1/2 by 
inducing the dissociation of AKT1S1 from mTORC1 through its phosphorylation (Sancak, 
Thoreen et al. 2007, Wang, Harris et al. 2007). Mammalian target of rapamycin complex 
1 activity is furthermore governed by a wide variety of influences from growth factors, amino 
acids, energy status, pro-inflammatory cytokines (i.e. TNF-α), hypoxia, to DNA damage and 
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many other inputs, which underlines the evident importance of this central growth pathway 
(Brugarolas, Lei et al. 2004, Inoki and Guan 2006, Lee, Kuo et al. 2007). 
 
The mTORC1 governs skeletal muscle size not only by facilitating increased MPS rates 
upon growth stimuli, but also plays a major role in regulating MPB. If the overall rate of MPB 
exceeds that of MPS, a muscle will shrink, or atrophy (Sandri 2013). In times of low nutrient 
availability and upon other catabolic stimuli, such as physical inactivity, Akt/PKB is inactive 
and no longer inhibits TSC1/2, resulting in greater mTORC1 inhibition. Simultaneously, while 
forkhead-box-protein (FoxO)-family transcription factors are kept in an inactivated state in 
the cytosol when Akt/PKB is active, they become activated, enter the nucleus and become 
transcriptionally active upon Akt/PKB inhibition (Sandri, Sandri et al. 2004). This 
contributes to muscular atrophy, as active FoxO-signaling increases ubiquitin-mediated 
proteolysis pathways, which occurs for example in insulin-deficient diabetes (O'Neill, 
Bhardwaj et al. 2019). Apart from FoxO-family transcription factors, several other factors, 
collectively termed “Atrogenes”, as these genes are involved in the induction of muscular 
atrophy, contribute to a negative muscle protein balance. The most prominent atrogenes are 
perhaps muscle ring finger 1 (MuRF1/TRIM63) and F-box protein 32 (MAFbx/Atrogin-1), 
both of which are E3 ubiquitin ligases enriched in muscle (Bodine and Baehr 2014). 
Forkhead-box-protein signaling drives the overall MPB rate, presumably by the coordinated 
regulation of ubiquitin-proteasome mediated proteolysis and of autophagy, which it 
facilitates via the regulation of a large amount of different atrogenes (Milan, Romanello et 
al. 2015, Taillandier and Polge 2019). A recently identified E3 ubiquitin ligase, ubiquitin 
protein ligase E3 component n-recognin 5 (UBR5), is inversely regulated compared to MuRF1 
and MAFbx during atrophy, recovery from atrophy, as well as during hypertrophy. UBR5 
becomes epigenetically altered via DNA-methylation events after human RE and retraining, 
indicating involvement of proteolytic activity in both anabolic as well as catabolic remodeling 
events (Seaborne, Strauss et al. 2018, Seaborne, Hughes et al. 2019). Nevertheless, the 
coordinated crosstalk between autophagy and the ubiquitin-proteasome system in skeletal 
muscle atrophy is still incompletely understood and remains an active research topic (Nam, 
Han et al. 2017).  
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Mechanical stimuli and resistance exercise in skeletal muscle hypertrophy 
As established above, physical activity alters skeletal myofiber size, metabolism and 
structural properties, but also affects the entire body through endo and paracrine signaling. 
Yet, we lack a deeper understanding of how exactly mechanical stimuli mediate muscular 
hypertrophy. This still somewhat enigmatic process was termed “mechanotransduction”. 
How does mechanotransduction allow muscle cells to convert mechanical stimuli into 
intracellular biochemical responses? How do muscle cells “sense” mechanical stimuli? What 
exactly comprises a mechanical stimulus capable of inducing hypertrophy? While the 
mTORC1-mediated increase in MPS was conclusively established as a key mechanism by 
which RE causes skeletal muscle hypertrophy, the initiating stimuli by which RE stimulates 
hypertrophy have remained elusive (Bodine, Stitt et al. 2001, Marcotte, West et al. 2015). 
All of these questions remain to be answered conclusively, but recent research has revealed 
several potential routes by which muscle cells may integrate mechanical stimuli and respond 
with hypertrophy. 
 
Normal levels of skeletal muscle mass are only maintained if normal levels of physical 
activity are adhered to, as severe muscular atrophy is evident upon immobilization (Appell 
1990). The force generated by a muscle contraction is transmitted to tendons and bones via 
longitudinal force transduction from one end of a myofiber to the other. However, there is 
also a lateral force component, which is transmitted from the force-generating sarcomeres 
through the sarcolemma and to the extracellular matrix via costameres (Street 1983). 
Sarcomeres are the smallest functional units of myofibers. They form repeating units 
between two Z-lines, which themselves are dense protein discs acting as anchoring points for 
actin filaments. Costameres are structural-functional components of myofibers connecting 
the sarcomere to the cell membrane (Pardo, Siliciano et al. 1983). They aid not only in 
lateral force transfer from sarcomeres to the extracellular matrix, but also in maintenance of 
sarcolemmal mechanical integrity (Peter, Cheng et al. 2011). As the structural anchor of 
myofibrils inside myofibers, costameres may exert mechanosensory capabilities through 
their two major protein constituents, the dystrophin-associated glycoprotein complex (DGC) 
and the focal adhesion vinculin-talin-integrin system (VTI) (Anastasi, Amato et al. 2003, 
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Bamman, Roberts et al. 2018, Wackerhage, Schoenfeld et al. 2019). One prominent 
example is the costamere and primary DGC protein dystrophin, mutations of which cause 
severe muscular dystrophies such as Duchenne muscular dystrophy, in which irreparable 
myofiber damage accumulates (Jaka, Casas-Fraile et al. 2015). Importantly, dystrophin 
levels decrease in aging skeletal muscle, causing increased susceptibility to mechanically 
induced damage (Hughes, Wallace et al. 2015). While both the DGC and the VTI are 
attractive candidate mechanotransducers in skeletal muscle hypertrophy signaling, the exact 
way by which they may translate mechanical stimuli into biochemical signals requires 
further investigation. 
 
The lipid second messenger phosphatidic acid (PA) may prove itself an intermediate 
mechanotransducer, as PA directly activates mTORC1 upon contractile activity (Hornberger 
2011, Jacobs, Goodman et al. 2014). Upon physical activity, diacylglycerol kinase zeta 
(DAGKZ) synthesizes PA via phosphorylation of diacylglycerol (Figure 1-2), thus suggesting 
DAGKZ to be a mechanosensitive enzyme capable of increasing PA levels and thereby 
activating mTORC1-mediated upregulation of protein synthesis (You, Lincoln et al. 2014). 
Nevertheless, while oral PA feeding increases muscle mTORC1 activity and MPS rates, the 
exact mechanism by which mechanical load induces DGKZ activity is once again not really 
understood (Mobley, Hornberger et al. 2015). Phosphatidic acid signaling can also be 
activated through the conversion of phosphatidylinositol 4, 5-bisphospate into PA, which is 
catalyzed by phospholipase Cγ1 (PLCG1). This conversion happens in a mechanosensitive 
way through attachment to the extracellular matrix, which can vary greatly in its stiffness, 
and also activates the Hippo signaling pathway with its effector proteins yes-associated 
protein 1 (YAP1) and its paralog WW domain containing transcription regulator 1 
(WWTR1/TAZ) (Meng, Qiu et al. 2018). Both YAP1 and WWTR1 are regulated by 
mechanical cues and mediate cellular responses to stiffness of the extracellular matrix 
(Halder, Dupont et al. 2012). This regulation works through the activation of the ras-
related protein Rap-2a (RAP2A), which itself is activated by low extracellular matrix stiffness 
and acts as an intracellular signal transducer for YAP1 and WWTR1 (Meng, Qiu et al. 2018). 
Therefore, mechanical load may activate YAP1 and WWTR1 through PA-mediated RAP2A 
activation. Activated YAP1 and WWTR1 then increase levels of the high-affinity leucine 
 General introduction 
23 
transporter LAT1 (also known as SLC7A5) mainly via co-activating TEA domain family 
transcription factors (TEAD), presumably sensitizing the contracting muscle to leucine-
mediated mTORC1 activation (Hansen, Ng et al. 2015, Dupont 2016). Extracellular matrix 
stiffness may also be affected by RE-induced myofiber and whole-muscle swelling, thus 
providing a potential mechanism by which mechanical stimuli influence cellular signaling 
pathways (Farup, de Paoli et al. 2015, Wackerhage, Schoenfeld et al. 2019). 
Furthermore, it has recently been shown that YAP signaling, while functional, is 
constitutively active in the mdx mouse model for Duchenne muscular dystrophy and that this 
hyperactivation of YAP may render muscles unresponsive to mechanical load. This could be 
due to an increased state of “pre-stress” with increased cytoskeletal and extracellular matrix 
stiffness (Iyer, Shah et al. 2019). Taken together, muscle contractile activity can increase PA 
production, which leads to mTORC1 activation through the Hippo signaling pathway with its 
effectors YAP1 and WWTR1 through activation of RAP2A. Yet, this once again illustrates 
intermediate mechanotransductive pathways, but does not reveal the primary 
mechanosensor itself, the identification of which remains to be achieved in future research 
efforts. 
 
Figure 1-2. Mechanoregulation of mTORC1 activity via phophatidic acids. Diacylglycerol kinases 
(DAGKs), lysophosphatidic acid acyltransferases (LPAATs) and phospholipase D (PLD) synthetize 
phosphatidic acids (PAs) that in turn can activate mTORC1 signaling, influencing muscle protein 
synthesis. The exact mechanism by which a mechanical stimulus induces PA synthesis is still 
unknown. Adapted from (Hornberger 2011).  
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Apart from costamere-based mechanotransduction through the DGC and VTI, titin has 
emerged as a potential mechanosensor during muscle contraction (Kruger and Kotter 
2016). Titin is the largest known protein and makes up around 10% of total muscle protein 
content, so an 80 kg adult human on average carries about 0.5 kg of it (Labeit, Kolmerer et 
al. 1997). Titin is critical for muscle function, and mutations in its gene can cause various 
myopathies of skeletal and cardiac muscle (Savarese, Sarparanta et al. 2016). The 
filamentous molecules of titin span from the Z-line to the M-line (which marks the middle of 
a sarcomere) of the sarcomeres, thus forming a third filament system next to actin and 
myosin. Therefore, titin plays an essential role for the structural integrity of the sarcomere 
and the passive tension response of a stretched myofiber. Different length-variants of titin 
are expressed between cardiac and skeletal muscle, providing an explanation for the ~10-
fold difference in passive tension between these muscle types (Linke, Popov et al. 1994). In 
skeletal muscles the so-called N2A titin isoform type is expressed in many muscle-specific 
splice variants, varies in its size between 3.3 and 3.7 MDa, and thus governs myofibrillar 
passive stiffness (Neagoe, Opitz et al. 2003). In addition to its structural support and role 
in myofiber elasticity, titin contains a stretch-activated c-terminal kinase domain. When 
stretch is applied to titin, this pulls several amino acids out of its usually blocked ATP-binding 
pocket, thus allowing ATP to bind, causing autophosphorylation and the subsequent 
activation of titins’ kinase domain (Puchner, Alexandrovich et al. 2008). In its activated 
form, titin kinase interacts directly with the autophagy cargo receptor NBR1 (NBR1), which 
forms a signaling complex with the ubiquitin-binding protein sequestosome 1 
(SQSTM1/p62) and muscle ring finger 2 (MuRF2/TRIM55). Titin-kinase-activated NBR1 
then targets SQSTM1 to the sarcomere, where it in turn interacts with MuRF2 and potentially 
prevents its nuclear translocation and thus its negative impact on hypertrophic signaling, as 
mechanical inactivity induces nuclear translocation of MuRF2 (Lange, Xiang et al. 2005). 
Furthermore, the titin-kinase-activated NBR1/SQSTM1-complex is involved in muscle 
protein balance and promotes proteasomal degradation by facilitating protein 
ubiquitination, as well as by targeting poly-ubiquitinated proteins to the autophagic protein 
turnover machinery via the autophagosomal membrane anchor microtubule-associated 
protein 1A/1B-light chain 3 (LC3) (Pankiv, Clausen et al. 2007, Seibenhener, Geetha et al. 
2007, Waters, Marchbank et al. 2009). Together, these findings suggest a way for titin to 
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“sense” mechanical stretch and to regulate protein turnover and gene expression in muscle 
cells. Titin thus serves as a candidate for pharmacological interventions aimed at 
ameliorating muscle loss in different disease conditions. Nevertheless, upon muscle 
contraction the forces acting on titin molecules actually decrease as it goes slack, calling into 
question its role as a true “mechanoreceptor”.  
 
Many more potential mechanosensors were recently investigated than described 
here, but the evidence remains mostly indirect and is difficult to interpret. It remains to be 
shown whether muscle cells actually have a unique mechanosensing system that goes 
beyond universal focal adhesion proteins such as costameres, which are present in most cell 
types and sense their mechanical surroundings. Resistance exercise provides a plethora of 
different kinds of stimuli that are difficult to isolate from one another. Knockout models of 
putative hypertrophy mediators are limited in their usefulness due to the knockout often 
causing myopathies and dystrophies, as the proteins in question are often required for 
normal muscle function. Targeted and inducible mouse models may help circumvent some of 
these limitations in future research. 
 
Approaches to ameliorate progressive skeletal muscle wasting in disease 
Various myopathies and diseases, such as Duchenne muscular dystrophy and cancer 
cachexia, lead to progressive skeletal muscle wasting and functional deterioration, which 
negatively influences quality of life and survival. Skeletal muscle mass losses incurred via 
certain muscular dystrophies or cancer-related mass losses are not always reversible via 
nutritional interventions or exercise alone (Rybalka, Timpani et al. 2015, Bruggeman, 
Kamal et al. 2016, Ryder, Leadley et al. 2017, Schmidt, Rohm et al. 2018). Although 
moderate intensity exercise is generally regarded to be beneficial, it can sometimes even 
worsen the condition, i.e. due to structural instability of the sarcolemma or due to metabolic 
perturbations caused by disease (Tisdale 1997, Siciliano, Simoncini et al. 2015, Chico, 
Ricci et al. 2017). Efforts so far have concentrated a lot on counteracting progressive skeletal 
muscle wasting by pharmacologically increasing muscle mass. 
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Figure 1-3. Atrophy signaling pathways. Atrogene expression can be induced via a variety of 
pathways upon a catabolic state. Activated ActRIIB-signaling is mediated via SMAD2/3 and regulates 
muscle mass via FoxO-dependent atrogene transcription. Glucocorticoids are catabolic factors that 
activate atrogene transcription upon binding glucocorticoid receptors, while inflammatory cytokines 
may act via cytokine receptors to influence atrogene expression via NF-κB. ActRIIB, activin receptor 
type IIB; NF-κB, nuclear factor-κB; Adapted from (Cohen, Nathan et al. 2015). 
 
Some recent approaches are targeting the myostatin/activin type II receptor (ActRII) 
pathway, which plays a major role in the regulation of skeletal muscle mass (Lee and 
McPherron 2001, Souza, Chen et al. 2008). Activation of the ActRII complex on the muscle 
membrane induces SMAD family member 2/3-mediated transcription, which then leads to 
FoxO-dependent transcription (Figure 1-3). This ultimately results in increased muscle 
protein breakdown via the ubiquitin-proteasome system and autophagy (Han, Zhou et al. 
2013). The activation of SMAD2/3-mediated transcription furthermore leads to the 
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inhibition of muscle protein synthesis by suppressing Akt/PKB-signaling (Sartori, Milan et 
al. 2009). Taken together, ActRII complex activation perturbs muscle protein balance and 
drives muscle wasting. Consequently, ActRII pathway interference has been considered in 
the treatment of muscular dystrophies with progressive muscle wasting resulting in 
weakness and frailty (Amthor and Hoogaars 2012). Antibodies were devised that 
specifically block ActRIIs and prevent myostatin from binding. In doing so, dramatic 
increases in skeletal muscle mass beyond simple myostatin inhibition have been reported in 
mice (Lach-Trifilieff, Minetti et al. 2014, Morvan, Rondeau et al. 2017). Furthermore, one 
of these antibodies, BYM338 (Bimagrumab), was reported to prevent glucocorticoid-induced 
atrophy and weakness in mice, highlighting the immense therapeutic potential of such agents 
(Lach-Trifilieff, Minetti et al. 2014). BYM338 subsequently entered clinical trials and 
proved effective in increasing muscle mass and mobility in older adults with sarcopenia 
(Rooks, Praestgaard et al. 2017). In a different approach of ActRII inhibition, an adeno-
associated virus-mediated gene transfer improved muscle mass and absolute strength in a 
mouse model of mild spinal muscular atrophy (SMA), but did not prevent the reduction in 
motor units (Liu, Hammers et al. 2016). Importantly, inhibition of the ActRII pathway with 
pharmacological means successfully counteracted progressive muscle wasting and 
prolonged lifespan in several animal models of disease (Han, Zhou et al. 2013). However, 
while skeletal muscle mass and absolute contractile force were increased by inhibition of the 
ActRII pathway, the specific muscle contractile force did not improve accordingly, indicating 
that the obtained muscular hypertrophy, while beneficial in absolute terms, was not entirely 
functional (Liu, Hammers et al. 2016).  
 
The force-producing capability of a muscle is directly proportional to its size and in 
turn the cross-sectional area of its myofibers. Skeletal muscle hypertrophy may occur even 
in the absence of satellite cells, which are skeletal muscle stem cells capable of donating their 
nuclei via fusion to increase the myonucleic pool of myofibers (Jackson, Mula et al. 2012, 
Murach, Fry et al. 2018). Individual myonuclei of a myofiber can only transcriptionally 
support a limited, but flexible amount of sarcoplasmic volume, termed their myonuclear 
domain (MND) (Van der Meer, Jaspers et al. 2011, van der Meer, Jaspers et al. 2011, 
Kirby, Patel et al. 2016). Importantly, the size of individual MNDs in hypertrophic muscles 
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has significant effects on specific contractile force and myosin content. Fast-twitch myofibers 
(e.g. EDL muscle) were reported to have larger MNDs compared to slow-twitch myofibers 
(e.g. Soleus (SOL) muscle), which suggests that hypertrophying fast-twitch muscles might 
reach the upper limits of their MNDs relatively quickly (Bruusgaard, Liestol et al. 2003, 
Qaisar, Renaud et al. 2012). The incorporation of additional myonuclei during de novo 
hypertrophy might consequently be crucial once the available MNDs are fully saturated (Goh 
and Millay 2017). The apparent lack of proportional strength gains observed with ActRII-
pathway inhibition may thus partly be explained by a lack of additional myonuclei 
contributed by satellite cells (Qaisar, Renaud et al. 2012). Indeed, muscle hypertrophy 
driven by myostatin blockade requires little or no satellite cell activity (Amthor, Otto et al. 
2009). It therefore seems plausible that non-mechanically mediated skeletal muscle 
hypertrophy differs fundamentally from overload-induced hypertrophy (Murach, Fry et al. 
2018). The underlying molecular mechanisms that trigger muscular growth and the 
inevitable adverse effects of a general long-term ActRII-pathway inhibition, which is not 
limited to skeletal muscle, remain to be thoroughly investigated. 
 
A lot of focus has been directed towards finding pharmacological means that 
counteract muscle mass losses incurred in different disease conditions, with the aim of 
ameliorating weakness and frailty, restoring locomotive autonomy, and improving quality of 
life in patients. Many such approaches, including the ones described here, successfully 
increase muscle mass and absolute muscle strength, but the obtained muscle mass often is 
not completely functional in terms of specific strength. This limits the therapeutic potential 
of such pharmacological interventions, as increasing muscular strength to ameliorate 
weakness is often the primary goal. Future research efforts should therefore focus on finding 
factors that better improve skeletal muscle force alongside muscle mass. 
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1.2 The neuromuscular system 
Bodily movement, posture, and breathing are under the control of the neuromuscular system, 
which is composed of skeletal muscles, as well as a neural circuit consisting of sensory and 
motor neurons. The motor neurons of the neuromuscular system can be subdivided into 
alpha-, beta- and gamma-motor neurons, each type of which constitutes different structural 
and functional properties. Alpha motor neurons innervate extrafusal myofibers, which are 
responsible for muscle contraction, whereas gamma motor neurons innervate intrafusal 
myofibers of the muscle spindle, which is involved in proprioception (Kroger 2018). Beta 
motor neurons innervate the intrafusal myofibers of the muscle spindles and additionally 
form collateral connections with extrafusal myofibers as well (Adal and Barker 1965, 
Banks 1994). Importantly, the axons of all three types of motor neurons become myelinated, 
which dramatically increases their action potential transmission rates.  
 
The neuromuscular system is functionally organized into so-called motor units. A 
motor unit comprises a particular (alpha-) motor neuron as well as all the myofibers it 
innervates. Individual motor neurons may differ substantially in their nerve impulse firing 
patterns. Motor units comprised primarily of slow-twitch, oxidative myofibers are 
characterized by a tonic low-frequency, long-lasting impulse activity, whereas motor units 
primarily comprised of fast-twitch, glycolytic fibers generally display a more phasic, high-
frequency and short-duration impulse activity (Hennig and Lomo 1985, Schiaffino and 
Reggiani 2011). The firing pattern of a motor units’ motor neuron and the myofiber type of 
the fibers it innervates correspond well based on fatigue resistance (Burke, Levine et al. 
1973). It therefore seems likely that the nervous discharge pattern exerts strong, if not 
complete influence on myofiber type.  
 
The neuromuscular junction (NMJ) is the interface at which motor neuron axons 
contact myofiber membranes and innervate them. Neuromuscular junctions are specialized, 
tripartite synapses consisting of the presynaptic motor nerve terminal, the perisynaptic basal 
lamina, and the postsynaptic specialization of the muscle membrane (Figure 1-4). While 
myofibers are wrapped by a basal lamina along their entire length, the perisynaptic part of 
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the basal lamina differs in its molecular composition, as it contains molecules secreted by 
both the muscle and the nerve (Patton, Miner et al. 1997). The motor axon nerve terminal 
is capped by specialized glial cells, the so-called perisynaptic or terminal Schwann cells, 
which contribute to the organization of the NMJ (Arbour, Vande Velde et al. 2017). The 
NMJ is additionally covered by one or several so-called kranocytes, which are fibroblast-like 
cells with a yet poorly defined role that extent their cytoplasmic processes over the entire 
synaptic endplate area (Court, Gillingwater et al. 2008, Sugiura and Lin 2011). Synaptic 
transmission at the NMJ is extremely efficient and reliable. The amount of acetylcholine 
receptors (AChR) situated at the junctional fold shoulders of the deeply folded postsynaptic 
specialization of the muscle membrane, as well as the amount of acetylcholine vesicles 
released from the presynaptic nerve terminal per nerve impulse, are much greater than what 
would be necessary to cross the membrane potential threshold. This margin of safety, coined 
“safety factor”, ensures reliable muscle contraction (Wood and Slater 2001).  
 
 
Figure 1-4. Schematic representation of the structure of the neuromuscular junction (NMJ). 
Adapted with minor modifications from (Li, Xiong et al. 2018). 
 
Fast-twitch type II and slow-twitch type I myofibers have developed structural and 
functional specializations of their NMJs. Postsynaptic fold density and concomitant voltage-
gated sodium channel accumulation, along with absolute nerve terminal area are larger at 
NMJs of fast-twitch myofibers (Milton, Lupa et al. 1992). The greater density of sodium 
channels enables fast-twitch fibers to respond to the fast firing rate of the corresponding 
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motor neuron, and results in powerful, but short-lived contractions. Yet, when normalized 
for fiber diameter, nerve terminal area is actually larger in slow-twitch fibers. Additionally, 
quantal content, the amount of neurotransmitter per synaptic vesicle, is larger at NMJs of 
fast-twitch fibers, yet slow-twitch fiber NMJs release far more vesicles per action potential 
(Prakash, Miller et al. 1996). Thus, initial acetylcholine release upon stimulation is greater 
in fast fibers, and so is the endplate potential (Reid, Slater et al. 1999). However, upon 
repeated stimulation, synaptic depression sets in, resulting in a reduction of synaptic vesicles 
released per stimulus and a pronounced decline in fast-fiber safety factor (Gertler and 
Robbins 1978). The enzyme acetylcholinesterase (ACHE) quickly and efficiently breaks 
down acetylcholine into choline and acetate, thus removing it from the synaptic cleft to allow 
subsequent stimulations of the AChRs as well as preventing their over-activation. 
Importantly, fast myofiber NMJs contain about four times as much ACHE, presumably 
enabling faster stimulation patterns (Pregelj, Trinkaus et al. 2007). 
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The Agrin/Lrp4/MuSK regulatory pathway in neuromuscular junction 
formation, structure and function 
Skeletal myofibers are multinucleated syncytia and typically contain dozens, if not hundreds 
of myonuclei (muscle cell nuclei). Only a small subset of these aggregate directly underneath 
the NMJ, and express a distinct gene program (Rossi, Vazquez et al. 2000, Ruegg 2005). 
These so-called fundamental myonuclei (Figure 1-5) presumably express most of the 
components necessary for the postsynaptic specializations of the myofiber membrane at the 
NMJ and expression of these components becomes silenced in extrajunctional myonuclei 
concomitant with innervation (Schaeffer, de Kerchove d'Exaerde et al. 2001). An 
extensive body of research has elucidated many different signaling pathways that contribute 
to the regulation of the NMJ gene program and enable the various post – and pre-synaptic 
specializations of the NMJ. The clustering of AChRs at the junctional fold shoulders is one of 
the central processes that are under the regulation of many different pathways. 
 
 
Figure 1-5. A small number of so-called fundamental myonuclei underlie the neuromuscular 
junction and express a distinct gene program compared with myonuclei elsewhere in a 
myofiber. α-BTX: α-Bungarotoxin staining postsynaptic acetylcholine receptors. DAPI: 4′,6-
diamidino-2-phenylindole stains nuclei. Merge: Composite image. Scale bar: 25 μm. 
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Agrin is a heparan sulfate proteoglycan (HSPG) synthetized by motor neurons and is 
subsequently transported down the axon and released into the synaptic basal lamina of the 
NMJ, where it exerts its function and triggers postsynaptic differentiation, including AChR 
clustering (Campanelli, Hoch et al. 1991, Ruegg, Tsim et al. 1992). Motor neuron-derived 
agrin is central to the most prominent regulatory nexus of AChR clustering at the NMJ, the 
complex of muscle-specific tyrosine kinase (MuSK) and low-density lipoprotein receptor-
related protein 4 (Lrp4) (Figure 1-6). Lrp4 serves as a receptor for neural agrin, binding of 
which to Lrp4 triggers phosphorylation of MuSK and is essential during the earliest steps of 
NMJ assembly (DeChiara, Bowen et al. 1996, Weatherbee, Anderson et al. 2006, Kim, 
Stiegler et al. 2008). Another essential process is the additional stabilization of MuSK by the 
muscle-specific adaptor protein docking protein 7 (Dok-7/Dok7) (Okada, Inoue et al. 
2006).
 
Figure 1-6. Motor neuron-derived agrin triggers a variety of intracellular signaling pathways 
regulating acetylcholine receptor clustering through the Lrp4-MuSK complex. Lrp4 serves as a 
receptor for agrin and triggers the phosphorylation of MuSK, which leads to Lrp4-MuSK dimerization. 
Dok-7 further stabilizes the phosphorylation of MuSK and a large variety of downstream signaling 
pathways is subsequently activated. Not all pathways illustrated here have been validated in vivo. 
Stars indicate protein-protein interactions. Adapted from (Wu, Xiong et al. 2010). 
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A lack of agrin results in defective NMJs in loss-of-function mouse models, underlining 
the importance of this regulatory pathway in NMJ formation (Gautam, Noakes et al. 1996). 
While agrin is also expressed by myofibers and by Schwann cells, which are located at the 
NMJ, neural agrin is several orders of magnitude more potent in inducing AChR clustering 
(Reist, Werle et al. 1992, Gesemann, Denzer et al. 1995). A lack of MuSK results in highly 
branched motor neuron nerve terminals that innervate a much broader region, indicating 
that involvement of the Lrp4-MuSK-complex not only in post-, but also in pre-synaptic 
differentiation (DeChiara, Bowen et al. 1996, Lin, Burgess et al. 2001, Yang, Arber et al. 
2001). 
 
The 43 kDa receptor-associated protein of the synapse (RAPSYN) is a synaptic 
peripheral membrane protein required for AChR clustering (Gautam, Noakes et al. 1995). 
RAPSYN also stimulates MuSK activity by clustering it as well (Gillespie, Balasubramanian 
et al. 1996). RAPSYN anchors AChRs in the synaptic fold shoulders by interacting with α-
actinin and β-catenin, thus linking them to the postsynaptic actin cytoskeleton. While α-
actinin is an actin crosslinker, β-catenin regulates α-catenin-dependent actin polymerization 
(Yamada, Pokutta et al. 2005). Lack of either protein results in deficiencies of neural agrin-
induced AChR clustering (Apel, Roberds et al. 1995, Moransard, Borges et al. 2003, 
Zhang, Luo et al. 2007, Dobbins, Luo et al. 2008). MuSK, RAPSYN, and the dystrophin-
associated glycoprotein complex (DGC) link the postsynaptic actin cytoskeleton to the 
synaptic basal lamina (Figure 1-7). The DGC consists of utrophin (UTRN; the synaptic 
homolog of dystrophin), which is linked to the actin cytoskeleton, three different groups of 
transmembrane proteins, namely the sarcoglycans, dystroglycan and sarcospan, as well as 
two groups of cytoplasmic proteins, the dystrobrevins and syntrophins (Singhal and Martin 
2011). Dystroglycan is posttranslationally cleaved into α- and β-dystroglycan (Ibraghimov-
Beskrovnaya, Ervasti et al. 1992). Importantly, α-dystroglycan becomes extensively 
glycosylated, and these modified sugar side-chains are required for the binding of α-
dystroglycan to its numerous ligands at the synaptic basal lamina, including agrin, various 
laminins, perlecan, and neurexin (Ervasti and Campbell 1993, Talts, Andac et al. 1999). 
Mutations of the various enzymes that are involved in the intricate glycosylation of α-
dystroglycan can cause a variety of congenital myasthenic syndromes (CMS), which are a 
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class of inherited disorders of neuromuscular transmission characterized by early-onset 
fatigable muscle weakness (Endo 2005). Genetic manipulations of the extent of 
glycosylation of α-dystroglcan provided further evidence for its stabilizing role at the NMJ, as 
well as the importance of glycosylation events for the structure and function of the synaptic 
basal lamina (Hara, Balci-Hayta et al. 2011, Goddeeris, Wu et al. 2013). Apart from α-
dystroglycan, many other proteins at the NMJ are glycosylated, including but not limited to 
agrin and MuSK, perlecan, and the AChRs themselves (Martin and Sanes 1995, Martin, 
Scott et al. 1999, Yamaguchi 2002). The N-terminal extracellular domains of AChR subunits 
contain N-linked glycans, glycosylations of which ensure proper AChR assembly and folding 
(Prives and Bar-Sagi 1983, Gehle, Walcott et al. 1997). While it has been established that 
specific glycans containing β-linked N-acetylgalactosamines are concentrated at the NMJ, the 
biological meaning of these highly diverse glycosylation events remains poorly understood 
and animal models investigating the impact of glycosylation events on NMJ structure and 
function are needed (Herbst, Iskratsch et al. 2009). 
 
 
Figure 1-7. The dystrophin-associated glycoprotein complex (DGC) anchors important 
synaptic components of the basal lamina to the actin cytoskeleton. The extensively glycosylated 
α-dystroglycan (αDG) links its diverse binding partners within the synaptic basal lamina via the 
membrane-spanning β-dystroglycan (βDG) and cytoplasmic utrophin to the actin cytoskeleton (f-
actin). Adapted from (Tintignac, Brenner et al. 2015). 
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A lack of RAPSYN, similar to a lack of MuSK or agrin, results in AChR deficiencies 
(Cossins, Burke et al. 2006). Mutations in the gene encoding for RAPSYN are causative for 
CMS, which often are treatable with cholinergic agonists (Maselli, Dunne et al. 2003, 
Cossins, Burke et al. 2006, Milone, Shen et al. 2009). Similarly, mutations in Dok-7, Lrp4, 
MuSK or AChRs themselves may cause different kinds of CMS requiring different types of 
treatment (Maselli, Arredondo et al. 2010, Rodriguez Cruz, Palace et al. 2014, 
Bevilacqua, Lara et al. 2017). Over 30 different CMS are recognized today (Figure 1-8), but 
we most likely still do not know more than half of the possible causative mutations of 
different NMJ components and identification of the disease-causing genes is crucial for 
determining optimal therapeutic measures (Engel 2018). 
 
 
Figure 1-8. Currently identified congenital myasthenic syndromes. Adapted from (Engel 2018). 
 
In addition to the MuSK-activity regulation by agrin, Lrp4, Dok-7, and RAPSYN, MuSK 
also interacts with tumorous imaginal discs (TID1/DNAJA3). TID1 is necessary for Dok-7 
binding to MuSK in response to neural agrin (Linnoila, Wang et al. 2008). MuSK becomes 
rapidly internalized upon its activation, a process that is mediated by the direct interaction 
with the ATPase N-ethylmaleimide sensitive fusion protein (NSF) and is required for MuSK 
internalization (Zhu, Yang et al. 2008). MuSK internalization can lead to its proteasomal 
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degradation mediated in part by the E3 ubiquitin ligase PDZ domain containing RING finger 
3 (PDZRN3), which constitutes an important regulator of MuSK signaling contributing to 
precise and dynamic control of synaptic development (Lu, Je et al. 2007). 
 
Subsynaptic transcriptional regulation of the neuromuscular junction gene 
program 
Genes coding for components of the NMJ often show nearly exclusive synaptic expression 
and become silenced in the extrasynaptic regions of a myofiber upon innervation. Site-
directed mutagenesis of such synaptically expressed gene promotors revealed a six base pair 
DNA element conferring this synaptic specificity, the so-called N-box (Koike, Schaeffer et al. 
1995, Duclert, Savatier et al. 1996). Importantly, a point mutation in the N-box element of 
the acetylcholine receptor epsilon subunit (CHRNE) promotor was reported to cause 
congenital myasthenia due to reduced expression of CHRNE at the NMJ (Nichols, Croxen et 
al. 1999, Ohno, Anlar et al. 1999). Moreover, subsynaptic expression of utrophin (UTRN) 
and acetylcholinesterase (ACHE) is also controlled by the presence of N-box elements in their 
respective gene promotors (Gramolini, Angus et al. 1999, Khurana, Rosmarin et al. 
1999). The mere presence of an N-box element in a genes’ promotor is not sufficient to 
explain its targeted expression to the NMJ. Indeed, the N-box is a conserved ETS binding site 
and likely facilitates the binding of ETS-related transcription factors, the most prominent 
example being the growth-associated binding protein alpha (GABPα), which is required for 
postsynaptic differentiation in vivo (Fromm and Burden 1998, Schaeffer, Duclert et al. 
1998, Briguet and Ruegg 2000). Transcriptional activation of genes by GABPα via its ETS 
domain requires heterodimerization with the GABPβ subunit, the latter of which provides a 
nuclear localization sequence and a transcriptional activation domain (LaMarco, Thompson 
et al. 1991, Sawa, Goto et al. 1996, Briguet and Ruegg 2000). However, enrichment of 
GABPα mRNA at the NMJ is relatively minor (Schaeffer, Duclert et al. 1998) and conditional 
inactivation of GABPα in skeletal muscle indicated that it is in fact dispensable for NMJ 
formation and subsynaptic gene expression (Jaworski, Smith et al. 2007), or at the very 
least causes only minor structural and functional alterations of the NMJ (O'Leary, Noakes et 
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al. 2007). Taken together, these findings imply that GABPα most likely is not the central 
regulator of the NMJ gene program. Another ETS-related transcription factor, ETS variant 5 
(ETV5/ERM) was found to facilitate the synapse-specific expression of many, but not all 
synaptic genes (Figure 1-9), although direct binding to the N-box element has not been 
confirmed as of yet (Hippenmeyer, Huber et al. 2007). However, while ETV5 depletion 
caused synaptic defects and symptoms resembling that of congenital myasthenia, it did not 
lead to complete disruption of synaptogenesis, implying that ETV5 might act as a synaptic 
gene expression booster rather than being an all-or-nothing trigger. It is not clear how 
expression of ETV5 itself becomes subsynaptically restricted as its expression is independent 
of innervation status (Hippenmeyer, Huber et al. 2007). The complete picture of how 
exactly the transcriptional regulation of the NMJ gene program is regulated still remains to 
be fully elucidated. 
 
 
Figure 1-9. ETV5/Erm is partially in control of the subsynaptic gene program of the 
neuromuscular junction. There are at least two alternative transcriptional pathways involved in the 
regulation of subsynaptic gene expression. Erm regulates many, but not all subsynaptically expressed 
genes. Adapted with minor modifications from (Hippenmeyer, Huber et al. 2007). 
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2 Aims of the Thesis 
Part I / Manuscript I: Ladder climbing as a physiological resistance exercise model for 
skeletal muscle hypertrophy in mice 
Physical exertion has been linked to increased muscular size, performance and health 
benefits. A sizable body of research has shed light on a plethora of complicated processes that 
control the adaptation of skeletal muscles to the physical demands placed on them. We now 
understand that regular resistance exercise (RE) triggers a transient increase in net muscle 
protein balance by inducing synthesis and concomitantly reducing breakdown of muscle 
protein, thus facilitating the accretion of muscle mass over time. A multitude of underlying 
pathways were discovered and thoroughly investigated, yet it remains unclear how exactly 
the mechanical stimulus of RE is converted into these biochemical signaling events required 
for muscular growth. The concept of a dedicated mechanoreceptor of muscle cells remains 
attractive, but no such protein was identified so far. A better understanding of how muscle 
growth is mechanically activated could lead to the development of pharmacological 
treatment strategies to counteract muscle wasting caused by disuse, disease and aging. 
 
In the first part of this thesis, we aimed to investigate the effects of RE on the mouse 
skeletal muscle transcriptome to identify putative mechanosensing proteins involved in 
adaptive hypertrophy. In order to accomplish this goal, we aimed to establish a physiological 
RE model in mice that would avoid the confounding effects of the currently available 
methodologies. 
 
Objective I: Establish a physiological resistance exercise model for mice and investigate the 
effect of chronic resistance exercise on the skeletal muscle transcriptome. 
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Part II / Manuscript II: Identification of Novel Synaptic Components by Transcriptome 
Profiling of the Murine Neuromuscular Junction 
The neuromuscular junction (NMJ) has been studied as a prototypical synapse for over a 
century and ample research on it has contributed immensely to our understanding of the 
inner workings of synapses of the central nervous system. We now understand a lot about 
how the NMJ conducts signal transmission from motor neurons to the skeletal muscles and 
that it possesses an extensive safety margin to ensure reliable muscle contractions. Still, the 
NMJ can be subject to various conditions that perturb its function, causing potentially lifelong 
disability or even premature death. We hypothesized that the emergence of powerful next-
generation sequencing technologies in recent years enables us to establish a more complete 
picture of the components making up the NMJ and thus provide novel target genes for 
consideration in the treatment of neuromuscular diseases affecting the NMJ. 
 
In the second part of this thesis, we aimed to utilize laser-capture microdissection and 
next-generation RNA-sequencing to investigate the transcriptome of the fundamental 
myonuclei underlying the NMJ in two different skeletal muscles and identify novel NMJ 
components. 
 
Objective II: Identify novel components of the neuromuscular junction in the EDL and SOL 
muscles using next-generation RNA-sequencing. 
 
Part III / Sinergia Project: Effects of Aging on the Neuromuscular Junction 
Transcriptome 
The third and final part of this thesis describes the findings of our contribution to the 
“Sinergia project for muscle wasting at high age”, which was a joint effort of several research 
groups. In simple terms, sarcopenia is a multifaceted disease associated with the aging 
process, which leads to skeletal muscle mass wasting and functional impairments, severely 
impacting quality of life. The mechanisms underlying sarcopenia are still poorly understood, 
but evidence suggests that aging causes structural and functional perturbations of the NMJ in 
rodents. It is therefore conceivable that aging leads to gradual changes in the synaptic gene 
expression program, thus contributing to the observed disturbances. Within the framework 
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of the project, we received skeletal muscle samples (tibialis anterior muscle; TA) from 10-
month-old and 30-month-old mice. Two different interventions, treatment with rapamycin 
and caloric restriction, were applied to the old groups starting from the age of 15 months. 
Our task was to generate RNA-sequencing datasets comparing the transcriptomes of young 
(10-month-old) and old (30-month-old) NMJs and to see how aging alters the NMJ 
transcriptome, as well as assess whether the different treatments ameliorated the putative 
aging-related adverse changes. 
 
Objective III: Determine whether aging leads to perturbations of the neuromuscular junction 
transcriptome. 
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3.1 Abstract 
Despite numerous studies investigating the adaptive hypertrophic response of skeletal 
muscle to resistance exercise (RE) it remains unclear how exactly a mechanical stimulus 
translates into muscular growth. Therefore, we aimed to investigate the effects of RE on the 
mouse skeletal muscle transcriptome to identify putative mechanosensing-involved proteins 
in adaptive hypertrophy. We trained ten adult male C57BL/6JRj wild-type mice to climb a 
60 cm high and near-vertical ladder device while carrying progressively heavier loads 
attached to their tails. Twelve weeks of 5-days-per-week RE enabled the mice to carry up to 
an additional 32 g, or roughly 110% of their own bodyweight for five sets of 5 min (15 to 20 
complete ladder climbs per set). Although the mice vastly improved their ability of climbing 
the ladder device with heavier weights and increased training volume, we did not observe 
significant muscular hypertrophy or functional adaptations elicited by RE. Potential reasons 
for this are motivational issues of the animals and insufficient training stimulus intensity, as 
options of increasing attached weight to the animals were limited. Future approaches should 
aim to improve training stimulus intensity by increasing the amount of weight increments 
and absolute load, for example by utilizing denser weight materials. 
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3.2 Introduction 
Skeletal muscle is a remarkably adaptive tissue that is capable of responding to metabolic as 
well as physical demands encountered in daily life. Skeletal muscle atrophies with disuse or 
malnourishment and hypertrophies upon increased contractile demands, for example in 
resistance exercise (RE) training (Mikesky, Giddings et al. 1991). Increasing lean body 
mass via RE is a widely pursued task by weight-lifting individuals and professional athletes 
alike, as there is a strong correlation between muscle cross-sectional area and muscular 
strength (Maughan, Watson et al. 1983). Additionally, maintenance of strength and muscle 
mass is directly associated with health and improved stress tolerance in the elderly, as well 
as throughout life (Wolfe 2006).  
 
Little is known about how the mechanical stimulus of skeletal muscle contractile 
overload translates into muscular growth and concomitant increases in strength. There is a 
variety of animal models developed to study overload-induced skeletal muscle hypertrophy. 
The ablation of different synergist muscles in the mouse hind limb (i.e. the Gastrocnemius 
(GAS) and Soleus (SOL) muscles) leads to a significant and chronic mechanical overload of 
the Plantaris (PLA) muscle. Significant increases in PLA muscle mass develop and are 
maintained two weeks (~87%), eight weeks (~120%) or even three months (~65%) after 
the intervention (Baldwin, Valdez et al. 1982, Roy and Edgerton 1995, Perez-Schindler, 
Summermatter et al. 2013). Yet, the acute hypertrophic adaptations in the synergist 
ablation (SA) model are masked by inflammation caused by the surgical nature of the 
intervention (Armstrong, Marum et al. 1979). This hampers the investigation and 
understanding of the early steps in overload-induced hypertrophic adaptations. 
Furthermore, the PLA muscle is chronically overloaded whenever the affected animal moves 
around in its cage. Unlike in human RE, there is no period of rest in order for the muscle to 
recover (i.e. supercompensation), which, paired with nutrition rich in amino acids, is crucial 
in human skeletal muscle growth. Indeed, overly short resting intervals between exercise 
bouts can lead to overtraining in humans, which may result in the deterioration of exercise 
performance (Fry and Kraemer 1997). 
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Interestingly, while the PLA muscle can double in size in response to SA, its maximum 
specific force does not increase proportionally. These functional deficits may in part be 
explained by an initial inflammatory swelling causing interstitial space enlargement and 
decreased protein concentration, while later changes might be due to intracellular changes 
(Kandarian and White 1989, Kandarian and White 1990). A time course of differential 
gene expression patterns in response to SA surgery is available (Chaillou, Lee et al. 2013). 
Unfortunately, the majority of top hits in the microarray data, especially during the first few 
days of the time course, are intermixed with genes associated with inflammation and immune 
response. While it seems plausible for these pathways to play important roles in the 
hypertrophic response (Koh and Pizza 2009, Tidball and Villalta 2010, Costamagna, 
Costelli et al. 2015), it cannot be ruled out that some if not most of these genes might be 
influenced by the surgery itself rather than by the mechanical overload. This makes it difficult 
to identify target genes and gene programs that may aid in understanding the complex 
transcriptional changes the hypertrophying muscle undergoes under mechanical load.  
 
Therefore, it would be ideal to be able to study gene expression upon the physiological 
stimulus of resistance exercise, mimicking intermittent human RE, and to gain novel insights 
into the workings of the conversion of a mechanical stimulus into the adaptation of skeletal 
muscle to overload. To our knowledge, no established physiological resistance exercise 
methodology capable of inducing robust skeletal muscle hypertrophy in mice was available 
at the time of this study (2015). A plethora of models was developed for use with the rat, for 
it is much easier to handle, motivate, and train them to conduct a certain task (Cholewa, 
Guimaraes-Ferreira et al. 2014). The rat animal model does not offer the same genetic tools 
that are available for mice, although the gap is closing (Ellenbroek and Youn 2016). Mice 
are natural-born climbers and capable of holding their own body weight even on an inverted 
grid for an extended period. Accordingly, we found the ladder-climbing model to be a very 
promising mode of RE that might also be adapted for use with mice. Here, the animal has to 
climb a vertical ladder at a certain angle (70-90°) while also carrying sufficient load to 
produce the need of physiological adaptation (i.e. hypertrophy).  
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In our study, we adopted the rat ladder-climbing model for use with mice to mimic 
human RE parameters and aimed to establish a physiological RE model that allows the study 
of transcriptional changes in hypertrophying mouse muscles with fully functional strength 
adaptations. To assess the efficacy of our RE model, we measured body composition and hind 
limb muscle weight, as well as grip strength and gene expression levels of putatively 
hypertrophy-related genes.  
 
3.3 Material and Methods 
Animals. Fifteen-week-old male C57B/6JRj wild-type mice (JANVIER LABS, France) were 
randomly assigned to either a resistance exercise group (EX; N = 10) or sedentary control 
group (SED; N = 8). Animals were fed an ad libitum, regular chow diet (Provimi 3432) and 
kept under a 12‐h/12‐h light–dark cycle (light phase: 06:00 am to 18:00 pm) in a 
temperature-controlled room (21-22°C). The SED animals were kept in their home cages 
throughout the duration of the study. Body composition was determined after 0, 3, 8, 10, and 
12 weeks with an EchoMRI-100 analyzer (EchoMRI Medical Systems). All experiments were 
performed in accordance with the principles of the Basel Declaration and with Federal and 
Cantonal Laws regulating the care and use of experimental animals in Switzerland, as well as 
institutional guidelines of the Biozentrum and the University of Basel. The protocol with all 
methods described here was approved by the cantonal veterinary office of the canton Basel-
Stadt, under consideration of the well-being of the animals and the 3R principle. 
 
Resistance exercise protocol. The EX animals were split into two training groups of five 
animals each for the duration of the study, as the ladder device only allowed for simultaneous 
training of five animals (Figure 3-1 A). The ladder was initially set to an inclination of about 
70°, and ample cushioning material was placed at the bottom of the ladder for safety in case 
a mouse would fall off the ladder grid during climbs. Before beginning the RE protocol, the 
mice were acclimatized to climbing the ladder in two sessions without any attached weight. 
Mice were placed at the bottom of the ladder and quickly climbed to the top, requiring the 
occasional prod at the base of the tail for motivation. Leaden bullet weights for fishing poles 
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were modified to enable temporary attachment to the base of the tail of a mouse via adhesive 
tape. Available weights were 11, 19, and 32 g. 
 
After the acclimatization sessions, the twelve-week RE protocol was started using 11 g 
weights for three sets of 5 min of continuous ladder climbing in session one. The rest period 
was 2 min between sets. A ladder climb counted as complete when a mouse climbed from the 
bottom of the ladder up to the top within 15 s. Upon reaching the top, mice were returned to 
the bottom immediately to perform another climb until a set was finished. Stopping and 
“coping behavior” (mice would jam the tips of their tails in between ladder steps, in order to 
rest the weight on the device itself) were initially quite common and required the occasional 
motivational prod to get them to climb again. Subsequent training sessions quickly lead to 
improved climbing speed and a reduction of falls and coping behavior. Set number and 
duration were continually increased until up to five sets of 5 min with 19 g of attached 
weight. Switching to 32 g of attached weight initially led to many falls and signs of 
exhaustion1 at around the third set of a session. After a month of 5-days-per-week training, 
the mice were able to handle the 32 g weights and successfully completed five sets of 5 min 
of ladder climbing, with six to eleven complete ladder climbs per set. At his point, ladder 
inclination was increased to from 70° to 80°, thus further increasing training intensity. 
Climbing performance continued to improve as mice completed more complete ladder climbs 
per training set in the following weeks. We attempted to increase the attached weight to 43 g 
by adding an additional 11 g weight to the 32 g one. While some mice managed to climb 
successfully, others had trouble coping and would inevitably fall. This might be due to most 
of the tail being covered by the weights, substantially inhibiting its use for balance. As no 
consistent amount of complete ladder climbs was achievable with 43 g, the exercise protocol 
was continued with only 32 g of attached weight, but the number of complete ladder climbs 
continued to improve from session to session. After twelve weeks of RE, the mice completed 
between 15 to 20 complete ladder climbs per set with 32 g of attached weight. 
 
                                                        
1 Mice would cling to the ladder steps without moving and even prodding would not get them to move up the 
ladder anymore. If this occurred, the set was stopped and the mice were set to rest. 
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Mice were sacrificed 48 h after their last training session by cervical dislocation to 
allow careful preparation of one EDL muscle per mouse for ex vivo contractile force 
measurements. The remaining hind limb muscles (Quadriceps, QUAD; gastrocnemius, GAS; 
tibialis anterior, TA; plantaris, PLA; extensor digitorum longus, EDL; soleus, SOL) were excised 
and weighed before snap-freezing in liquid nitrogen or embedding for cryosectioning (only 
GAS, SOL, and PLA) in 10% Tragacanth (Sigma-Aldrich, catalog no. G1128) using liquid 
nitrogen-cooled 2-methylbutane.  
 
Grip strength test. Maximal grip strength of all four limbs was measured after 0, 3, 8, 10, and 
12 weeks of training by using a grip strength meter (Chatillon). Briefly, mice were lifted 
gently by their tail and allowed to grip with all four limbs on a grid, which was attached to 
the grip strength meter. The mice were then pulled horizontally backwards and away from 
the grip strength meter, until they released their grip and let go of the grid. Peak force in 
grams force (gf) was measured. The mean of the highest three out of five measurements was 
used for the analysis. Measurements were taken with 1-min intervals of recovery in-between. 
Care was taken to always conduct the experiment in the same room and at the same time of 
day, which was on a Monday following a weekend, during which no RE sessions had taken 
place and the mice were properly recovered.  
 
Weight-bearing four-limbs hanging time test. Four-limbs hanging time while bearing an 
additional weight of 19 g was measured once at the end of the last week of the exercise 
protocol. 19 g weights were attached to SED and EX animals and they were put on an inverted 
grid on top of a tall box. Time until they dropped onto the cushioning below was measured. 
Five such measurements were taken with at least 5 min of rest between measurements. The 
single best value was used for the analysis. 
 
Ex vivo contractile force measurements. One EDL muscle per mouse was subject to ex vivo 
contractile force measurements. After careful dissection, EDL muscles were maintained in a 
Sylgard-covered (Sigma-Aldrich, catalog no. 761036) petri dish containing Krebs-Ringer 
solution with continuous oxygen supply. Krebs-Ringer solution contained 137 mM NaCl, 24 
mM NaHCO3 11 mM Glucose, 5 mM KCl, 2 mM CaCl2-2H2O, 1 mM MgSO4-7H2O, and 1 mM 
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NaH2PO4-H2O (Chemicals were purchased from Fluka). Knotting loops of surgical silk around 
an EDL muscles’ distal and proximal tendons allowed its attachment to a force transducer 
(1200A Isolated Muscle System; Aurora Scientific) on one end and to a fixed pin on the other. 
The muscle was gradually adjusted to its optimal length (Lo), which is achieved at peak twitch 
force (Pt), by lengthening in 5 mN increments. Peak tetanic force (Po) was recorded with 500-
ms stimulation at 120 and 150 Hz. Specific peak and twitch forces were calculated by 
normalization to the cross-sectional area (CSA) according to the formula: CSA (mm2) = 
muscle wet weight (mg)/[fiber length (lf, mm) x 1.06 mg/mm3], with lf = lo × 0.44 for EDL 
(Brooks and Faulkner 1988). DMAv5.010 software was used for analyzing the data. 
 
Muscle cross-sectional area. Cryosections of GAS, PLA, and SOL muscles were cut with a 
cryostat at 12 µm thickness (Leica, CM1950). Sections were air-dried for 2 h at RT and 
incubated overnight with a Wheat Germ Agglutinin, Alexa Fluor™ 488 conjugate (Invitrogen, 
catalog no. W11261) diluted 1:500 in 0.1% Triton-X/PBS at 4°C. The next day, sections were 
washed twice with PBS for 5 min, followed by EtOH-dehydration for 2 min each in 70% and 
100% EtOH respectively. Sections were mounted with CitiFluor™-AF1 (VWR, catalog no. 
100496-532) and pictures taken for cross-sectional area analysis using a ZEISS Axio Scan.Z1 
slide scanner system. Cross-sectional area was measured by quantifying the minimum 
distance of parallel tangents at opposing particle borders (minimal “Feret’s diameter”) of 
whole muscle sections using the ImageJ and cell^p software packages (Olympus Soft Imaging 
Solutions).  
 
Isolation of RNA and synthesis of cDNA. Total RNA was extracted from muscle tissue by 
phase-separation using TRI Reagent (Sigma Aldrich, catalog no. T9424) as per the 
manufacturers’ protocol. RNA concentration and purity were measured with a NanoDrop 
1000 spectrophotometer (Thermo Scientific). One μg of isolated RNA was used for cDNA 
synthesis with the SuperScript II reverse transcriptase (Invitrogen, catalog no. 18064-014). 
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Semiquantitative real-time PCR. Relative mRNA levels were measured by semiquantitative 
real-time PCR (qPCR) on a StepOnePlus™ Real-Time PCR System (Applied Biosystems, 
catalog no. 4376600) using Fast SYBR™ Green Master Mix (Applied Biosystems, catalog no. 
4385612). The expression values of the reference genes Tbp and Hprt were averaged and 
used for normalization. Gene expression fold changes relative to the SED group were 
calculated with the comparative ΔΔCT method for relative quantification as per the 
manufacturers’ instructions (Applied Biosystems). Primer pairs were checked for similar 
PCR efficiency. Melting curve analysis was performed to control for the formation of multiple, 
unspecific PCR products or primer-dimers. Two technical replicates were done for each PCR 
reaction, and negative control reactions were added (i.e., no template and no reverse 
transcription controls). Primer sequences used are shown in Table 3-1. 
 
Table 3-1. Primer sequences used for gene expression analyses with qPCR. 
Gene name Forward Reverse 
Ccnd1 TCAAGTGTGACCCGGACTG ATGTCCACATCTCGCACGTC 
Ckmt2 CCACACCAGGGTGATCTCAAT TCGAGGGGCAAGTCAAAATGT 
Hprt TCAGTCAACGGGGGACATAAA GGGGCTGTACTGCTTAACCAG 
Igf-1 ATAGAGCCTGCGCAATGGAATA ATTGGTGGGCAGGGATAATGA 
Igf-2 AGCTGACCTCATTTCCCGAT GAATGTGCGACGGGACAGAA 
Mmp2 AACGGTCGGGAATACAGCAG GTAAACAAGGCTTCATGGGGG 
Mstn GCTGGCCCAGTGGATCTAAA GCCCCTCTTTTTCCACATTTT 
Ppargc1a AGCCGTGACCACTGACAACGAG GCTGCATGGTTCTGAGTGCTAAG 
Tbp ATATAATCCCAAGCGATTTGC GTCCGTGGCTCTCTTATTCTC 
Ubtf GGATGCCACTACGAAGGAGG GATGTTCAGCTCAGGGTGCT 
Primers are listed in 5’-3’ direction. 
 
Statistical analyses. All statistical analyses were performed using GraphPad Prism 8 
(GraphPad Software) unless indicated otherwise. Differences in body composition, hind limb 
muscle weights, and four limb grip strength between SED and EX groups were compared 
using multiple t-tests with correction for multiple comparisons using the Holm-Sidak method 
without assuming equal standard deviations. Differences in weight-bearing inverted grid 
hanging test time were compared using an unpaired, nonparametric Mann-Whitney rank 
comparison test. Differences in gene expression were compared with multiple t-tests with 
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correction for multiple comparisons using the Holm-Sidak method on the ΔCT values. 
Differences in ex vivo contractile force measurements between the SED and EX groups were 
compared with parametric t-tests. In general, p-values lower than 0.05 were considered to 
indicate statistical significance. 
 
3.4 Results 
Body composition, muscle weight and myofiber size 
We determined body composition at week 0 (prior to the exercise intervention), as well as 
after 3, 5, 8, and 12 weeks (immediately before sacrifice) of the study. Body composition 
before and after the exercise intervention, final muscle weights and myofiber size are shown 
in Figure 3-1 B-D and summarized in Table 3-2. 
 
Table 3-2. Body composition before (week 0) and at the end (week 12) of the twelve-week 
resistance exercise intervention, as well as final muscle weights. 
Group  SED EX 
Body weight (g) Week 0 
Week 12 
27.66 ± 1.13 
29.72 ± 1.90 
28.31 ± 1.31 
28.97 ± 1.48 
Fat mass (g) Week 0 
Week 12 
2.46 ± 0.49 
3.31 ± 1.11 
2.33 ± 0.35 
2.39 ± 0.30 
Lean mass (g) Week 0 
Week 12 
22.67 ± 0.69 
23.14 ± 1.18 
23.19 ± 1.22 
23.50 ± 1.38 
Muscle weight (mg) Soleus 





9.91 ± 1.35 
12.06 ± 0.75 
18.89 ± 1.17 
55.39 ± 3.95 
135.56 ± 6.61 
225.65 ± 8.45 
10.94* ± 1.02 
12.14 ± 1.11 
19.20 ± 1.37 
58.99 ± 3.50 
145.97* ± 6.70 
229.84 ± 8.18 
Myofiber size 
(min. ferets’ diameter 




23.06 ± 1.24 
20.00 ± 1.15 
16.90 ± 1.51 
22.82 ± 1.41 
19.87 ± 1.72 
17.14 ± 0.65 
Groups: SED = sedentary control group; EX = resistance exercise group. Data shown as mean ± SD; * 
p ≤ 0.05; N = 8-10. 
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Grip strength 
We assessed grip strength at week 0 (prior to the exercise intervention), as well as after 3, 5, 
8, and 12 weeks (the day before sacrifice) of the study via four-limb grip strength tests. 
Additionally, in the last week of the study, we performed a weight-bearing inverted grid 
hanging time test, to which the animals were not acclimatized beforehand. The EX group held 
on to the grid significantly longer compared with the SED group. Overall, four-limb grip 
strength increased in both, SED and EX animals over the course of the study, without a 
significant difference between groups at any time point. In the weight-bearing inverted grid 
hanging time test at week twelve, EX animals performed significantly better compared to SED 
animals (p < 0.003; Table 3-3 and Figure 3-2). 
 
Table 3-3. Four-limb grip strength measurements before (Week 0) and at the end (Week 12) 
of the 12-week resistance exercise intervention, as well as weight-bearing inverted grid 
hanging time test results. 
Group  SED EX 




251.63 ± 25.75 
298.00 ± 25.36 
249.34 ± 16.35 
319.6 ± 19.73 
Weight-bearing inverted grid 
hanging test time (s) 
Week 12 27.63 ± 24.65 142.80** ± 107.81 
The weight-bearing inverted grid hanging time test was only performed during the last week of the 
resistance exercise intervention (Week 12). Groups: SED = sedentary control group; EX = resistance 
exercise group. Data shown as mean ± SD; ** p < 0.01; N = 8-10. 
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Ex vivo contractile force 
We measured ex vivo muscle force of the EDL muscle to compare contractility between the 
SED and EX groups after the exercise intervention (Figure 3-3). There were no significant 
differences in any of the measurements, which are summarized in Table 3-4. 
 
Table 3-4. Ex vivo muscle contractility of the EDL muscle after 12 weeks of resistance exercise. 
Group Frequency SED EX 
Peak twitch force (mN)  49.82 ± 5.72 50.62 ± 5.03 
Specific peak twitch force (mN/mm2)  49.30 ± 7.26 53.57 ± 5.84 
Peak tetanic force (mN) 120 Hz 
150 Hz 
301.51 ± 42.75 
332.88 ± 29.50 
320.21 ± 37.74 
357.35 ± 32.38 
Specific peak tetanic force (mN/mm2) 120 Hz 
150 Hz 
313.14 ± 53.23 
345.54 ± 44.44 
339.51 ± 47.03 
378.86 ± 45.00 




To investigate whether twelve weeks of RE influence the gene expression levels of several 
putatively hypertrophy-related genes (selected based on literature), we determined their 
relative expression levels with qPCR in the GAS and QUAD muscles (Figure 3-4 A-B). None 
of the measured genes were differentially expressed between the SED and EX groups at the 
end of the study. 
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3.5 Discussion 
The physiological resistance exercise model of weight-bearing ladder climbing described 
here lead to task-specific performance improvements, but did not induce significant 
muscular hypertrophy. 
 
The twelve-week RE intervention did not influence overall body composition (Figure 
3-1 D-F), which is in line with the observations of hind limb muscle weight and cross-
sectional area (Figure 3-1 B-C). The resistance exercise group (EX) tended to having a 
slightly reduced fat mass relative to body weight(p > 0.08 at weeks 3, 5, 8 and 12), which 
might have been due to the RE training and/or increased stress levels caused by the 
intervention itself. This observation might in turn explain the trend towards a slightly 
increased lean mass relative to body weight at week 12 (p > 0.057) in the EX group. We 
detected a slight increase in muscle mass relative to body weight in the SOL (~ 10%) and GAS 
muscles (~ 6%), but the magnitude of these increases is marginal compared to ladder 
climbing exercise study results in the rat (23% absolute increase in FHL muscle weight, 
(Hornberger and Farrar 2004); 20% increase in QUAD cross-sectional area, (Jung, Ahn et 
al. 2015)).  
 
The EX animals displayed a larger capacity to resist gravity in a weight-bearing 
inverted grid hanging test when compared to the sedentary control group (SED) (Figure 3-2 
B). This experiment was confounded by the fact that the SED animals were not acclimatized 
to carrying weights attached to their tails. Other measurements of strength, such as 
longitudinal four-limb grip strength tests (Figure 3-2 A) and ex vivo contractility 
measurements of the EDL muscle (Figure 3-2 C) did not indicate general performance 
improvements. These observations might indicate that adaptations of the EX animals to the 
model were mostly specific to the task, and that the measurements of strength taken were 
not suitable to accurately determine performance. Although the ex vivo contractility 
measurements of the EDL muscle (Figure 3-2 C) avoided issues with balance and behavior, 
they displayed no difference in strength between SED and EX animals. It is possible that the 
EDL muscle is not strongly involved in the ladder-climbing task and therefore displayed no 
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increases in its contractility. It would therefore have been interesting to see contractility 
measures of other, potentially more involved muscles as well. Nevertheless, the EX animals 
greatly improved their capacity of weight-bearing ladder climbing over the duration of the 
RE training. 
 
The physiological resistance exercise model of weight-bearing ladder climbing 
described here lead to task-specific performance improvements, but did not induce 
significant muscular hypertrophy. The described RE model therefore does not facilitate 
studies of transcriptional changes related to skeletal muscle hypertrophy. Involuntary RE 
models, such as the ladder climbing described here, are unlikely to produce sufficient 
hypertrophy with mice. Compared to rats, mice are more difficult to motivate, which hampers 
exercise compliance, and options to provide sufficiently stimulating progressive overload are 
limited (Spangenberg and Wichman 2018). Future efforts should focus on establishing a 
voluntary RE protocol with sufficient intensity to induce hypertrophy and include analysis of 
the forelimb muscles. Ideally, the chosen RE modality excludes or reduces aerobic 
components as much as possible. 
  
Manuscript I: Ladder climbing as a physiological resistance exercise model for skeletal muscle 




Figure 3-1. Muscle mass and size, as well as body composition after twelve weeks of ladder-
climbing resistance exercise. A) Photo of the weight-bearing ladder climbing resistance exercise. 
Weights were attached to the base of the tail and mice had to repeatedly climb a near-vertical ladder 
device. B) Muscle weight normalized to body weight of six different hind limb muscles. N = 7-10. C) 
Muscle cross-sectional area determined by measuring the minimal ferets’ diameter. N = 4. D) Body 
weight, fat- and lean-mass as determined by EchoMRI. Fat- and lean-mass were normalized to body 
weight. N = 8-10. Groups: SED = sedentary control group; EX = resistance exercise group. Data shown 
as mean ± SD; * p ≤ 0.05. 
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Figure 3-2. Grip strength measurements. A) Longitudinal four-limb grip strength tests of 
sedentary control group (SED) and resistance exercise group (EX) mice. Grip strength measurements 
took place in week 0, 3, 5, 8, and 12. B) Weight-bearing inverted grid hanging time test of SED and EX 
mice after twelve weeks of resistance exercise. Hanging time in seconds was normalized to body 
weight. Groups: SED = sedentary control group; EX = resistance exercise group. Data shown as mean 
± SD; ** p ≤ 0.01; N = 8-10. 
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Figure 3-3. Ex vivo muscle force measurements of the EDL muscle after twelve weeks of 
resistance exercise. A) Peak twitch force. B) Peak tetanic force (120 Hz). C) Peak tetanic force (150 
Hz). D) Specific peak twitch force. E) Specific peak tetanic force (120 Hz). F) Specific peak tetanic 
force (150 Hz). Groups: SED = sedentary control group; EX = resistance exercise group. Data shown 
as mean ± SD; N = 8-10. 
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Figure 3-4. Twelve weeks of resistance exercise did not induce gene expression of putative 
hypertrophy-related genes. Expression of putative hypertrophy-related genes in EX relative to SED 
(dotted lines) animals in the A) Gastrocnemius and B) Quadriceps muscles was measured with 
semiquantitative qPCR. Groups: SED = sedentary control group; EX = resistance exercise group. 
Values are fold change of EX relative to SED ± fold-change range; N = 8-10. 
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The neuromuscular junction (NMJ) has been studied for over a century, yet we still do not 
have a complete picture of all its structural and functional components, knowledge of which 
is paramount in devising treatment strategies for certain neuromuscular diseases. We 
hypothesized that we could identify novel NMJ components by performing next-generation 
RNA-sequencing on fundamental myonuclei underlying the NMJ of fast-twitch extensor 
digitorum longus (EDL) and slow-twitch soleus (SOL) muscles. We successfully generated EDL 
and SOL NMJ gene expression profiles and validated several known and novel NMJ genes with 
semiquantitative qPCR. We found the expression levels of canonical NMJ genes to be nearly 
identical between the EDL and SOL, which suggests that the core NMJ gene program might 
be well conserved between different skeletal muscle types. We overexpressed one of our 
potential novel NMJ components, the transcription factor T-box 21 (TBX21), in the tibialis 
anterior (TA) muscle and observed an increased density of postsynaptic acetylcholine 
receptors. TBX21 may thus represent a novel transcription factor contributing to the 
regulation of the NMJ gene program, with a role in postsynaptic sensitivity. Our NMJ gene 
expression profiles provide novel target genes that may support and inform future studies 
into neuromuscular diseases. 
  




The neuromuscular junction (NMJ) has been studied for over a century and ample research 
has revealed many insights into its molecular structure and function as a prototypical 
synapse (Hughes, Kusner et al. 2006). Skeletal myofibers are multinucleated syncytia and 
typically contain far in excess of a hundred myonuclei. Only a small subset of these aggregate 
directly underneath the NMJ and express a distinct gene program (Ruegg 2005). These so-
called fundamental myonuclei presumably express most of the components necessary for the 
postsynaptic specializations of the myofiber membrane at the NMJ and expression of these 
components becomes silenced in the extrajunctional myonuclei concomitant with 
innervation (Schaeffer, de Kerchove d'Exaerde et al. 2001). Several previous studies have 
attempted to unravel the NMJ transcriptome, identifying novel genes that potentially code 
for functional and structural NMJ components (Kishi, Kummer et al. 2005, McGeachie, 
Koishi et al. 2005, Nazarian, Bouri et al. 2005, Sieburth, Ch'ng et al. 2005, Jevsek, 
Jaworski et al. 2006, Ketterer, Zeiger et al. 2010). However, it is likely that we are still 
missing the complete picture of all the different proteins involved in NMJ development, 
maintenance and stabilization, owing to the limitations of previously available sequencing 
technologies and the inherent difficulties of isolating the fundamental myonuclei that 
underlie the NMJ. We hypothesized that the emergence of powerful next-generation 
sequencing technologies in recent years may enable us to establish a more complete picture 
of the components making up the NMJ. This would allow us to potentially provide novel 
target genes for therapeutic approaches aimed at treating neuromuscular diseases such as 
congenital myasthenic syndromes. Congenital myasthenic syndromes are a class of diseases 
caused by gene mutations of various components of the NMJ. To date over 30 different such 
myasthenic syndromes are known, yet a large number of causative genetic mutations are still 
undiscovered. Furthermore, fast-twitch muscles and consequently fast-type NMJs are more 
frequently affected by perturbations caused by neuromuscular diseases compared to slow-
twitch muscles and slow-type NMJs (Wang and Pessin 2013, Nijssen, Comley et al. 2017). 
This might be due to the fact that fast- and slow-type NMJs structurally and functionally differ 
(Fahim, Holley et al. 1984, Waerhaug and Lomo 1994, Sieck and Prakash 1997). It is 
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therefore conceivable that there are underlying transcriptomic differences between the 
fundamental myonuclei of these two NMJ types. 
 
In order to provide a more complete picture of the NMJ transcriptome and to identify 
new NMJ components and potential differences between slow- and fast-type NMJs, we 
combined laser-capture microdissection with highly sensitive next-generation RNA-
sequencing to interrogate the NMJ transcriptomes of the predominantly fast-twitch extensor 
digitorum longus (EDL) and the predominantly slow-twitch soleus (SOL) muscles. Here, we 
report the successful expression profiling of NMJs of the EDL and SOL muscles and provide a 
large number of genes potentially encoding for novel NMJ components. We also compared 
the EDL and SOL NMJ transcriptomes and report on commonalities and differences. 
Furthermore, we overexpressed one such potential novel NMJ gene, the transcription factor 
T-box 21 (TBX21), in the tibialis anterior (TA) muscle and describe how overexpression of 
TBX21 influences NMJ morphology and thus may represent a novel regulator of the NMJ gene 
program. 
 
4.3 Material and Methods 
Animals. Adult male C57B/6JRj wild type mice were purchased from JANVIER LABS, France. 
Animals were fed an ad libitum, regular chow diet (Provimi 3432) and kept under a 12‐h/12‐
h light–dark cycle (light phase: 06:00 am to 18:00 pm) in a temperature-controlled room (21-
22°C) in the animal facility of the Biozentrum (University of Basel). All experiments were 
performed in accordance with the principles of the Basel Declaration and with Federal and 
Cantonal Laws regulating the care and use of experimental animals in Switzerland, as well as 
institutional guidelines of the Biozentrum and the University of Basel. The protocol with all 
methods described here was approved by the cantonal veterinary office of the canton Basel-
Stadt, under consideration of the well-being of the animals and the 3R principle. 
 
Tissue preparation for laser capture microdissection. The EDL and SOL muscles of six 
15-week-old adult male C57B/6JRj wild type mice were rapidly dissected and immediately 
immersed in Krebs-Ringer solution (137 mmol/L NaCl, 24 mmol/L NaHCO3, 11 mmol/L 
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Glucose, 5 mmol/L KCl, 2 mmol/L CaCl2-2H2O, 1 mmol/L MgSO4-7H2O, and 1 mmol/L 
NaH2PO4-H2O; chemicals were purchased from Fluka) containing α-Bungarotoxin, Alexa 
Fluor™ 488 conjugate (diluted 1:500; Thermo Fisher Scientific, catalog no. B13422) for 
45 min to allow visualization of NMJs. After incubation, muscles were washed two times 
2 min in Krebs-Ringer solution, partially embedded in 10% Tragacanth (Sigma-Aldrich, 
catalog no. G1128), frozen in liquid nitrogen-cooled 2-Methylbutane (-150°C; Sigma-Aldrich, 
catalog no. M32631), and stored at -80°C until further processing. Serial cross-sections of 
20 µm thickness containing NMJ areas were cut at -20°C with a cryostat (Leica Biosystems). 
Up to 30 serial sections were mounted per RNase AWAY®-treated (Sigma-Aldrich, catalog 
no. 83931-250ML) regular glass slide (Menzel). To inactivate endogenous RNases, sections 
were dehydrated inside the cryostat chamber for 10 min and then stored at -80°C in 50 ml 
conical tubes containing several grams of desiccant (ROTH, silica Gel Orange, catalog no. 
P077.4) to prevent tissue rehydration. Slides were processed within 72 h.  
 
Laser-capture microdissection of NMJ and non-NMJ areas. Laser capture microdissection 
(LCM) was performed using a PALM MicroBeam system (Zeiss) consisting of an inverted 
microscope with a motorized stage, an ultraviolet laser and an X-Cite fluorescence 
illuminator. The microdissection process was visualized with an AxioCam ICc camera (Zeiss) 
coupled to a computer and controlled by the PALM RoboSoftware (Zeiss). Specifically, 
synaptic regions were visualized under fluorescence microscopy with an x20 objective. 
Synaptic (“NMJ”) and extrasynaptic (“XNMJ”) tissue areas of roughly 0.5 mm2 (the equivalent 
of about 200 NMJ areas) were selected, cut and catapulted by laser pulses, utilizing 
automated laser-pressure catapulting (autoLPC) mode, into the caps of opaque AdhesiveCap 
500 PCR tubes (Zeiss, catalog no. 415190-9211-001). For every sample, the AdhesiveCap PCR 
tube cap was checked for presence of catapulted tissue, indicating laser capture success. We 
captured roughly 180 NMJ areas per biological replicate (six animals, both EDL and SOL 
muscles), thus totaling about 2200 captured NMJ areas. The LCM procedure is depicted in 
Figure 4-1 A. The sample collection for RNA-sequencing culminated in the addition of 10 µl 
of Single-cell lysis buffer (Clontech, catalog no. 635013) and incubation at RT for 5 min. 
Afterwards, samples were frozen on dry ice for transport and stored at -80°C until further 
processing. Sequencing libraries were prepared from the total lysates without isolation of 
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RNA. The sample collection for qPCR analyses was conducted separately and is described 
below. We thus generated synaptically-enriched RNA-sequencing data of two different types 
of skeletal muscle. Two synaptically enriched “NMJ” biological replicates of the SOL muscle 
and one “XNMJ” control sample of the EDL muscle failed the RNA-sequencing process, leaving 
four “NMJ” samples for the SOL and five “XNMJ” samples for the EDL muscle. All other 
samples were sequenced successfully. 
 
RNA extraction and cDNA synthesis from laser-captured tissue. Total RNA extraction 
was performed by spin-column-based and phenol-free separation suitable for LCM frozen 
tissue samples with the RNAqueous™-Micro Total RNA Isolation Kit (Thermo Fisher 
Scientific, catalog no. AM1931). The manufacturers’ protocol was adapted for use with 
AdhesiveCap 500 PCR tubes from Zeiss, as efficient tissue lysis is crucial for successful RNA 
extraction from LCM tissue. To lyse laser-captured material, 10 µl lysis buffer (from the Kit) 
was added into the top of an AdhesiveCap PCR tube and pipetted up and down at least ten 
times before dispensing the lysate into the bottom of the tube. This step was repeated a 
second time, resulting in a total volume of 20 µl lysis buffer. The tubes were then frozen on 
dry ice for transport and storage in a -80°C freezer. The AdhesiveCap lid was checked under 
the microscope after each pipetting step and the absence of captured material indicated 
successful suspension of tissue in the lysis buffer. Prior to RNA-extraction, additional lysis 
buffer was added to a final volume of 100 µl. Samples were then mixed by gentle pipetting, 
and subjected to 30 min incubation at 42°C in a water bath. The remaining steps were then 
performed as per the manufacturers’ protocol. The optional DNAse treatment step was 
performed utilizing the RNase-Free DNase Set (Qiagen, catalog no. 79254). Finally, the RNA 
was eluted in two times 10 µl of preheated elution solution and stored at -80°C until further 
processing. 
 
Low-input RNA-Sequencing. The laser-captured whole tissue lysates were used for RNA-
sequencing library generation as per the SMART-Seq2 methodology (Picelli, Faridani et al. 
2014). The protocol used was the SMART-Seq2 NexteraXT Standard Protocol. Quality control 
of the cDNA-sequencing-libraries was conducted with the Agilent Bioanalyzer (Agilent) and 
the average fragment size of the libraries was determined. The libraries were sequenced 
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(Single-end reads, 76 sequencing cycles) using a NextSeq 500 system (Illumina) at the 
Quantitative Genomics Facility of the Department of Biosystems Science and Engineering (D-
BSSE) of the ETH Zürich in Basel. The entire process from sequencing library preparation to 
RNA-sequencing was conducted by D-BSSE personnel. 
 
RNA-sequencing data preprocessing, read mapping and analysis. The raw sequencing 
reads (FASTQ-files) were quality filtered and sequencing adapters were trimmed using 
BBDuk from BBTools (Version 38.57) with the following non-standard parameters: ktrim = 
r, k = 21, mink = 11, hdist = 2, qtrim = rl, trimq = 12, ftm = 5. The following annotation files 
were used for read mapping: Gencode Release M22 (GRCm38.p6) of the transcript sequences, 
which includes the nucleotide sequences of all transcripts on the reference chromosomes. 
GTF file: comprehensive gene annotation (regions: CHR), which contains the comprehensive 
gene annotation on the reference chromosomes only. Salmon (Version 0.14.1) was used to 
generate an index with the following non-standard parameters: --k 29, --type quasi, --
gencode (as Gencode annotation files are used). Salmon quasi-mapping was run with these 
parameters: --libType U, --validateMappings, --fldMean 454, --fldSD 66, --seqBias (the 
average fragment length of the sequencing libraries was 454 with a standard deviation of 66) 
(Patro, Duggal et al. 2017). 
 
RNA-sequencing data analysis was conducted with R (Version 3.6.0) and R-Studio (Version 
1.1.463) running on CentOS Linux 7 (sciCORE R-Studio server service). The edgeR package 
(Version 3.26.7) from Bioconductor (Version 3.9.0) was used for differential gene expression 
analysis. Other packages used for data handling and plotting were tidyverse (1.2.1), 
pheatmap (1.0.12), biomaRt (2.40.3), RColorBrewer (1.1.2), tximport (1.12.3) and 
GenomicFeatures (1.36.0).  
 
We defined a gene to be differentially expressed, or synaptically enriched at the NMJ, if it had 
at least a 2-fold change in expression and a false discovery rate (FDR) adjusted p-value of < 
0.05. After sequencing library normalization and pre-filtering to remove low-count genes, 
14981 genes were found to be expressed in our dataset. 
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Calculations were performed at sciCORE (http://scicore.unibas.ch/) scientific computing 
core facility at University of Basel. 
 
Semiquantitative real-time PCR. Relative mRNA levels were determined by 
semiquantitative real-time PCR (qPCR) on a StepOnePlus system (Applied Biosystems, 
catalog no. 4376600) using Fast SYBR green PCR master mix (Applied Biosystems, catalog 
no. 4385612). Expression of the reference gene Hprt was used for the normalization of the 
ΔCT method for relative quantification. qPCR data was analyzed with unpaired, two-tailed 
student’s t-test on the ΔCT-values. Primer pairs were checked for similar PCR efficiency, and 
melting curve analysis was performed to control for the formation of multiple, unspecific PCR 
products or primer-dimers. Two technical replicates were done for each PCR reaction, and 
negative control reactions were added (i.e., no template and no reverse transcription 
controls). Primer sequences used are shown in Table 4-1. 
 
Table 4-1. Primer sequences used for gene expression analyses with semiquantitative qPCR. 
Gene name Forward Reverse 
Aplp2 CTCTCCAAGGGAAAGTGCGT TCGGGGGAATCATCGCTTTA 
B4galnt3 CCCTGAACCACAGGTATGGC ATCAACGGCTGGGATGTTCC 
Chpf AGGCCGTCAGAACTCGGTAT GGTGTCCCAGAGTTCGGTTT 
Chrne CTCTGCCAGAACCTGGGTG GACAGTTCCTCTCCAGTGGC 
Crym CCACAAAGCTGTTGAAGCCC GCGGTTCCACATTCTCACCT 
Dlk1 AAGTGTGTAACTGCCCCTGG TGCAAGCCCGAACGTCTATT 
Dmd TAATGTCAGGTTCTCCGCGTATAG GATATCCATGGGCTGGTCATTTTG 
Hprt TCAGTCAACGGGGGACATAAA GGGGCTGTACTGCTTAACCAG 
Hs6st2 CAGGCGGATGCACGACC ATCCATGTTCCCGACGCTGG 
Nell2 CACTACCCATCTCCTTCGGT GGAAAAGGAACCCAGCCAAAG 
Scn3b AGCTCAGGAAAATGCGTCTGA CACCCACATCCACCTTACCC 
Tbx21 ACTAAGCAAGGACGGCGAAT TAATGGCTTGTGGGCTCCAG 
Utrn GAGGCTCGCTTCTACATGCT TGATGACACCATCGCCAGAC 
Primers are listed in 5’-3’ direction.  
 
In vivo muscle electroporation. MYC-DDK-tagged Tbx21 (Origene, catalog no. MR227202) 
and pCAG-eGFP (Sonidel) expression plasmids were prepared with the EndoFree® Plasmid 
Maxi Kit (Qiagen, catalog no. 12362) according to the manufacturers’ protocol. The working 
plasmid concentration for the intramuscular injections was adjusted to 1 μg/μl with Opti-
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MEM (Thermo Fisher Scientific, catalog no. 31985062). Three twelve-week-old adult male 
C57B/6JRj wild type mice (JANVIER LABS, France) were anesthetized via isoflurane 
inhalation and analgetically treated with Meloxicam (Metacam® injectable (5mg/ml)) at 5 
mg/kg by s.c. injection. After both legs were shaved, the tibialis anterior (TA) muscle was 
bilaterally injected transcutaneous with 25 μl of 80 IU/ml hyaluronidase solution (Irvine 
Scientific, catalog no. 90101), at two separate sites each (50 μl total injection volume) to 
ensure optimal distribution of the solution within the muscles. Hyaluronidase solution was 
used to improve transfection efficiency. During the ensuing 1-hour incubation time the 
mouse was returned into its home cage and allowed to recover from the anesthesia. 
Electroporations were carried out with the NEPA21 Super Electroporator (NEPAGENE) 
equipped with a CUY650P10 (NEPAGENE, catalog no. CUY650P10) tweezer-type electrode 
and according to manufacturers’ recommendations if not stated otherwise. After the 1-hour 
incubation with the hyaluronidase solution, the mouse was re-anesthetized and two times 
25 μl of the diluted MYC-DDK-tagged Tbx21 plasmid preparation were injected at two 
opposite sites of one TA muscle. Electroporation was conducted immediately after the 
injections, with three trains of three poration pulses each (poration pulse voltage: 80 V; 
number of poration pulses: 3; pulse length: 30 ms; pulse interval: 50 ms; decay rate : 10%; 
polarity: bipolar; current limit: ON (in vivo)). The procedure was then repeated on the other 
TA muscle with the pCAG-eGFP control plasmid. The mice were returned to their home cage 
after the procedure. Another dose of Meloxicam was administered the following day. The 
mice were sacrificed after six weeks and their TA muscles dissected and fixed for 30 min with 
4% paraformaldehyde (PFA) for subsequent immunostainings and NMJ-morphology 
analysis. 
 
Immunohistochemistry. The electroporated and PFA-fixed TA muscles were carefully pried 
apart with sharp forceps under a dissection microscope into small myofiber bundles of a few 
and up to several dozen myofibers each. These small myofiber bundles (around 60 per TA 
muscle) were washed with PBS, neutralized with 0.1M Glycin in PBS for 15 min at RT, and 
then permeabilized and simultaneously blocked with 3% BSA and 1% Triton-X in PBS for 2h 
at RT. Afterwards, the bundles were incubated with the primary antibody solution o/n (~ 
16 h) at 4°C on a rocking platform. The primary antibody solution consisted of antibodies 
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targeting Neurofilament “2H3” (used at 0.05 μg/ml; from Developmental Studies Hybridoma 
Bank (DSHB)), Synaptic vesicle glycoprotein 2A “SV2” (used at 0.2 μg/ml; from DSHB), and 
Anti-DDK (used at 1 μg/ml; from Origene, catalog no. TA50011-100). Both, 2H3 and SV2 
antibodies have the isotype IgG1. The small myofiber bundles were then washed with PBS 
and incubated for 2h at RT with the secondary antibody solution, which consisted of α-
Bungarotoxin, Alexa Fluor™ 647 conjugate (used at 1 µg/ml; Thermo Fisher Scientific, catalog 
no. B35450), Goat anti-Mouse IgG2a Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488 
(used at 2 µg/ml; Thermo Fisher Scientific, catalog no. A-21131) and Goat anti-Mouse IgG1 
Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 568 (used at 2 µg/ml; Thermo Fisher 
Scientific, catalog no. A-21124). The muscle bundles were then washed with PBS and about 
20 such bundles were arranged per Superfrost Plus™ glass slide (VWR, catalog no. 630-0951), 
mounted with several drops of VECTASHIELD® Antifade Mounting Medium with DAPI 
(Vector Laboratories, catalog no. H-1200-10), and finally a glass coverslip (#1.5; VWR, 
catalog no. 631-0147) was used with very little pressure to enclose the arranged muscle 
bundles. The slides were allowed to cure over night, sealed with nail polish the next day, and 
stored at 4°C in the dark until use. 
 
2H3 was deposited to the DSHB by Jessell, T.M. / Dodd, J. (DSHB Hybridoma Product 2H3). 
SV2 was deposited to the DSHB by Buckley, K.M. (DSHB Hybridoma Product SV2). 
 
Confocal imaging and NMJ-morphology analysis. The small myofiber bundles were 
imaged at the Biozentrum Imaging Core Facility with a SP8 confocal microscope (Leica 
Microsystems) with a x63 1.4 NA oil-immersion objective and x2 zoom at a resolution of 
512x512 pixels and a frame size of 92.44x92.44 µm. The pinhole aperture was set to 1 Airy 
unit. Confocal Z-stacks with system-optimized step size were acquired at a scanning speed of 
200 Hz and with two-times line averaging. Correctly oriented (“face up”) NMJs were checked 
for the expression of TBX21 by confirming the presence of MYC-DDK-signal in their 
fundamental nuclei (for a high-resolution example see Figure 4-8 B). The NMJs of eGFP-
transfected myofibers were imaged in the same fashion to serve as controls (Figure 4-8 A). 
Several NMJ morphological parameters were measured with Fiji as described by others 
(Schindelin, Arganda-Carreras et al. 2012, Jones, Reich et al. 2016). Briefly, thresholding 
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was applied to maximum intensity Z-stack projections of the imaged postsynaptic endplate 
and the presynaptic nerve terminal, respectively. After manual optimizations and cleaning of 
excess noise, this resulted in binary representations of the postsynaptic endplate and the 
presynaptic nerve terminal. The innervating axon diameter was measured and the axon then 
manually erased from the presynaptic image in order to measure nerve terminal area and 
perimeter with standard Fiji functions. Area and perimeter of the AChR of the postsynaptic 
endplate was measured in analogue fashion. Then, after subtraction of the background and 
another binarization, a representation of the entire endplate was generated. Diameter, 
perimeter and area of this was measured. We also calculated postsynaptic “compactness”, 
which is a derived variable defined as AChR area divided by the endplate area multiplied by 
100. A total of 33 NMJs (~ 11 NMJs / animal; N = 3) against 28 NMJs (~ 10 NMJs / animal; N 




Expression profiling of fast-twitch EDL and slow-twitch SOL neuromuscular junctions 
We used laser-capture microdissection (LCM) to isolate neuromuscular junction areas 
(“NMJ” or “synaptically enriched tissue”) and equal amounts of adjacent, extrasynaptic tissue 
as control (“XNMJ” or “extrasynaptic control tissue”) from serial cryosections of the fast-
twitch EDL and the slow-twitch SOL muscles of six 15-week-old male C57B/6JRj wild type 
mice (JANVIER LABS, France) (Figure 4-1). The isolated tissues were lysed and used for 
RNA-sequencing. Principal coordinate analysis (PCoA) showed four distinct clusters of 
samples (Figure 4-2), each belonging to one of the four expected conditions: Synaptically 
enriched EDL (“EDL_NMJ”), extrasynaptic EDL control (“EDL_XNMJ”), synaptically enriched 
SOL (“SOL_NMJ”), and extrasynaptic SOL control (“SOL_XNMJ”). 
 
We then assessed differentially expressed genes and summarized the results of the 
different comparisons in Table 4-2. We found 652 genes to be synaptically enriched with a 
positive fold change > 2 in the EDL muscle (Figure 4-3 A; comparison: EDL_NMJ vs. 
EDL_XNMJ), and 159 such genes for the SOL muscle (Figure 4-4 A; comparison: SOL_NMJ vs. 
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SOL_XNMJ). Among the top 50 synaptically enriched genes in the EDL according to both fold 
change and FDR p-value (fold change > 32, FDR p-value < 0.001) were well-known NMJ genes 
such as Musk, Chrna1, Chrnd, Colq, and Nes (Figure 4-3 B). Among the top 50 synaptically 
enriched genes in the SOL (fold change > 16, FDR p-value < 0.01) were the well-known NMJ 
genes Ache, Dusp6, Dok7, and Etv5 (Figure 4-4 B). These results indicated that we had 
successfully captured synaptically enriched genes of the NMJ for both muscles. Additionally, 
we directly compared the synaptically enriched EDL with the synaptically enriched SOL 
samples (EDL_NMJ vs. SOL_NMJ) to identify genes that are differentially expressed between 
the NMJs of the two muscles. This comparison yielded a list of 36 genes that were more 
abundant in the synaptic EDL and 141 genes that were more abundant in the synaptic SOL 
(Figure 4-5 A). The top three genes that were more expressed in the synaptic EDL according 
to their fold change were H2-Aa, Ifitm10, and Dlk1, while for the synaptic SOL these were 
Serpinb1a, Nell2, and Igfbp2 (Figure 4-5 B). We also created a list of 77 genes that were 
synaptically enriched in both muscles. This “core NMJ” list contains many well-known NMJ 
genes, but also ones that have not previously been shown to be enriched at the NMJ, according 
to literature queries (Figure 4-6). 
 
Table 4-2. Differentially expressed genes of the different comparisons. 
Comparison Genes with positive fold 
change 
Genes with negative fold 
change 
EDL_NMJ vs. EDL_XNMJ 652 217 
SOL_NMJ vs. SOL_XNMJ 159 12 
EDL_NMJ vs. SOL_NMJ 36 (EDL)1 141 (SOL)1 
Groups: EDL_XNMJ, extrasynaptic EDL; EDL_NMJ, synaptic EDL; SOL_XNMJ, extrasynaptic SOL; 
SOL_NMJ, synaptic SOL. 1, 36 genes were higher in the EDL, while 141 genes were higher in the SOL 
in this direct synaptic vs. synaptic sample comparison. 
 
Gene ontology enrichment analysis 
We performed functional annotation analysis using PANTHER Gene Ontology Enrichment 
(GO) Analysis, focusing on genes with a positive fold change (Ashburner, Ball et al. 2000, 
Huang da, Sherman et al. 2009, Huang da, Sherman et al. 2009, The Gene Ontology 
2019). Before submitting our different comparison lists, we removed predicted and non-
coding genes (e.g. 4933427D14Rik, Gm49015, Gm2115… ), resulting in a list of 525 
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differentially expressed genes with a positive fold change for the EDL (EDL_NMJ vs. 
EDL_XNMJ) and a list of 142 such genes for the SOL (SOL_NMJ vs. SOL_XNMJ). We determined 
the five most enriched GO terms according to FDR-adjusted p-value for the biological process 
(BP), molecular function (MF), and cellular component (CC) categories of our different 
comparison lists. For the synaptic EDL vs. extrasynaptic EDL comparison, postsynaptic 
membrane organization, extracellular matrix structural constituent, and neuromuscular 
junction were the top hits for BP, MF, and CC, respectively (Figure 4-3 C-E). For the synaptic 
SOL vs. extrasynaptic SOL comparison, positive regulation of postsynaptic membrane 
organization, protein binding, and neuromuscular junction were the top hits for BP, MF, and 
CC, respectively (Figure 4-4 C-E). For the synaptic EDL vs. synaptic SOL comparison, 
transition between fast and slow fiber, striated muscle thin filament, and actin binding were 
the top hits for BP, MF, and CC, respectively (Figure 4-5 C-E). Our gene ontology enrichment 
analysis indicated that we successfully generated NMJ gene expression profiles for the EDL 
and SOL muscles, as all of the most significant GO terms were involved with the NMJ. The GO 
terms enriched in the comparison of synaptic EDL with synaptic SOL samples indicated a 
large influence of general myofiber type differences. 
 
Validation of RNA-sequencing data with semiquantitative qPCR 
We verified our RNA-sequencing results using semiquantitative qPCR with biologically 
independent samples (Figure 4-7). As expected, known NMJ genes such as Chrne, Utrn, and 
Dcn were synaptically enriched in the EDL and SOL muscles, while the gene coding for 
Dystrophin (Dmd), which is known to be more expressed extrasynaptically, was not. We 
verified the synaptic enrichment of the potentially novel NMJ genes Crym, Hs6st2, Tbx21, 
B4galnt3 and Chpf. Dlk1 was synaptically enriched in the EDL muscle, but not in the SOL, 
while Nell2 and Scn3b were synaptically enriched in the SOL but not the EDL. Aplp2 was 
synaptically enriched in both muscles, but showed stronger expression in the EDL compared 
to the SOL. Several of the investigated genes were barely or not at all detectable in the 
extrasynaptic tissue samples. We also compared the fold changes in our RNA-sequencing 
data vs. our qPCR measurements. For example, synaptic enrichment of Chrne was 
comparable between the different methods. The comparisons are summarized in Table 4-3. 
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Synaptic: Indicates that a gene was detected only in the synaptic samples and was undetectable in the 
extrasynaptic samples and therefore a fold change could not be determined. N.D. indicates that a gene 
was undetected in all samples of the respective comparison. Groups: EDL_XNMJ, extrasynaptic EDL; 
EDL_NMJ, synaptic EDL; SOL_XNMJ, extrasynaptic SOL; SOL_NMJ, synaptic SOL. Data shown as fold 
change; * p ≤ 0.05, ** p ≤ 0.01, ***, p ≤ 0.001; n.s., not significant; None, no data available. 1, potential 
novel NMJ genes. 
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Effects of in vivo muscle electroporation of TBX21 on NMJ morphology 
We queried the animal transcription factor data base 3.0 (Hu, Miao et al. 2019) with the list 
of our synaptically enriched genes in the EDL and SOL to potentially identify transcription 
factors which might be involved in regulating the NMJ gene program. Our query revealed the 
transcription factor T-box 21 (TBX21) among our most highly synaptically enriched genes. 
T-box 21 is perhaps best known for its role in T-helper cell lineage commitment (Miller and 
Weinmann 2010, Kanhere, Hertweck et al. 2012). Since the transcription factor ETV5, 
which partially controls subsynaptic gene expression at the NMJ (Hippenmeyer, Huber et 
al. 2007), plays a role in T-helper cell development as well (Koh, Hufford et al. 2016), we 
hypothesized that TBX21 may thus be involved in the regulation of NMJ structure and 
function by acting as a novel NMJ transcription factor. We overexpressed TBX21 in the TA 
muscle via in vivo muscle electroporation of a Tbx21 expression plasmid with a MYC-DDK tag. 
NMJs transfected with TBX21 displayed reduced presynaptic nerve terminal area and 
increased postsynaptic AChR “compactness” (which indicates a larger quantity of AChRs 
within the endplate area.) when compared to eGFP-transfected controls. Other measured 
morphological parameters of the NMJ, such as axon diameter, nerve terminal perimeter, or 
endplate diameter, remained unchanged (Figure 4-8 C-K). These findings indicate a role of 
the transcription factor TBX21 in regulating NMJ morphology. 
  




We utilized laser-capture microdissection (LCM) and next-generation RNA-sequencing to 
investigate the transcriptome of fundamental myonuclei that underlie the NMJ, and which 
express a distinct gene program compared to extrajunctional myonuclei. We successfully 
generated transcriptomic datasets of the NMJ for the predominantly fast-twitch EDL (Figure 
4-3) and the predominantly slow-twitch SOL (Figure 4-4) muscles as evidenced by the large 
enrichment of canonical NMJ genes in our synaptic samples, which in turn enriched gene 
ontology terms clearly associated with the NMJ. We validated several known and potentially 
novel NMJ genes by semiquantitative qPCR (Figure 4-7). 
 
Our LCM- and RNA-sequencing-based approach lead to strong synaptic enrichment, 
as we detected over 300 genes with fold changes above 50-fold in the EDL and over 60 such 
genes in the SOL muscle. A study performed over a decade ago utilized a similar approach of 
LCM coupled with microarray technology to conduct transcriptomic profiling of NMJs of the 
TA muscle and reported average mRNA fold changes of 8.9, 5.5, and 4 for the known NMJ-
associated genes Chrne, Chrna1 and Nes, while we now report fold changes of 41, 38 and 33, 
respectively (Nazarian, Bouri et al. 2005). Another such study comparing synaptic with 
extrasynaptic TA using LCM and microarray-based NMJ expression profiling reported larger 
fold changes of 300 for Chrna1, 117 for Chrne and 79 for Nes (Ketterer, Zeiger et al. 2010). 
However, Ketterer et al. (2010) reported less than 20 genes with fold changes larger than 50 
in their synaptic vs. extrasynaptic TA comparison. Compared to these literature results, our 
RNA-sequencing-based approach lead to improved synaptic enrichment. Granted, we have to 
be careful when drawing conclusions from dataset comparisons involving different muscles 
and technologies, as the EDL, SOL and TA are all different muscles and it is known that 
significant transcriptomic diversity among skeletal muscles exist (Terry, Zhang et al. 2018). 
Furthermore, a large fold change value does not necessarily imply strong expression of a 
gene, which is important to consider for genes with little or no expression in the samples a 
comparison is made with. Nevertheless, our EDL and SOL NMJ expression profiles contain 
many known and previously described NMJ genes, including various acetylcholine receptor 
(AChR) subunits and other examples such as Nes, Musk, Prka1a, Cd24a, Etv5, Dusp6, Phldb2 
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and Scn3b (Beam, Caldwell et al. 1985, Kishi, Kummer et al. 2005, McGeachie, Koishi et 
al. 2005, Nazarian, Bouri et al. 2005, Jevsek, Jaworski et al. 2006, Hippenmeyer, Huber 
et al. 2007, Ketterer, Zeiger et al. 2010). We also provide a large number of potentially 
novel NMJ genes, many of which show far larger synaptic enrichment than known NMJ genes, 
perhaps owing to their exceptionally low expression in extrasynaptic regions of the myofiber. 
 
Among the most highly enriched genes at the EDL NMJ was Tbx21, with a fold change 
of over 900. We confirmed the synaptic enrichment of Tbx21 with semiquantitative qPCR and 
found that it was equally expressed at the SOL NMJ (Figure 4-7 G). Furthermore, Tbx21 was 
indicated to be expressed in the synaptic endplate band of the mouse diaphragm, underlining 
its potential importance at the NMJ (Hippenmeyer, Huber et al. 2007). Tbx21 encodes for 
the T-box transcription factor T-box 21 (TBX21), which is also known as T-Bet and so far has 
no established role at the NMJ. T-box proteins are involved in a broad range of pathways and 
often function as transcriptional activators or repressors. We hypothesized that TBX21 might 
be involved in the regulation of the NMJ gene program in the fundamental NMJ-associated 
myonuclei. Indeed, TBX21 has the ability to alter the state of chromatin towards 
transcriptional activation by associating with histone-modifying complexes and recruiting 
methyltransferase activity to target promotors (Lewis, Miller et al. 2007, Miller, Huang et 
al. 2008). Overexpression of TBX21 in the TA muscle lead to reduced presynaptic nerve 
terminal area and increased postsynaptic AChR density six weeks after the muscle 
electroporation (Figure 4-8). This increase in postsynaptic AChR density might indicate a 
role of TBX21 in AChR turnover and/or clustering, and may thus have a positive impact on 
postsynaptic sensitivity. However, we have to take into account that our results are based on 
a relatively small number of images (~ 10 images per biological replicate, N = 3) due to the 
rarity of correctly positioned (“face up”) NMJs with Tbx21-transfected myonuclei. Thus, 
further research is needed to confirm and expand our observed effects of TBX21 on the NMJ. 
Specifically, an inducible, muscle-specific transgenic mouse model for TBX21 with an 
expression tag would allow circumventing the restrictions of in vivo muscle electroporation 
described above and allow confirmation of our described morphologic effects of TBX21 
overexpression on the NMJ. Furthermore, electrophysiological measurements would shed 
light in the potential effect on neurotransmission strength, and LCM together with RNA-
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sequencing could reveal the potential influence of TBX21 on the NMJ gene program. These 
studies could be complemented with an additional TBX21 loss-of-function approach, e.g. via 
intramuscular injection of adeno-associated viruses (AAV) to express shRNAs against TBX21. 
Finally, ChIP-Seq experiments utilizing the expression tag would reveal TBX21 DNA binding 
sites, although it has to be established first whether whole-muscle tissue could be used or 
whether LCM would be required for these experiments. 
 
To investigate whether there are fundamental differences between the NMJ 
transcriptomes of fast- and slow-type NMJs that would help explain their structural and 
functional differences, we compared our NMJ gene expression profiles of the predominantly 
fast-twitch EDL and the predominantly slow-twitch SOL muscles. Principal coordinate 
analysis revealed two major differences between the samples of our study (Figure 4-2). One 
major difference was due to LCM region, being either synaptic or extrasynaptic, and the other 
due to muscle type, being either EDL or SOL. While the synaptic EDL and SOL samples cluster 
together based on their muscle type, the distance between the two synaptic clusters on the 
first principal coordinate is relatively short in comparison to the large difference due to 
muscle type that separates the two muscles on the second principal coordinate, indicating 
that the two synaptic clusters might be relatively similar. Indeed, the direct synaptic EDL vs. 
synaptic SOL comparison was dominated by large expression differences of myofiber type-
specific genes, such as various myosin heavy chains (e.g. Myh2, Myh6, Myh7,), troponins (e.g. 
Tnni1, Tnnt1) and calcium-buffering proteins (Pvalb), indicating a possible contamination of 
our synaptic samples with extrasynaptic myonuclei. This observation was further supported 
by the top gene ontology terms (e.g. transition between fast and slow fiber) that were enriched 
by the synaptic EDL vs. synaptic SOL comparison (Figure 4-5 C-E). Consequently, the direct 
comparison of the synaptic EDL with the synaptic SOL samples revealed a relatively small set 
of genes differing between the two muscles when these general muscle differences were 
accounted for via filtering out genes that were not synaptically enriched in the respective 
synaptic vs. extrasynaptic comparisons of the EDL and SOL (Figure 4-5 B). Furthermore, the 
expression level of canonical NMJ genes, such as Chrne, Chrnd, Chrna1, Chrnb1, MuSK, Etv5, 
and Utrn, was nearly identical between the synaptic EDL and SOL samples, which indicates 
that the different muscles share great similarity of their NMJ gene programs (Figure 4-9 A-
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G). One of the genes with the largest expression differences between the synaptic samples of 
the muscles was delta like non-canonical Notch ligand 1 (Dlk1); its expression was over 400-
fold higher in the synaptic EDL vs. synaptic SOL. Furthermore, Dlk1 mRNA was undetectable 
in all but the synaptic EDL samples in our semiquantitative qPCR validation experiments, 
suggesting its exclusive synaptic expression in the fast-twitch EDL (Figure 4-7 K). Despite 
the large fold change of Dlk1, its expression strength in the synaptic EDL samples was still at 
a relatively low ~ 2 counts per million (CPM) in our sequencing dataset (Figure 4-9 J). 
Interestingly, DLK1 alone is sufficient to drive the fast motor neuron biophysical signature 
by suppressing Notch signaling (Muller, Cherukuri et al. 2014), which raises the question 
whether fast motor neuron-derived Dlk1 mRNA is transported to and locally translated at the 
nerve terminal to exert similar functions, since Notch signaling was found the be required for 
activity-dependent synaptic plasticity at the Drosophila NMJ (de Bivort, Guo et al. 2009). 
 
Regardless of muscle type, contamination with other cell types present at the NMJ 
reveal certain limitations of the LCM technique in isolating fundamental NMJ myonuclei, as 
genes expressed in e.g. Schwann cells were highly enriched in the synaptic tissue samples 
(e.g. Sox10 with a 1193-fold change in the synaptic vs. extrasynaptic EDL comparison). We 
are therefore unable to distinguish whether a synaptically enriched gene in our NMJ 
expression profile actually originated from muscle itself or was expressed by another cell 
type present at the NMJ that was co-isolated with LCM. This highlights the importance of 
further experiments that confirm the origin of a potential novel NMJ gene, especially when 
considering the concept of motor neuron-derived mRNAs at the NMJ. In situ hybridization 
approaches could be used to confirm the origin of candidate genes such as Dlk1. The 
limitations discussed above may have hindered our ability to assess the full extent of 
transcriptomic differences between EDL and SOL muscle NMJs. However, the idea of a 
powerful determinant of NMJ type such as a DLK1 appears attractive and future research will 
evaluate the potential role of DLK1 in determining NMJ type. 
  





Figure 4-1. Laser-capture microdissection (LCM) procedure for the isolation of neuromuscular 
junction areas. The “before” image shows several synaptic areas (green fluorescence signal) marked 
for LCM. A defocused UV-laser impulse was fired at each individual purple dot in the marked areas to 
isolate the desired tissue by lifting it up into a specialized adhesive PCR tube cap. The “after” image 
confirms the successful microdissection of the desired tissue areas. The “inside cap” picture shows 
the bits of isolated tissue that were captured by the LCM procedure. Scale bar, 150 μm. 
  




Figure 4-2. Principal coordinate analysis (PCoA) reveals sample clusters according to synaptic 
or extrasynaptic origin, as well as according to muscle type. Each plot symbol represents a 
sample. Distance between samples can be interpreted as the typical log2 fold change of the top 500 
genes that distinguish them. Groups: EDL_XNMJ, extrasynaptic EDL; EDL_NMJ, synaptic EDL; 
SOL_XNMJ, extrasynaptic SOL; SOL_NMJ, synaptic SOL. 
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Figure 4-3. Neuromuscular junction gene expression profile of the EDL muscle. A) Mean-
difference plot of synaptic vs. extrasynaptic EDL muscle showing log2 fold changes (log2FC) of genes 
on the Y-axis plotted against the average gene expression strength in log2 counts per million (log-
CPM) on the X-axis. Each black dot represents an expressed gene in the study (legend “0”). 
Differentially expressed genes (FDR p-value < 0.05) with a positive fold change are marked in purple 
(legend “1”), while genes with a negative fold change are marked in orange (legend “-1”). B) 
Unclustered heatmap visualization of the top 50 synaptically enriched genes in the synaptic EDL 
samples according to both fold change as well as FDR p-value (fold change > 32, FDR p-value < 0.001). 
Shown are scaled CPM expression values of all synaptic and extrasynaptic EDL samples. Darker hues 
of blue represent stronger expression in these samples. Groups: EDL_XNMJ, extrasynaptic EDL; 
EDL_NMJ, synaptic EDL. C-E) PANTHER gene ontology enrichment analysis of the biological process, 
molecular function, and cellular component categories. Shown are the top five terms in each category 
according to FDR p-value. 
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Figure 4-4. Neuromuscular junction gene expression profile of the SOL muscle. A) Mean-
difference plot of synaptic vs. extrasynaptic SOL muscle showing log2 fold changes (log2FC) of genes 
on the Y-axis plotted against the average gene expression strength in log counts per million (log-CPM) 
on the X-axis. Each black dot represents an expressed gene in the study (legend “0”). Differentially 
expressed genes (FDR p-value < 0.05) with a positive fold change are marked in purple (legend “1”), 
while genes with a negative fold change are marked in orange (legend “-1”). B) Unclustered heatmap 
visualization of the top 50 synaptically enriched genes in the synaptic SOL samples according to both 
fold change as well as FDR p-value (fold change > 16, FDR p-value < 0.01). Shown are scaled CPM 
expression values of all synaptic and extrasynaptic SOL samples. Darker hues of blue represent 
stronger expression in these samples. Groups: SOL_XNMJ, extrasynaptic SOL; SOL_NMJ, synaptic SOL. 
C-E) PANTHER gene ontology enrichment analysis of the biological process, molecular function, and 
cellular component categories. Shown are the top five terms in each category according to FDR p-
value. 
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Figure 4-5. Neuromuscular junction gene expression differences between the EDL and SOL 
muscles. A) Mean-difference plot of synaptic EDL vs. synaptic SOL showing log2 fold changes 
(log2FC) of genes on the Y-axis plotted against the average gene expression strength in log-counts-
per-million (log-CPM) on the X-axis. Each black dot represents an expressed gene in the study (legend 
“0”). Differentially expressed genes (FDR p-value < 0.05) which are more strongly expressed in the 
synaptic EDL are marked in purple (legend “1”), while genes more strongly expressed in the synaptic 
SOL are marked in orange (legend “-1”). B) Unclustered heatmap visualization of strongly 
differentially expressed genes according to both fold change as well as FDR p-value (fold change > 8, 
FDR p-value < 0.05) between synaptic EDL and synaptic SOL. In order to filter out the general muscle 
difference effect, only genes that were also synaptically enriched in the respective synaptic vs. 
extrasynaptic comparisons of the EDL and SOL were included. Shown are scaled CPM expression 
values of all synaptic EDL and SOL samples. Darker hues of blue represent stronger expression in 
these samples. C-E) PANTHER gene ontology enrichment analysis of the biological process, molecular 
function, and cellular component categories. Shown are the top five terms in each category according 
to FDR p-value. Groups: EDL_XNMJ, extrasynaptic EDL; EDL_NMJ, synaptic EDL; SOL_XNMJ, 
extrasynaptic SOL; SOL_NMJ, synaptic SOL. 
 
  




Figure 4-6. Unclustered heatmap visualization of all genes that were synaptically enriched in 
both the EDL as well as the SOL. Shown are scaled CPM expression values of all synaptic and 
extrasynaptic EDL and SOL samples. Darker hues of blue represent stronger expression in these 
samples. Groups: EDL_XNMJ, extrasynaptic EDL; EDL_NMJ, synaptic EDL; SOL_XNMJ, extrasynaptic 
SOL; SOL_NMJ, synaptic SOL. 
  




Figure 4-7. RNA-sequencing data validation with semiquantitative qPCR of laser-captured 
synaptic and extrasynaptic tissue of the EDL and SOL muscle. All expression values are fold 
changes relative to the reference gene Hprt. Black dots indicate extrasynaptic (XNMJ) biological 
replicates, while orange diamonds indicate synaptic (NMJ) ones. Data shown as mean ± SD of 
triplicate samples, * p < 0.05, ** p < 0.01, *** p < 0.001; N.D., undetected. 
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Figure 4-8. Overexpression of TBX21 in the tibialis anterior (TA) muscle leads to increased 
acetylcholine receptor (AChR) density in the synaptic endplate. Confocal microscopy images of 
NMJs in TA myofiber bundles electroporated with A) an eGFP expression plasmid, or B) 
electroporated with a MYC-DDK-tagged Tbx21 expression plasmid. C-K) NMJ morphology parameters 
determined six weeks after electroporation with either eGFP or Tbx21. C) Total postsynaptic endplate 
area. D) Postsynaptic endplate perimeter. E) Postsynaptic endplate diameter. F) Perimeter of the 
postsynaptic AChRs. G) Total area of the postsynaptic AChRs. H) “Compactness” (AChR density at the 
synaptic endplate). I) Axon diameter. J) Perimeter of the presynaptic nerve terminal. K) Total area of 
the presynaptic nerve terminal. α-BTX: α-Bungarotoxin; 2H3/SV2: Two different antibodies staining 
Neurofilament (2H3) and synaptic vesicle glycoprotein 2A (SV2). eGFP: Enhanced green fluorescent 
protein. MYC-DDK: Antibody targeting the MYC-DDK tag; merge: Compound image of all respective 
channels. Data shown as median ± 95% confidence intervals; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
Images of three biological replicates per condition were combined for the analysis. Scale bar: 25 μm. 
  




Figure 4-9. Gene expression plots of known and potential novel NMJ genes. Gene expression in 
log2 counts per million (logCPM) of the RNA-sequencing count data of the indicated individual genes 
across all experimental groups is shown. Each diamond represents a sample. Groups: EDL_XNMJ, 
extrasynaptic EDL; EDL_NMJ, synaptic EDL; SOL_XNMJ, extrasynaptic SOL; SOL_NMJ, synaptic SOL. 
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5 Sinergia Project: Effects of Aging on the Neuromuscular 
Junction Transcriptome  
Contributions to this project: Martin Weihrauch received tibialis anterior muscles from 
young and old mice from Dr. Daniel J. Ham. Martin Weihrauch conducted all of the 
experiments and analyses pertaining to this project report. 
 
Contributions to future manuscript: 
The sequencing dataset of laser-capture microdissected NMJs described here will be included 
in a joint Sinergia project publication with several other authors. Martin Weihrauch also 
contributed to the initial analysis of the dataset. 
 
5.1 Abstract 
The hallmarks of aging include progressive loss of muscle mass and strength, alongside 
neurophysiological perturbations. The neuromuscular junction (NMJ) is critically involved in 
age-related musculoskeletal impairments, but it remains unclear whether detrimental 
alterations of the NMJ precede or follow the functional decline of muscle. We hypothesized 
that aging might lead to dysregulation of the NMJ gene program and thus contribute to the 
structural and functional decline of the NMJ. We used laser-capture microdissection to isolate 
fundamental myonuclei underlying the NMJ and generated NMJ gene expression profiles of 
the tibialis anterior (TA) muscle of 10-month-old and 30-month-old mice with next-
generation RNA-sequencing to investigate whether aging leads to perturbations of the NMJ 
gene program. Our results revealed the NMJ gene program to be remarkably stable, with 
identical gene expression levels of canonical NMJ genes. Our findings argue against the 
hypothesis that aging leads to a broad deterioration of the NMJ gene program that would 
contribute to perturbations of NMJ structure and function. 
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5.2 Introduction 
Aging causes progressive loss of muscle mass and function, also known as sarcopenia, which 
gravely impacts quality of life in the elderly, predisposing them to an increased risk of all-
cause mortality (Janssen, Shepard et al. 2004, Narici and Maffulli 2010). One 
neurophysiological consequence of aging is the remodeling of the neuromuscular junction 
(NMJ), which leads to reduced size, fragmentation and functional impairments of the 
postsynaptic apparatus (Valdez, Tapia et al. 2010, Jang and Van Remmen 2011). Aging 
myofibers undergo denervation and re-innervation cycles that lead to remodeling of motor 
units. Fast-twitch fibers are more susceptible to such denervation events and may become 
re-innervated through axonal sprouting of slow motor neurons, resulting in a conversion of 
fast-twitch type II to slow-twitch type I myofibers. Importantly, age-related remodeling 
events at the NMJ may precede myofiber alterations (Deschenes, Roby et al. 2010). It has 
been suggested that aging changes neuromuscular junctions mainly through the 
accumulation of myofiber segment damage at the NMJ. While the myofiber segment first 
degenerates and then quickly regenerates, this leaves the affected NMJ permanently 
perturbed (Li, Lee et al. 2011). However, it is also conceivable that aging leads to 
perturbations of the NMJ gene program, the dysregulation of which might lead to prolonged 
acetylcholine receptor turnover and disruption of pre- and post-synaptic apposition. If aging 
perturbs the NMJ gene program this may predispose them to damage.  
 
Caloric restriction (CR), the reduction of daily caloric intake by about 30 to 40%, 
ameliorates detrimental effects of aging and increases lifespan (Golbidi, Daiber et al. 2017). 
Importantly, CR attenuates age-related changes in mouse NMJs by significantly reducing the 
occurrence of fragmented, faint, and denervated postsynaptic sites (Valdez, Tapia et al. 
2010). Various CR mimetics exist and can slow the aging of NMJs and myofibers (Stockinger, 
Maxwell et al. 2017). One such CR mimetic is rapamycin (RM), which provides health 
benefits and extends lifespan in rodents (Ehninger, Neff et al. 2014, Zhang, Bokov et al. 
2014). Since both, CR and RM may exert beneficial effects on the NMJ gene program and 
counteract its putative age-related perturbation, we set out to investigate the effect of aging 
on the NMJ transcriptome and included experimental groups with CR and RM treatment. 
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In this study, we combined laser-capture microdissection of the NMJ with next-
generation RNA-sequencing to generate NMJ gene expression profiles of the tibialis anterior 
(TA) muscle of 10-month-old and 30-month-old mice to investigate whether aging leads to 
perturbations of the NMJ gene program. Furthermore, we examined the effect of treatment 
with CR and RM on the aging NMJ transcriptome. 
 
5.3 Material and Methods 
Animals, tissue harvest and sample preparation. There were four different groups of male 
C57BL/6 mice, 10-month-old (only control (CT)) and 30-month-old mice (from control (CT), 
rapamycin-treated (RM), and caloric restriction-treated (CR) groups). The 30-month-old 
mice were treated with either RM (~ 4 mg/kg per day) or CR starting from the age of 15-
month. The mice were raised and treated by Dr. Daniel J. Ham. Tibialis anterior (TA) muscles 
of 10-month-old (only control (CT)) and 30-month-old mice (from control (CT), rapamycin-
treated (RM), and caloric restriction-treated (CR) groups) were rapidly dissected and 
immediately immersed in 1 ml of preservative Krebs-Ringer solution containing α-
Bungarotoxin (Alexa Fluor™ 488 conjugate; 3 µl/ml) for 1 hour. After incubation the muscles 
were partially embedded in 10% gum tragacanth (Sigma-Aldrich, catalog no. G1128), frozen 
in liquid nitrogen-cooled 2-Methylbutane (-150°C; Sigma-Aldrich, catalog no. M32631), and 
stored at -80°C until further processing. 
 
Serial frozen cross-sections of 20 µm thickness containing NMJ areas were cut at -20°C 
using a cryostat (Leica). Up to 30 serial sections were mounted per RNase AWAY®-treated 
(Sigma-Aldrich) regular glass slide (Menzel). In order to deactivate endogenous RNases, 
sections were dehydrated in 100% EtOH inside the cryostat chamber for 5 min and then 
stored at -80°C in 50-ml conical tubes containing several grams of desiccant (ROTH, silica Gel 
Orange, catalog no. P077.4) to prevent tissue rehydration. The TA muscles of eight animals 
per condition were used for the laser-capture experiments. 
 
Laser-capture microdissection Laser-capture microdissection (LCM) was performed using 
a PALM MicroBeam system (Zeiss) consisting of an inverted microscope with a motorized 
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stage, an ultraviolet laser and an X-Cite fluorescence illuminator. The microdissection 
process was visualized with an AxioCam ICc camera coupled to a computer and controlled by 
the PALM RoboSoftware. Synaptic regions were visualized utilizing fluorescence (α-
Bungarotoxin - Alexa Fluor™ 488 conjugate) microscopy with an x20 objective. A yellow 
fluorescent protein (YFP)-filter was used to reduce background noise and improve 
visualization. About 300 synaptic regions (“NMJ”) and an equivalent amount of extrasynaptic 
(“XNMJ”) tissue areas equaling roughly 0.65 mm² were collected per sample, resulting in a 
total number of about 9600 collected NMJ areas. Selected areas were cut and catapulted by 
laser pulses, utilizing automated laser-pressure catapulting (autoLPC) mode, into opaque 
AdhesiveCap 500 PCR tubes (Zeiss). For every sample, the lid of the AdhesiveCap PCR tube 
was checked for presence of successfully catapulted tissue, indicating laser-capture success. 
 
In order to lyse laser-captured material, 10 µl Single-Cell Lysis Buffer (Clontech, catalog no. 
635013) supplemented with freshly-added Protector RNase Inhibitor (Roche) was added 
into the top of an AdhesiveCap PCR tube and pipetted up and down about ten times before 
dispensing the lysate into the bottom of a 1.5 ml reaction tube (Eppendorf). Afterwards the 
AdhesiveCap lid was checked under the microscope and the absence of captured material 
indicated successful suspension of tissue in the lysis buffer. Samples were lysed for 5 min at 
RT and then stored immediately at -80°C until further processing. The whole process from 
thawing a slide until completed tissue lysis was kept under an hour to avoid RNA degradation 
by endogenous RNAses present in the tissue. 
 
Low-input RNA-Sequencing. The laser-captured whole tissue lysates were used for RNA-
sequencing library generation with the SMART-Seq v4 Ultra Low Input RNA Kit for 
Sequencing (Clontech, catalog no. 634894) and according to the SMART-Seq v4 Half Volume 
NexteraXT Standard Protocol. Usage of this kit and protocol supposedly improves upon the 
SMART-Seq2 method that was employed in the preceding NMJ-sequencing project detailed 
in Manuscript II of this thesis. Quality control of the cDNA-sequencing-libraries was 
conducted with the Agilent Bioanalyzer (Agilent) and the average fragment size of the 
libraries was determined. The libraries were sequenced (Single-end reads, 76 sequencing 
cycles) using a NextSeq 500 system (Illumina) at the Quantitative Genomics Facility of the 
 Sinergia Project: Effects of Aging on the Neuromuscular Junction Transcriptome 
128 
Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zürich in Basel. The 
entire process from sequencing library preparation to RNA-sequencing was conducted by D-
BSSE personnel. 
 
RNA-sequencing data preprocessing, read mapping and analysis. The raw sequencing 
reads (FASTQ-files) were quality-filtered and sequencing-adapter-trimmed using BBDuk 
from BBTools (Version 38.57) with the following non-standard parameters: ktrim = r, k = 23, 
mink = 11, hdist = 1, qtrim = rl, trimq = 10, ftm = 5, minlen = 35. The following annotation 
files were used for read mapping: Gencode Release M22 (GRCm38.p6) of the transcript 
sequences, which includes the nucleotide sequences of all transcripts on the reference 
chromosomes. GTF file: comprehensive gene annotation (regions: CHR), which contains the 
comprehensive gene annotation on the reference chromosomes only). Salmon (Version 
0.14.1) was used to generate an index with the following non-standard parameters: --k 29, -
-type quasi, --gencode (as Gencode annotation files are used). Salmon quasi-mapping was run 
with these parameters: --libType U, --validateMappings, --fldMean 102, --fldSD 62, --seqBias 
(the average fragment length of the sequencing libraries was 102 with a standard deviation 
of 62) (Patro, Duggal et al. 2017). 
 
RNA-sequencing data analysis was conducted with R (Version 3.6.0) and R-Studio (Version 
1.1.463) running on CentOS Linux 7 (sciCORE R-Studio server service). The edgeR package 
(Version 3.26.7) from Bioconductor (Version 3.9.0) was used for differential gene expression 
analysis. Other packages used for data handling and plotting were tidyverse (1.2.1), 
pheatmap (1.0.12), biomaRt (2.40.3), RColorBrewer (1.1.2), tximport (1.12.3) and 
GenomicFeatures (1.36.0). 
 
Differential gene expression was determined via genewise statistical tests relative to a fold 
change threshold of log2(1.5) with the glmTreat() methodology of the edgeR package, which 
improves upon the false discovery rate of existing methods and potentially identifies more 
biologically relevant genes (McCarthy and Smyth 2009). Genes that passed this fold change 
threshold and had a FDR p-value < 0.05 were called differentially expressed in this study. 
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After sequencing library normalization and pre-filtering to remove low-count genes, 18621 
genes were found to be expressed in our dataset. 
 
Functional annotation analyses with the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) Bioinformatics Resources 6.8 and term enrichment were 
based on FDR p-values. 
 
Calculations were performed at sciCORE (http://scicore.unibas.ch/) scientific computing 
core facility at University of Basel. 
 
5.4 Results 
Expression profiling of young and old neuromuscular junctions of the tibialis anterior 
muscle 
We used laser-capture microdissection (LCM) to isolate neuromuscular junction areas 
(“NMJ” or “synaptically enriched tissue”) and equal amounts of adjacent, extrasynaptic tissue 
as control (“XNMJ” or “extrasynaptic control tissue”) from serial cryosections of the tibialis 
anterior (TA) muscle of 10-month-old (“young”) sedentary control mice, as well as of 30-
month-old (“old”) sedentary control mice, 30-month-old RM-treated mice, and of 30-month-
old CR-treated mice. The LCM-isolated tissues were lysed and the total lysate used for RNA-
sequencing. We used principal coordinate analysis (PCoA) to investigate whether there are 
any distinct patterns of gene expression among the samples. The first principal coordinate 
clearly separates the samples into either extrasynaptic or synaptic origin, while the second 
principal coordinate does not clearly subdivide the samples into additional clusters (Figure 
5-1 A). Further analysis of the second and third principal coordinates did not reveal further 
sample clusters (Figure 5-1 B). 
 
We then investigated differential gene expression between the various experimental 
conditions and summarized the results in Table 5-1. We found 1079 genes to be synaptically 
enriched in the 10-month-old synaptic control samples compared to the respective 
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extrasynaptic control samples (10M.NMJ.CT vs. 10M.XNMJ.CT). The same comparison with 
the 30-month-old control samples yielded 744 genes (30M.NMJ.CT vs. 30M.XNMJ.CT). We did 
not detect any differentially expressed genes between the young and old synaptic samples 
(30M.NMJ.CT vs. 10M.NMJ.CT). The different comparisons of the young and old control 
groups are shown in Figure 5-2. 
 
Table 5-1. Differentially expressed genes between the different comparisons. 
Comparison Genes with positive fold 
change 
Genes with negative fold 
change 
10M.NMJ.CT vs. 10M.XNMJ.CT 1079 464 
30M.NMJ.CT vs. 30M.XNMJ.CT 744 289 
30M.NMJ.CT vs. 10M.NMJ.CT 0 0 
30M.XNMJ.CT vs. 10M.XNMJ.CT 38 23 
30M.NMJ.RM vs. 30M.XNMJ.RM 710 103 
30M.NMJ.CR vs. 30M.XNMJ.CR 867 173 
30M.NMJ.CR vs. 30M.NMJ.CT 1 4 
30M.NMJ.RM vs. 30M.NMJ.CT 0 0 
Differential gene expression was determined via gene-wise statistical tests relative to a fold change 
threshold of log2(1.5); FDR p-value < 0.05. Groups: 10M.NMJ.CT, 10-month control, synaptic; 
10M.XNMJ.CT, 10-month control, extrasynaptic; 30M.NMJ.CT, 30-month control, synaptic; 
30M.XNMJ.CT, 30-month control, extrasynaptic. 30M.NMJ.RM, 30-month rapamycin-treated, 
synaptic; 30M.XNMJ.RM, 30-month rapamycin-treated, extrasynaptic; 30M.NMJ.CT, 30-month 
control, synaptic; 30M.NMJ.CR, 30-month caloric restriction-treated, synaptic; 30M.XNMJ.CR, 30-
month caloric restriction-treated, extrasynaptic. 
 
To confirm whether we successfully enriched synaptic tissue we looked at the genes with the 
strongest fold changes and lowest p-values in the 10-month control group (Figure 5-3 A) 
and the 30-month control group (Figure 5-3 B). Among the top 50 synaptically enriched 
genes of the 10-month control were Ache, Chrne, Chrna1, Chrnd, Gdnf, Erbb3, Etv5, Dusp6 and 
many others, all of which represent well-known NMJ genes (Nazarian, Bouri et al. 2005, 
Hippenmeyer, Huber et al. 2007, Wu, Xiong et al. 2010). The top synaptically enriched 
genes in the 30-month control group were very similar. These findings confirmed the 
successful enrichment of synaptic tissue with LCM. 
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Gene expression of canonical neuromuscular junction components is not different 
between young and old mice 
Since we did not detect any differentially expressed genes between the 10-month-old and 30-
month-old groups, we decided to look directly at log2-transformed counts per million 
(logCPM) of canonical neuromuscular junction components, as it is conceivable that there are 
slight expression differences that did not pass our cutoffs for differential gene expression. 
The genes Chrne (Figure 5-6 A) and Etv5 (Figure 5-6 B) are well known to be enriched at 
the neuromuscular junction. Both genes showed equally strong and stable expression values 
across the experimental conditions, although Etv5 appeared to be expressed slightly stronger 
in the extrasynaptic samples. The median difference in synaptic versus extrasynaptic 
expression of Chrne was over 1000 counts per million, irrespective of age and conditions, 
highlighting its immense synaptic enrichment. As expected, Utrn (Figure 5-6 C) was 
synaptically enriched, while Dmd (Figure 5-6 D), which is known to be more expressed 
extrasynaptically, was not. Expectedly, both Utrn and Dmd showed stronger extrasynaptic 
expression than Chrne or Etv5, further strengthening the validity of our RNA-sequencing 
dataset. While Aplp2 (Figure 5-6 E) was moderately expressed in the extrasynaptic samples, 
it was nevertheless strongly enriched at the NMJ. Dusp6 (Figure 5-6 F) showed synaptic 
expression values comparable to Chrne. While Musk (Figure 5-6 G) was certainly enriched at 
the NMJ, it was less so than Chrne.  
 
As there were no differentially expressed genes between the synaptic samples of the 
30-month and 10-month control groups (Figure 5-2 C), we looked at their respective 
extrasynaptic samples, which yielded 38 genes with stronger expression in the old samples 
(Figure 5-4 B) and 23 genes with stronger expression in the young samples (Figure 5-4 A) 
(Comparison: 30M.XNMJ.CT vs. 10M.XNMJ.CT). Functional annotation analysis of these genes 
with DAVID Bioinformatics Resources 6.8 did not reveal any enriched terms, most likely 
owing to the small number of genes detected. 
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Treatment with rapamycin or caloric restriction had no pronounced effects on the 
neuromuscular junction transcriptome 
While we detected a large amount of synaptically enriched genes in the RM-treated and CR-
treated samples compared to their respective controls, the comparison of the synaptic RM 
and CR against the synaptic 30-month-old control samples yielded few or even no 
differentially expressed genes (Table 5-1 and Figure 5-5). 
 
5.5 Discussion 
The goal of this study was to investigate whether aging perturbs the NMJ gene program, a 
dysregulation of which could contribute to the observed age-related structural and 
functional alterations of the NMJ. We also examined the effect of treatment with caloric 
restriction (CR) and rapamycin (RM) on the aging NMJ transcriptome. Our results revealed 
the NMJ gene program to be remarkably stable, with nearly identical gene expression levels 
of canonical NMJ genes, regardless of age or treatment.  
 
Although the results of this study did not reveal overt effects of aging on the NMJ 
transcriptome, it is possible that aging leads to subtle gene expression changes in a large 
number of genes, which could have a cumulative affect resulting in profound biological 
effects. As the skeletal muscle transcriptome undergoes significant changes with age 
(Shafiee, Asgari et al. 2018), we investigated whether we detected such general aging 
differences between our young and old extrasynaptic samples. However, we detected only a 
very small number of genes to be differentially expressed. Given the ultra-low input and lack 
of precise control of input amount in this RNA-sequencing dataset, it seems reasonable that 
smaller fold changes between genes, especially of ones with lower expression strength, may 
go undetected when using conventional cutoff detection values (i.e. fold change > 2, adjusted 
p-value < 0.05). Additionally, the effects of noise are generally more pronounced for genes 
with relatively small expression strengths in a given sample or experimental condition. In 
this case, gene set enrichment analyses and comparison with whole-muscle aging time 
course data may reveal common patterns of gene expression perturbation induced by aging. 
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A recent transcriptomic study of the effects of sarcopenia on skeletal muscle reported 
gene expression changes associated with the neuromuscular junction (Lin, Chang et al. 
2018). Specifically, Lin et al. (2018) reported decreased gene expression of apolipoprotein E 
(ApoE), docking protein 7 (Dok7), syntrophin alpha 1 (Snta1), and aquaporin 4 (Aqp4), as 
well as genes encoding several serpins in the aging muscle. They also report increased gene 
expression of cholinergic receptor nicotinic alpha 1 subunit (Chrna1), cholinergic receptor 
nicotinic beta 1 subunit (Chrnb1), and of low density lipoprotein receptor-related protein 4 
(Lrp4). According to Lin et al. (2018), the observed increase of Chrna1, Chrnb1, and Lrp4 
expressions reflects the change of myofiber types during aging, as slow-twitch myofibers 
have wider NMJs and larger nerve terminal areas than the fast-twitch myofibers. They 
conclude that their observed changes of neuromuscular junction-associated genes suggest a 
potential compensatory mechanism during NMJ decline by up-regulating acetylcholine 
receptors (Lin, Chang et al. 2018). Our NMJ-specific results did not reflect the described 
age-related changes in NMJ-associated genes, as none of the above genes were differentially 
expressed between our young and old synaptic samples. Furthermore, there also was no 
striking increase or decrease in the respective fold changes of these genes in the young 
synaptic vs. extrasynaptic and the old synaptic vs. extrasynaptic comparison of these genes. 
For example, Chrnb1 had a 5-fold change in the young and only a slightly lower 3.5-fold 
change in the old mice, which might indicate a somewhat lower synaptic enrichment in the 
old. However, as shown in Figure 5-6, gene expression of all canonical NMJ genes we looked 
at was nearly identical between young and old NMJs. We have to take into account that Li et 
al. (2018) compared 3-month-old with 24-month-old mice, while we compared 10-month-
old to 30-month-old mice.  
 
We conclude that our findings argue against the hypothesis that aging leads to a broad 
deterioration of the NMJ gene program that would contribute to perturbations of NMJ 
structure and function. 
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Figure 5-1. Principal coordinate analysis (PCoA) reveals sample clusters according to synaptic 
or extrasynaptic origin, but does not clearly separate samples by age. Principal coordinate 
analysis of the A) First and second, and of the B) second and third principal coordinates. Each plot 
symbol represents a sample. Distance between samples can be interpreted as the typical log2 fold 
change of the top 500 genes that distinguish them. Legend symbols: 10M, 10-month-old; 30M, 30-
month-old; CT, untreated control group; CR, caloric restriction group; RM, rapamycin group; NMJ, 
synaptic samples; XNMJ, extrasynaptic samples. 
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Figure 5-2. Aging does not lead to pronounced changes in gene expression at the 
neuromuscular junction. Mean-difference plots showing log2 fold changes (log2FC) of genes on the 
Y-axis plotted against the average gene expression strength in log2 counts per million (log-CPM) on 
the X-axis. Each black dot represents an expressed gene in the study (legend “0”). Differentially 
expressed genes (FDR p-value < 0.05) with a positive fold change are marked in purple (legend “1”), 
while genes with a negative fold change are marked in orange (legend “-1”). A) Synaptic vs. 
extrasynaptic 10-month-old control. This comparison yielded a large number of differentially 
expressed genes. B) Synaptic vs. extrasynaptic 30-month-old control. C) Synaptic 30-month-old 
control vs. synaptic 10-month-old control. The direct comparison of old vs. young synaptic samples 
did not yield any differentially expressed genes. D) Extrasynaptic 30-month-old control vs. 
extrasynaptic 10-month-old control. The direct comparison of old vs. young extrasynaptic samples 
yielded a low number of differentially expressed genes. Groups: 10M.NMJ.CT, 10-month control, 
synaptic; 10M.XNMJ.CT, 10-month control, extrasynaptic; 30M.NMJ.CT, 30-month control, synaptic; 
30M.XNMJ.CT, 30-month control, extrasynaptic. 
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Figure 5-3. Top 50 synaptically enriched genes of 10-month and 30-month-old animals. 
Unclustered heatmap visualization of the top 50 enriched genes by fold change (FDR p-value < 1*10-
8) in the synaptic samples of the A) 10-month control and B) 30-month control animals. Shown are 
scaled CPM expression values of all respective synaptic and extrasynaptic samples. Darker hues of 
blue represent stronger expression in these samples. Groups: CT.10M.XNMJ, 10-month control, 
extrasynaptic; CT.10M.NMJ, 10-month control, synaptic; CT.30M.XNMJ, 30-month control, 
extrasynaptic; CT.30M.NMJ, 30-month control, synaptic. 
 
  
 Sinergia Project: Effects of Aging on the Neuromuscular Junction Transcriptome 
138 
 
Figure 5-4. Unclustered heatmap visualization of all differentially expressed genes between 
young and old extrasynaptic controls. A) Genes with stronger expression in the 10-month-old 
extrasynaptic control samples. B) Genes with stronger expression in the 30-month-old extrasynaptic 
control samples. Shown are scaled CPM expression values of all respective extrasynaptic samples. 
FDR p-value cutoff for differential expression was set to < 0.05. Darker hues of blue represent 
stronger expression in these samples. Groups: CT.10M.XNMJ, 10-month control, extrasynaptic; 
CT.30M.NMJ, 30-month control, extrasynaptic. 
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Figure 5-5. Treatment with rapamycin (RM) or caloric restriction (CR) had no pronounced 
effects on the neuromuscular junction transcriptome when compared to the aging control. 
Mean-difference plots showing log2 fold changes (log2FC) of genes on the Y-axis plotted against the 
average gene expression strength in log2 counts per million (log-CPM) on the X-axis. Each black dot 
represents an expressed gene in the study (legend “0”). Differentially expressed genes (FDR p-value 
< 0.05) with a positive fold change are marked in purple (legend “1”), while genes with a negative fold 
change are marked in orange (legend “-1”). A) Synaptic vs. extrasynaptic 30-month RM. B) Synaptic 
RM vs. synaptic 30-month control. C) Synaptic CR vs. extrasynaptic CR. D) Synaptic CR vs. synaptic 
30-month control. Groups: 30M.NMJ.RM, 30-month rapamycin-treated, synaptic; 30M.XNMJ.RM, 30-
month rapamycin-treated, extrasynaptic; 30M.NMJ.CT, 30-month control, synaptic; 30M.NMJ.CR, 
30-month caloric restriction-treated, synaptic; 30M.XNMJ.CR, 30-month caloric restriction-treated, 
extrasynaptic. 
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Figure 5-6. Gene expression of canonical neuromuscular junction components is remarkably 
stable between young and old mice. Gene expression in log2 counts per million (logCPM) of 
individual genes across all experimental groups is shown. The two dashed lines show the median 
expression value either of all synaptic samples (red) or of all extrasynaptic samples (black), 
irrespective of age and condition. The median difference in logCPM is given in the plot subtitles. 
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6 General discussion 
6.1 Ladder climbing as a physiological resistance exercise model 
for skeletal muscle hypertrophy in mice  
Discussion and future perspectives 
Objective I: Establish a physiological resistance exercise model for mice and investigate the 
effect of chronic resistance exercise on the skeletal muscle transcriptome. 
 
Progressive resistance exercise training is the most effective strategy to physiologically 
increase muscle mass and strength in humans. Interestingly, low muscle strength in the 
elderly is independently associated with elevated risk of all-cause mortality irrespective of 
muscle mass (Newman, Kupelian et al. 2006, Li, Xia et al. 2018). Many pharmacological 
approaches have aimed at increasing muscle mass, however the resulting larger muscle mass 
was often not entirely functional and displayed reductions in specific muscular strength 
(Lach-Trifilieff, Minetti et al. 2014, Liu, Hammers et al. 2016, Morvan, Rondeau et al. 
2017). Despite numerous studies in recent decades, we still understand relatively little about 
the exact mechanisms by which skeletal muscle hypertrophy occurs in response to 
mechanical stimulation during muscle contraction (Burkholder 2007, Schoenfeld 2012). 
 
The three primary mechanisms presumably driving skeletal muscle hypertrophy are 
mechanical tension, metabolic stress, and muscle damage. It is clear that mechanical tension 
such as during resistance exercise (RE) leads to transient increases in muscle protein 
synthesis, which subsequently causes protein accumulation within myofibers, but the exact 
role of muscle damage and metabolic stress remains unclear (Tang, Perco et al. 2008, 
Damas, Phillips et al. 2016). Long-term increases in muscle size due to RE were linked to 
activation of mTOR and its downstream target RPS6KB1, which results in increased protein 
synthesis rates (Baar and Esser 1999, Terzis, Georgiadis et al. 2008). However, changes 
in the balance of muscle protein synthesis alone cannot explain the complex orchestration of 
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myofiber growth. There must be some way for myofibers to detect mechanical tension and 
turn this stimulus into signals that mediate hypertrophy. Specialized mechanoreceptors 
were hypothesized to facilitate this task, some of which are discussed in the introduction to 
this thesis, but so far they have eluded efforts to detect them (Goodman, Hornberger et al. 
2015, Bamman, Roberts et al. 2018).  
 
The absolute mechanical load does not seem to govern the degree of muscular 
hypertrophy as long as the RE is carried out to muscular failure (Schoenfeld, Grgic et al. 
2017). Yet, larger RE training volume enhances hypertrophy without additional strength 
gains (Schoenfeld, Contreras et al. 2019). Indeed, it has been shown that high-load versus 
low-load RE training confers different adaptations in terms of muscular strength, despite 
equal ensuing hypertrophy, reflecting most likely neuromuscular adaptations (task 
specificity). In addition, the influence of metabolic stress on skeletal muscle hypertrophy has 
been investigated by combining low-load RE with blood flow restriction of the exercised 
muscle groups. Similar degrees of hypertrophy were found in this modality compared with 
traditional high-load RE (Lixandrao, Ugrinowitsch et al. 2018). However, the exact 
mechanisms behind the apparent effects of metabolic stress and muscle damage on 
hypertrophy and strength are difficult to study, as neither occur in an entirely independent 
way from mechanical tension.  
 
Recently, the changes that occur in the muscle transcriptome upon RE have received 
increasing attention. Synergist ablation (SA) surgery has been used as an animal model of 
skeletal muscle hypertrophy and a robust increase of myonuclear transcriptional activity was 
reported during the early stages of myofiber hypertrophy (Kirby, Patel et al. 2016). Yet, the 
acute hypertrophic adaptations in the SA model are masked by inflammation caused by the 
surgical nature of the intervention (Armstrong, Marum et al. 1979). Transcriptomic studies 
in human subjects are extremely challenging due to large differences between different 
classes of non-, modest-, and extreme-responders to RE, large differences between myofiber 
types, and large differences between young and old subjects (Raue, Trappe et al. 2012, 
Thalacker-Mercer, Stec et al. 2013). However, pronounced differences in myonuclear 
transcriptional ability were detected between young and old humans, as well as in aged mice 
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(Kirby, Lee et al. 2015, Brook, Wilkinson et al. 2016). It is clear from these various studies 
of the muscle transcriptome in response to RE that increased ribosomal biogenesis, in part 
mediated by mTORC1 and its downstream target p70S6K, is a central hallmark of skeletal 
muscle hypertrophy (Bamman, Roberts et al. 2018). Yet, the exact transcriptional 
mechanisms governing muscle transcriptomic changes in response to RE warrant further 
investigation. 
 
Therefore, it would be ideal to be able to study changes in gene expression patterns 
upon the physiological stimulus of RE mimicking human RE, but at the same time avoiding 
many of the confounding issues discussed above. This would allow us to gain novel insights 
into the workings of the conversion of a mechanical stimulus into the adaptation of skeletal 
muscle to overload. To this end, we aimed at establishing ladder climbing as a physiological 
resistance exercise model for skeletal muscle hypertrophy in mice. However, our devised 
training model had several shortcomings that prevented it from robustly inducing 
hypertrophy, which we will address in the following paragraphs. The training protocol 
employed in our study might have been insufficient to induce larger adaptations in muscle 
mass. For example, available weights (originally leaden bullet weights for fishing) were 
limited to 11, 19, or 32 g, which probably did not allow for sufficiently fine-grained 
progressive overload in terms of weight. Instead, we eventually had to increase exercise 
volume by conducting more ladder climbs at the same maximal intensity (32 g) per training 
session. Additionally, it was evident that the resistance exercise group (EX) could have 
handled larger absolute weights if only the weights had not impaired their balance by 
covering too much of their tails (i.e. adding a 11 g weight in addition to a 32 g weight). It 
would most likely be beneficial to use weights of smaller dimensions (i.e. using denser 
materials, for example Wolfram (density of 19.25 g/cm2) compared to Lead (density 
11.342 g/cm2) and more fine-grained incremental steps for RE training (weights in proper 
steps of 5 g, from 5 to 100 g). This might enable sufficiently stimulating progressive overload 
to induce hypertrophy.  
 
In a similar ladder training model with rats (Hornberger and Farrar 2004), the rats 
were eventually able to carry up to 287% of their own body weight, a much greater intensity 
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compared to what we achieved in our model (~110% of body weight). However, unlike with 
rats, for which a load-carrying device can be attached to their relatively sturdy tails, this kind 
of setup is not feasible with mice. In another study with rats, the authors employed a 
weighted harness to apply the progressive overloading, mimicking weight-bearing human 
exercise. Increased GAS muscle mass and hind limb grip strength was reported (Strickland, 
Abel et al. 2016). We considered a similar approach using weighted vests with mice, but 
discarded the idea as compliance in mice would be a big issue. Compared to rats, which can 
be coerced into ladder climbing with a behavior-reinforcing food reward, mice are much 
more difficult to motivate. If task intensity grows too difficult, it is likely that mice would 
rather stop or simply drop from the ladder, hampering training protocol compliance. 
 
In terms of RE volume, the typical rat ladder-climbing study conducted about four to 
nine complete ladder climbs per training session, three to six times per week, albeit with 
increasing intensity within or between sessions (Hornberger and Farrar 2004, Strickland, 
Abel et al. 2016). Resistance exercise training volume may be beneficial in terms of muscular 
hypertrophy (Schoenfeld, Contreras et al. 2019). In our study, the mice eventually carried 
32 g, or approximately 110% of their own body weight for 5 sets per session, each lasting 
5 min. During each individual training set, a mouse would complete between 15 and 20 
ladder climbs before it could no longer be motivated to continue the task and required a 
resting period. We conducted the training sessions 5 days a week, Monday through Friday. 
Thus, total weekly RE volume (up to 500 complete ladder climbs) was larger compared with 
the rat studies, yet exercise intensity was markedly lower due to loading constraints, possibly 
resulting in a more aerobic exercise component. We did not assess aerobic performance, as 
a maximum running capacity test would have confounded our results. Despite the relatively 
large RE volume when compared to the above-mentioned rat studies, no overt hypertrophy 
of the assessed muscles ensued. 
 
Resistance exercise model approaches other than weight-bearing ladder climbing 
were developed recently. One such RE modality that is feasible with mice is so-called 
resistance running, a type of loaded treadmill or voluntary wheel running. In one study, 10 
weeks of voluntary resistance-wheel exercise (RWE) elicited muscle mass increases of the 
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SOL (~ 52%), GAS (~ 26.5%) and QUAD (~ 16.5%) muscles (Soffe, Radley-Crabb et al. 
2016). In several studies of RWE, the SOL muscle usually shows the largest hypertrophic 
response, whereas the TA and EDL muscles were reported to be exempt from hypertrophy 
(Konhilas, Widegren et al. 2005, Legerlotz, Elliott et al. 2008, Soffe, Radley-Crabb et al. 
2016). Interestingly, no additional benefits in terms of SOL muscle hypertrophy between a 
“low resistance” (resistance capped at 5 g) and “high resistance” (resistance capped at 12 g) 
wheel-running protocol was reported (Konhilas, Widegren et al. 2005). Perhaps 
unexpectedly, RWE did not induce hypertrophy in the triceps brachii muscle of the forelimb, 
yet grip strength was improved (Soffe, Radley-Crabb et al. 2016), except in one study of a 
mdx mouse model, which is a popular model for studying Duchenne muscular dystrophy 
(Bulfield, Siller et al. 1984, Call, McKeehen et al. 2010). Although RWE has certain 
benefits, it does bring a substantial aerobic component and thus presents more of a mixed 
type of exercise, not necessarily reflecting pure muscular adaptations in terms of 
hypertrophy, as discussed by Roemers et al. (Roemers, Mazzola et al. 2018). The authors 
argue that a RWE group should always be tested together with a non-resistance wheel-
running group to discern resistance from endurance exercise adaptations. Furthermore, 
unloaded voluntary tower climbing in the home cage was recently investigated as a potential 
RE model, but no functional or muscular changes were reported (Roemers, Mazzola et al. 
2018). This stands in contrast to the findings of a comparable study in which just 3x3 min of 
unloaded isometric strength training (simply holding on to a vertical grid) induced sizable 
gains in muscle mass and cross-sectional diameter (Kruger, Gessner et al. 2013). We also 
tried this isometric RE modality, but even adding weights to the exercise paradigm (the mice 
carried 32 g for three times 5 min of vertical grid holding in week eight of the pilot study) did 
not lead to gains in muscle mass in our hands (Figure 6-1).  
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There is significant interest and need of a physiological resistance exercise model 
capable of inducing robust functional skeletal muscle hypertrophy in mice. Hypothetically, if 
the ladder climbing model described here can be improved by the measures discussed above 
and indeed induces robust hypertrophy of several mouse muscles, the model can then be 
used to study early, as well as late adaptations to physiological RE. By conducting a time 
course of RE training, we could analyze the muscle transcriptome, proteome, and secretome 
response to acute and chronic RE. Sampling should take place before and after the first 
exercise bout, after one week of RE, and then after two, four, eight, and 16 weeks in order to 
capture the entire range of the adaptive process. Blood samples would aid in the discovery 
of potential secreted myokines and improve our understanding of the secretion of already 
established myokines in response to contractile activity. While certainly labor-intensive, 
conducting the study as a time course would allow to trace temporal changes in gene 
expression, protein abundance, myokine levels and perhaps even epigenetic changes in 
response to RE. We could investigate epigenetic changes by conducting reduced 
representation bisulfite sequencing to analyze genome-wide methylation profiles, as it has 
recently been shown that transient DNA hypomethylation of gene-specific promotor regions 
precedes increases in mRNA expression in response to acute exercise (Meissner, Gnirke et 
al. 2005, Barres, Yan et al. 2012). It would also be interesting to conduct ATAC-seq (Assay 
for Transposase-Accessible Chromatin using sequencing) in order to gain a better 
understanding of how chromatin accessibility changes throughout the adaptive process to 
RE (Buenrostro, Giresi et al. 2013). The obtained gene expression and proteomic data 
could then be analyzed in combination to narrow down key changes that occur in response 
to RE and during skeletal muscle hypertrophy both on a transcriptional and translational 
level. The identified, highly upregulated (or repressed) candidate genes could help to find 
novel mechanosensitive participants and pathways, thus aiding our understanding of 
mechanotransduction. To this end, investigating the phosphoproteome might yield 
additional information about potential protein activity modifications upon acute and chronic 
contractile activity, possibly revealing novel kinases or activity of kinase domains of already 
known proteins involved in these signaling events. 
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The established model, as well as results obtained from the hypothetical time course 
study above, could then also be used to investigate various disease models. Perhaps certain 
genes/proteins/myokines identified to play important roles in skeletal muscle hypertrophy 
in our hypothetical time course study may ameliorate insulin sensitivity in mouse models of 
obesity and type 2 diabetes mellitus. We could use the resistance exercise intervention itself 
to find potential factors that may ameliorate symptoms of metabolic syndrome and diabetes, 
as RE may perhaps be particularly effective in these cases. To this end we could use our RE 
model to train e.g. high-fat diet mice (if feasible) or a genetic diabetes model to study in detail 
how, on a molecular level, physiological RE improves glycemic control, insulin sensitivity, 
lean muscle mass, and bone mineral density (Miller, Sherman et al. 1984, Nelson, 
Fiatarone et al. 1994, Baribault 2016). Furthermore, the RE model could be used to 
investigate the effect of pharmacological compounds on the development of grip strength and 
muscle contractility. For this, in situ muscle force measurements could be used to evaluate 
beneficial effects of compounds on muscle force-producing capabilities. 
 
Systemic and muscular diseases, such as cancer cachexia, metabolic syndrome, 
diabetes and sarcopenia cause muscle wasting, insulin resistance, weakness, frailty and 
metabolic perturbations, leading to increased all-cause mortality. Associated healthcare 
costs are immense and there is an urgent need for treatment and novel therapeutic 
interventions. A sparsity of pharmaceutical and physiological interventions for the 
amelioration of muscle mass and functional losses in disease, disuse and aging puts emphasis 
on the importance of a better understanding of the transcriptional and posttranscriptional 
control of muscular size. Pharmacological treatment options should focus first on 
ameliorating muscular weakness and second on increasing muscle mass. A physiological RE 
model and the various study approaches proposed in this thesis could help us in better 
understanding fundamental processes in hypertrophy and strength gains and therefore 
provide means to find therapeutic options and potentially design more effective resistance 
exercise programs to better promote skeletal muscle growth. 
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Figure 6-1. Muscle weight after eight weeks of isometric strength training. Mice were trained to 
hold on to a vertical grid with progressively heavier weights attached to the base of their tails 
(“Isometric” group). At the end of the study, the mice performed three times 5 min of vertical grid 
holding while carrying 32 g, three times per week. Control animals were sedentary. Shown is muscle 
weight normalized to body weight. Data shown as mean ± SD; N = 5. 
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6.2 Identification of Novel Synaptic Components by Transcriptome 
Profiling of the Murine Neuromuscular Junction  
Discussion and future perspectives 
Objective II: Identify novel components of the neuromuscular junction in the EDL and SOL 
muscles using next-generation RNA-sequencing. 
 
In this project, we set out to develop a methodology that combines laser-capture 
microdissection (LCM) with next-generation RNA-sequencing technology to identify novel 
components of the neuromuscular junction (NMJ). We achieved our primary goal and 
successfully identified a large number of potential novel NMJ genes in the EDL and SOL 
muscles, thus improving upon previous approaches from literature. However, our attempts 
to validate the localization of several novel NMJ genes, namely Tbx21, Crym, Hs6st2, Dlk1 and 
Nell2, to the NMJ via immunostaining with commercially available antibodies were 
unsuccessful. None of our attempts yielded a specific signal, either due to problems with 
antibody penetration into our muscle whole-mount and even single-fiber preparations, or 
due to inherent problems of the antibodies themselves (unsuitable for staining muscle tissue, 
or generally unspecific binding). It might be worthwhile to generate at least two different 
custom affinity-purified polyclonal antibodies against synthetic peptides of each candidate, 
which might lead to less unspecific staining. Alternatively, in situ hybridization approaches 
such as RNAscope® could be used to validate localization of the candidate mRNA to the NMJ. 
 
In order to compile a more concrete set of candidates for future investigations, we 
conducted some additional pathway analysis. We used DAVID Bioinformatics Resources 6.8 
to conduct further functional annotation analysis of our EDL and SOL muscle NMJ expression 
profiles and focused on the overlap of both muscles (Huang da, Sherman et al. 2009, Huang 
da, Sherman et al. 2009). DAVID “SEQ_FEATURE” and “KEYWORD” are functional 
annotation categories similar to GO / KEGG. The analysis revealed the DAVID SEQ_FEATUREs 
signal peptide and glycosylation site: N-linked (GlcNAc…) along with the KEYWORDs 
glycoprotein and signal as highly enriched terms in both muscles (Figure 6-2 F-G). The 
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number of genes associated with an enriched DAVID term was lower for the SOL, relative to 
the lower number of differentially expressed genes in that list (see Table 4-2). The functional 
annotation analysis of our EDL and SOL NMJ expression profiles clearly hints at the 
importance of signaling events involving glycosylation, as well as the organization of the 
extracellular matrix. This finding is perhaps not overly surprising, since it is known that 
specific glycans are concentrated at the NMJ and exert important regulatory functions 
(Yamaguchi 2002). One example would be the extensive glycosylation of α-dystroglycan, 
which loses its ability to properly anchor various canonical NMJ components at the basal 
lamina if it becomes hypoglycosylated, for example due to mutations in its glycosylating 
enzymes in congenital myasthenia (Ervasti and Campbell 1993, Talts, Andac et al. 1999, 
Endo 2005). Deficiencies in post-translational modifications of α-dystroglycan are thought 
to involve O-glycosylation pathways (Grewal and Hewitt 2003). Our gene expression 
profiles included the gene encoding for glutamine-fructose-6-phosphate transaminase 1 
(Gfpt1; fold change of 10 in the EDL NMJ). Deficiency of GFPT1 in muscle is known to cause 
congenital myasthenic syndrome with glycosylation defects, and was reported to result in 
reduced cell-surface expression of muscle AChRs (Zoltowska, Webster et al. 2013, Issop, 
Hathazi et al. 2018). Modified glycosaminoglycans such as chondroitin, dermatan and 
heparan sulfate proteoglycans are ubiquitous components of the cell surface, extracellular 
matrix and of basement membranes, where they exert important structural and regulatory 
functions. For example, acetylcholinsterase is anchored to the synaptic basal lamina by its 
collagenic tail ColQ, which contains two heparin-binding domains that interact with surface 
heparan sulfate proteoglycans (Aldunate, Casar et al. 2004). Also, agrin is perhaps the most 
prominent heparan sulfate proteoglycan within the NMJ basal lamina, where it is bound by 
laminin and plays fundamental roles in NMJ formation, function and maintenance (Denzer, 
Brandenberger et al. 1997, Li, Xiong et al. 2018). The immense enrichment of genes in 
DAVID functional annotation (Figure 6-2) and PANTHER gene ontology terms (Figure 4-3 
C-E) such as postsynaptic membrane organization, synaptic membrane adhesion, basement 
membrane, heparin binding, glycoprotein, signal peptide and many more prompted us to 
curate a selection of highly synaptically enriched enzymes that are putatively involved in the 
modulation of basal lamina components at the NMJ and thus potentially contributing to the 
regulation of a multitude of NMJ components via post-translational modifications (Figure 
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6-3). Interestingly, a targeted glycan-related screen revealed the functional pair of Sulf1 and 
Hs6st in the regulation of WNT and BMP trans-synaptic signaling at the Drosophila NMJ 
(Dani, Nahm et al. 2012). Our curated list contains Hs6st1, Hs6st2, as well as Sulf2, as highly 
enriched prospective NMJ components of the EDL muscle, and the findings at the Drosophila 
NMJ suggest a potentially similar role of these enzymes at the vertebrate NMJ, warranting 
further research.  
 
To provide further support for the importance of these potentially basal lamina-
modifying enzymes with structural and functional implications for the NMJ, we looked at the 
overlap of our EDL NMJ expression profile from Manuscript II and our young TA NMJ 
expression profile (10M.NMJ.CT vs. 10M.XNMJ.CT) from the Sinergia project dataset (Figure 
6-4). The overlap included and thus further validated the importance of the genes Hs6st2, 
Chpf, Chst15, Galnt15, Galnt18, and B4galnt3. Unique to the TA were further potentially 
important genes encoding for enzymes such as Hs3st3a1, Hs3st3b1, Gal3st1 and many more 
examples. Congenital myasthenic syndromes with glycosylation defects often involve 
mutations in enzymes that control central processes in glycoprotein modifications. For 
example, GFPT1 is the rate-limiting enzyme of the hexosamine pathway and regulates the 
availability of precursors for N- and O-linked glycosylation of proteins. Mutations of GFPT1 
thus have broad implications for the glycosylation of a potentially large number of NMJ 
components (Senderek, Muller et al. 2011). Importantly, mutations in other genes further 
downstream of GFPT1 may cause myasthenias as well, with critical roles in the impairment 
of neutransmission (Issop, Hathazi et al. 2018). Another example is dolichyl-phosphate 
(UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (DPAGT1), which is 
an essential enzyme catalyzing the first committed step of N-linked protein glycosylation, and 
mutations of which cause congenital myasthenic syndrome with tubular aggregates (Belaya, 
Finlayson et al. 2012). It is therefore highly likely that mutations of other enzymes further 
downstream of the N- and O-linked glycosylation pathways, but also of other 
posttranslational modifications, such as heparan sulfate proteoglycan sulfation, play an 
important role in neuromuscular disease. We strongly suggest further investigation of our 
provided candidate list in Figure 6-3, as there is a high likelihood that there are at least some 
candidates with highly important roles at the NMJ among them. Another interesting, albeit 
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unrelated candidate gene would be Pdzrn4, which is the fourth most highly enriched gene in 
the synaptic EDL, with a fold change of 2853. Since MuSK internalization can lead to its 
proteasomal degradation mediated in part by the E3 ubiquitin ligase PDZ domain-containing 
RING finger protein 3 (PDZRN3), which constitutes an important regulator of MuSK signaling 
contributing to precise and dynamic control of synaptic development (Lu, Je et al. 2007), 
investigating the potential role of the PDZRN3-paralog PDZ domain-containing RING finger 
protein 4 (PDZRN4) in MuSK-signaling would be interesting. Functional investigation of the 
suggested candidates could be achieved with inducible, muscle-specific mouse models 
assessing NMJ morphology, ultrastructure and neurotransmission strength. These studies 
could be complemented with loss-of-function experiments utilizing intramuscular AAV-
shRNA injections. Alternatively, a CRISPR approach to generate muscle-specific knockout of 
our suggested candidates may be used as well. Functional evaluation of our suggested 
candidates could provide novel targets for treatment strategies of neuromuscular diseases 
such as congenital myasthenic syndromes. 
 
We compared the fold changes obtained in our different studies and comparisons and 
included the TA NMJ dataset from Ketterer et al., 2010 (Table 6-1). From this comparison, it 
is clear that no single dataset is perfect on its own. Perhaps our TA dataset from the Sinergia 
project is the most comprehensive NMJ transcriptome available yet, but nevertheless most 
likely still does not contain every existing NMJ component. We definitely achieved a better 
quality dataset in the Sinergia project compared to the preceding EDL and SOL project. This 
was due to several improvements we made to the methodology. For one, we collected a 
slightly larger amount of NMJs per sample (300 vs. < 200) and worked with a larger number 
of biological replicates (N = 8 vs. N = 6). Perhaps the best improvements came from different 
sequencing library preparation kits used by the D-BSSE, which led to more robust data with 
much less noise overall for the Sinergia TA dataset. However, both studies worked with 
whole tissue lysates without RNA-isolation, which comes with the caveat of a lack of control 
over the exact input amounts of RNA. We controlled input amount solely by capturing equal 
numbers of NMJ areas and equal amounts of extrajunctional control tissue (based on area in 
mm2). In order to judge the RNA quality of our LCM tissue, we once collected a large 
representative sample of several times the amount of NMJ areas we would collect for a 
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regular sample in the study, isolated RNA and measured RNA integrity with an Agilent 
BioAnalyzer RNA 6000 Pico Kit. Our LCM tissue had a RNA integrity number (RIN) of 8, 
indicating good-quality RNA. It might be worth trying to collect a larger amount of NMJs (> 
600; with a lower number of biological replicates to reduce workload) and to conduct RNA-
isolation, thus gaining control over the exact input amounts for RNA-sequencing. It would be 
worth evaluating whether we could conduct NMJ proteomics to evaluate and support our 
transcriptomic findings with protein data.  
 
In conclusion, we were able to identify a large number of potential novel NMJ genes 
with our approach, and our NMJ gene profile analyses of the EDL and SOL muscles revealed 
a set of highly interesting candidates to follow up on in future research. We most likely still 
have not identified all components that make up the NMJ, but transcriptomic studies such as 
this allow us to appreciate the incredible biological complexity of the neuromuscular 
synapse, a better understanding of which provides the basis for discovering novel treatment 
approaches in neuromuscular disease. 
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Table 6-1. Gene expression fold change comparison of known and potentially novel NMJ 
components of the EDL and SOL (from Manuscript II study) and of the TA (from Sinergia 
project), as well as of the available TA dataset from Ketterer et al., 2010. 
Gene Name EDL SOL TA 
(Sinergia project) 
TA 
(Ketterer et al., 2010) 
Aplp2 10.4 3.4 17.1 - 
B4galnt3 323.3 506.7 18 - 
Chpf 203.4 22.4 10.8 - 
Chst15 23.2 - 5.7 - 
Chrna1 38.8 8.2 57.9 300.7 
Chrnb1 7 n.s. 5.1 2.5 
Chrnd 1020.9 12.4 652.2 13 
Chrne 40.9 53.5 556.7 117.5 
Crym n.s. 246.4 232.6 20.3 
Dusp6 24 19.4 81.6 60/80/100 
Erbb3 n.s. n.s. 58.24 - 
Dlk1 423.5 n.s. 78.3 - 
Etv5 n.s. 112.6 494.4 164 
Galnt15 27.2 - 3.6 - 
Galnt18 46.8 - 11.14 - 
Hs6st2 9524 n.s. 232.4 - 
Musk 668.8 n.s. 14.9 - 
Nell2 n.s. 141.2 21.9 - 
Pdzrn4 2853.3 23.4 126.1 7.3 
Sox10 1193 938.4 58.6 2.6 
Tbx21 918.6 n.s. 129.1 - 
Fold changes are from the respective synaptic vs. extrasynaptic comparisons of our datasets. The TA 
dataset from Ketter et al., 2010 was taken from their supplemental table S2 TAsin vs TAfib (set 2) 
(Ketterer, Zeiger et al. 2010). If a gene was not detected to be differentially expressed due to a cutoff 
FDR p-value > 0.05, this was indicated with n.s., not significant.  
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Figure 6-2. DAVID functional annotation analysis of the EDL and SOL muscles individually, as 
well as of their overlap. A) Significant DAVID SEQ_FEATURE and B) KEYWORD terms resulting from 
functional annotation analysis of all synaptically enriched genes of the EDL muscle. C) Significant 
DAVID SEQ_FEATURE and D) KEYWORD terms resulting from functional annotation analysis of all 
synaptically enriched genes of the SOL muscle. E) Venn-diagram depicting overlap and difference of 
synaptically enriched genes in the EDL and SOL muscles. F) Significant DAVID SEQ_FEATURE and G) 
KEYWORD terms of the EDL and SOL overlap (77 genes) indicated by the black dotted line. 
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Figure 6-3. Curated list of synaptically enriched enzymes putatively involved in the structural 
and functional modulation of the NMJ basal lamina. The information for involved processes and 
function of the genes was adapted from the NCBI gene databank at ncbi.nlm.nih.gov and the UniProt 
knowledgebase (UniProtKB) at uniprot.org. Fold changes are from the synaptic against extrasynaptic 
EDL RNA-sequencing comparison. 
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Figure 6-4. DAVID functional annotation analysis of the overlap of the EDL (Manuscript II) and 
TA (Sinergia project) muscle NMJ expression profiles. The Venn-diagram shows the overlap and 
difference of differentially expressed genes with a positive fold change (UP: synaptically enriched 
genes). The five most significant DAVID KEYWORDs and SEQ_FEATUREs resulting from querying 
DAVID Bioinformatics Resources with the overlap (227 genes) are shown. Numbers next to the 
barplots indicate the number of genes enriching the respective terms. 
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6.3 Effects of Aging on the Neuromuscular Junction Transcriptome 
Discussion and future perspectives 
Objective III: Determine whether aging leads to perturbations of the neuromuscular junction 
transcriptome. 
 
The neuromuscular junction (NMJ) is critically involved in age-related musculoskeletal 
impairments. We hypothesized that aging might lead to dysregulation of the NMJ gene 
program and thus contribute to the structural and functional decline of the NMJ that is 
observed with age. It has been suggested that aging changes NMJs mainly through the 
accumulation of myofiber segment damage at the NMJ. While the myofiber segment first 
degenerates and then quickly regenerates, this leaves the affected NMJ permanently 
perturbed (Li, Lee et al. 2011). However, it is also conceivable that aging leads to 
perturbations of the NMJ gene program, the dysregulation of which might lead to prolonged 
acetylcholine receptor turnover and disruption of pre- and post-synaptic apposition. If aging 
perturbs the NMJ gene program this may predispose them to damage. We used laser-capture 
microdissection to isolate fundamental myonuclei underlying the NMJ and generated NMJ 
gene expression profiles of the tibialis anterior (TA) muscle of young (10-month-old) and 
very old (30-month-old) mice with next-generation RNA-sequencing to investigate whether 
aging leads to perturbations of the NMJ gene program. Our results revealed the NMJ gene 
program to be remarkably stable, with identical gene expression levels of canonical NMJ 
genes. Our findings argue against the hypothesis that aging leads to a broad deterioration of 
the NMJ gene program that would contribute to perturbations of NMJ structure and function. 
We have thus achieved the primary goal of the project. 
 
The direct comparison of 10-month-old against 30-month-old synaptic control 
samples did not yield any differentially expressed genes. However, there was a difference in 
the total number of synaptically enriched and decreased genes (Table 5-1). We grouped all 
of the young and old synaptically enriched genes, as well as all of the young and old 
synaptically decreased genes of the respective comparisons into two separate Venn-
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diagrams. This allowed us to see which genes were synaptically enriched or decreased in 
both groups, and which genes were particular to just young or old NMJs (Figure 6-5). We 
found an overlap of 423 genes that were synaptically enriched in both age groups, while 656 
genes were unique to the young group and 321 genes were unique to the old (Figure 6-5 A). 
Furthermore, 130 genes were synaptically decreased in both groups, while 167 were unique 
to the young group and 54 were unique to the old (Figure 6-5 B). Before submitting the 
different lists of overlapping and differing genes to DAVID Bioinformatics Resources for 
functional annotation analysis, we removed predicted and non-coding genes, as those are not 
available in the respective annotation databanks. The synaptically enriched overlap of both 
groups (423 genes) was thus reduced to 378 genes for the submission. DAVID 
“SEQ_FEATURE” and “KEYWORD” are functional annotation categories similar to GO / KEGG. 
The most enriched DAVID KEYWORDs of this overlap were glycoprotein, disulfide bond, 
secreted and signal, together with the DAVID SEQ_FEATUREs signal peptide, glycosylation site: 
N-linked (GlcNAc…) and disulfide bond. The most enriched DAVID KEYWORDs in the subset 
of 527 synaptically enriched genes unique to the 10-month control were glycoprotein, 
disulfide bond, phosphoprotein, collagen, immunity and signal, as well as the DAVID 
SEQ_FEATUREs signal peptide and glycosylation site: N-linked (GlcNAc…). The most enriched 
DAVID KEYWORDs in the subset of 266 synaptically enriched genes unique to the 30-month 
control were disulfide bond, glycoprotein, phosphoprotein, cell adhesion and secreted, as well 
as the DAVID SEQ_FEATUREs disulfide bond, signal peptide and glycosylation site: N-linked 
(GlcNAc…). All of the synaptically enriched terms we found here are in agreement with our 
findings in the discussion to Manuscript II (Figure 6-2) and our comparison of the two 
different NMJ transcriptome datasets (Figure 6-4), lending further support to our proposed 
list of interesting candidate genes to investigate in future research (Figure 6-3).  
 
The subset of 130 genes that were synaptically decreased in both the young and old 
groups (Venn-diagram overlap in Figure 6-5 B) could not be used for DAVID functional 
annotation analyses, as this list contained many entries that were not available in the DAVID 
annotation databank. The list contained a large amount of mitochondrially encoded 
components of the electron transport chain (e.g. mt-Atp6, mt-Atp8, mt-Co1 to mt-Co3, mt-Cytb, 
mt-Nd1 to mt-Nd6, mt-Rnr1, mt-Rnr2, and 22 different mitochondrial transfer RNAs). 
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Fittingly, the subset of 167 genes unique to the 10-month-old control group enriched the 
DAVID KEYWORDs transit peptide, mitochondrion, and mitochondrion: Inner membrane, as 
well as the DAVID SEQ_FEATURE transit peptide: Mitochondrion. Among the genes enriching 
most of these terms were Ubiquinol cytochrome c reductase core protein 2 (Uqcrc2), Creatine 
kinase, mitochondrial 2 (Ckmt2), Oxoglutarate dehydrogenase (Ogdh) and ATP synthase 
subunit delta, mitochondrial (Atp5d). The subset of 54 synaptically decreased genes unique 
to the 30-month-old control did not enrich any DAVID terms, probably due to the relatively 
low number of entries in the list. Taken together, our analysis of synaptically decreased genes 
suggests a reduction of mitochondrial bioenergetic complexes in mitochondria at the NMJ, 
mostly irrespective of age as we found most mitochondrially encoded genes in the Venn-
diagram overlap (Figure 6-5 B). Importantly, most of the mitochondrially encoded genes 
mentioned above have some of the strongest gene expression values in the entire dataset, 
and in some cases exhibit expression strength in excess of 200000 counts per million (Figure 
6-6 A-B). To visualize this we representatively plotted mt-Atp6, mt-Cytb, mt-Co3, and mt-Nd3 
(Figure 6-6 C-F).  
 
The overall reduction in mitochondrially encoded genes seems surprising, as 
synapses generally possess a large amount of mitochondria and we would assume that we 
isolated comparatively more mitochondria with LCM in the synaptic samples compared to 
the extrasynaptic ones (Ly and Verstreken 2006, Vos, Lauwers et al. 2010). If anything, 
we would have expected a larger reduction of these genes in the old group. Perhaps age-
related mitochondrial perturbations led to an increased amount of dysfunctional 
mitochondria at the NMJ and we simply measured the result of that. Alternatively, age-related 
perturbations in the extrajunctional muscle tissue, which we used as a control, had greater 
variability and led to the observed outcome in our old synaptic versus extrasynaptic 
comparison. Another possibility is the fact that mitochondria cluster within the presynaptic 
nerve terminal and release calcium to modulate synaptic potentiation at the NMJ and 
therefore might be specialized for calcium buffering at the NMJ, especially for synaptic vesicle 
handling on the presynaptic side (Yang, He et al. 2003, Lee and Peng 2006, Vos, Lauwers 
et al. 2010). Mitochondrial calcium uptake is essential for neuromuscular transmission 
(David and Barrett 2003). Synaptic and extrasynaptic mitochondria have been successfully 
 General discussion 
164 
isolated and characterized from the rat brain and variations in mitochondrial enzymatic 
activities dependent upon the subcellular localization of the organelle were reported (Lai, 
Walsh et al. 1977). Proteomic profiling of neuronal mitochondria revealed an upregulation 
of mitochondrial inner membrane bioenergetics complexes, which suggests that distinct 
synaptic and non-synaptic mitochondrial protein expression may reflect altered local 
requirements for energetic expenditure. Additionally, synaptic mitochondria in the brain 
differed morphologically compared to non-synaptic mitochondria and are more susceptible 
to calcium overload (Brown, Sullivan et al. 2006, Graham, Eaton et al. 2017).  
 
Our results are in disagreement with the above observations of synaptic mitochondria 
in central nervous system. The Krebs cycle generates the master metabolite α-ketoglutarate, 
transamination of which yields the neurotransmitter glutamate. Glutamate can further be 
decarboxylated to yield GABA, another neurotransmitter (Bak, Schousboe et al. 2006). 
Since the vertebrate NMJ uses the neurotransmitter acetylcholine exclusively, one possible 
hypothesis is that mitochondria at the NMJ might be specialized for calcium handling and 
therefore downregulate their expression of electron transport chain and Krebs cycle proteins 
as opposed to synaptic mitochondria in the brain. Indeed, in addition to our observed 
downregulation of a large amount of mitochondrially encoded components of the electron 
transport chain, we observed decreased expression of the gene encoding for α-ketoglutarate 
dehydrogenase (Ogdh) (Figure 6-6 G), a rate-limiting enzyme in the Krebs cycle. 
Furthermore, the gene encoding for mitochondrial isocitrate dehydrogenase 2 (Idh2) (Figure 
6-6 H), an enzyme that produces α-ketoglutarate from isocitrate, was synaptically decreased 
as well. It would thus be interesting to investigate respiration and calcium buffering 
capabilities of NMJ mitochondria and compare the results with non-synaptic mitochondria of 
the muscle and brain, although this might be challenging to do experimentally. We could 
perform mitochondrial calcium uptake assays on NMJ mitochondria isolated via LCM. 
However, cryopreservation of functionally intact mitochondria, as would be required for 
LCM of serial muscle cryosections, might be a limiting factor. Skeletal muscle mitochondria 
are difficult to cryopreserve, and simple freeze-thawing of muscle tissue is associated with 
severe damage of mitochondria. One study found that cryopreservation of functionally intact 
muscle mitochondria might be possible by using fine-tuned amounts of glycerol and DMSO 
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(Kuznetsov, Kunz et al. 2003). Perhaps this method could also be applied to our LCM 
workflow and allow the isolation of functionally intact NMJ mitochondria. Furthermore, 
collecting adequate amounts of tissue in order to analyze mitochondrial respiration and 
calcium buffering might not be feasible via LCM. Dysregulation of calcium handling is a 
common underlying event in the pathophysiology of muscular dystrophies (Vallejo-
Illarramendi, Toral-Ojeda et al. 2014). Understanding whether (pre-) synaptic 
mitochondria possess specializations in calcium handling might have implications for 
neuromuscular diseases where perturbations of calcium handling plays a role and have not 
been taken into consideration previously. 
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Figure 6-5. DAVID functional annotation analysis of young and old neuromuscular junction 
gene expression patterns. Venn-diagrams showing overlap and difference of differentially 
expressed genes with a A) positive fold change (UP: synaptically enriched genes) or B) negative fold 
change (DOWN: synaptically decreased genes) between the respective young and old synaptic 
against extrasynaptic control group comparisons. Dotted lines indicate the respective subset of genes 
used for DAVID functional annotation analysis. For each subset, significant (FDR p-value < 0.25) 
DAVID KEYWORDs and SEQ_FEATUREs are shown. Numbers next to the barplots indicate the number 
of genes enriching the respective terms. Young NMJ: Differentially expressed genes of the synaptic 
vs. extrasynaptic 10-month control group; Old NMJ: Differentially expressed genes of the synaptic vs. 
extrasynaptic 30-month control group. 
  




 General discussion 
169 
Figure 6-6. Reduced expression of mitochondrially encoded electron transport chain and 
Krebs cycle components at the NMJ. A, B) Mean-difference plots showing log2 fold changes 
(log2FC) of genes on the Y-axis plotted against the average gene expression strength in log2 counts 
per million (log-CPM) on the X-axis. Each black dot represents an expressed gene in the study (legend 
“0”). Differentially expressed genes (FDR p-value < 0.05) with a positive fold change are marked in 
purple (legend “1”), while genes with a negative fold change are marked in orange (legend “-1”). The 
red circles mark mitochondrially encoded genes, which are synaptically decreased in both young and 
old samples, but are among the genes with the strongest expression in the dataset. A) Synaptic vs. 
extrasynaptic 10-month-old control. B) Synaptic vs. extrasynaptic 30-month-old control. C-H) Gene 
expression in log2 counts per million (logCPM) of individual genes across all experimental groups is 
shown. The two dashed lines show the median expression value either of all synaptic samples (red) 
or of all extrasynaptic samples (black), irrespective of age and condition. The median difference in 
logCPM is given in the plot subtitles. Groups: 10M.NMJ.CT, 10-month control, synaptic; 
10M.XNMJ.CT, 10-month control, extrasynaptic; 30M.NMJ.CT, 30-month control, synaptic; 
30M.XNMJ.CT, 30-month control, extrasynaptic. 30M.NMJ.RM, 30-month rapamycin-treated, 
synaptic; 30M.XNMJ.RM, 30-month rapamycin-treated, extrasynaptic; 30M.NMJ.CT, 30-month 
control, synaptic; 30M.NMJ.CR, 30-month caloric restriction-treated, synaptic; 30M.XNMJ.CR, 30-
month caloric restriction-treated, extrasynaptic. 
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7.1 Appendix A: Pharmacological targeting of exercise adaptations 

























7.2 Appendix B: BDNF is a mediator of glycolytic fiber-type 
specification in mouse skeletal muscle 
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